# **Governor's Pharmacy Reimbursement Commission**

# Wisconsin Medicaid Fee-for-Service Drug Cost and Utilization Report

➤ State Fiscal Year 2005

## **Contents**

#### Part 1: Performance Summary Data

- > SFY 2005 Performance Summary
- > SFY 2005 Trends in Performance Summary Variables
- ➤ Classes Comprising Greatest Share of Total \$\$\$ and Rx's and Changes to Cost Per Rx for these Classes.
- ➤ Graph: Brand vs Generic Cost Per Rx Trend, July 2002 June 2005.
- > 50 Highest Cost Drugs
- > 50 Most Frequently Prescribed Drugs

#### Part 2: SFY 2005 Detail Data

➤ Cost, Utilization and Market Share Data by Drug (HIC-4) and Class

## **Uses and Sources of this Report**

#### Uses:

- ➤ Determine variables affecting Medicaid FFS Pharmacy cost increases and factors achieving cost savings.
- ➤ Provide quick reference source for drug and class cost and utilization.

#### Sources:

➤ Medicaid Fee-for-Service Drug Datamart (Business Objects)

#### Caution:

- ➤ Individual drugs may fall under more than one therapeutic category. Because of this, expenditures for a drug listed within one class may not represent 100% of all MA FFS spending on that drug year-to-date.
- > Data does not include SeniorCare.

# Part One

# Performance Summary Data

#### Medicaid Fee-for Service (FFS) Drug Utilization Data

SFY 2005 Final

Performance Summary	(Paid Amounts are All Funds and Pre-Rebate)
---------------------	---

Average Members (FFS SFY05 Recipient Months/12)	301,820	FFS Paid PMPM:	\$169.09
Total Prescriptions:	10,119,546	Avg FFS Paid/Prescription:	\$60.52
Rx/Mbr/YTD	33.5	Avg Days Supply:	24.9
Rx/Mbr/Month	2.79	% Mbr Utilizing Rx's:	61.6%
Total Billed:	\$844,081,778	Generic Utilization	
Total Paid:	\$612,425,954	% Generic Filled:	58.5%
Total Dispensing Fee:	\$46,538,042	% Generic Opportunity:	59.7%
Total Copay:	\$9,142,690	% Generic Efficiency:	98.0%
Avg Copay/Prescription:	\$0.90	Generic Fill Rate for June 05 v	vas 61.1%


#### **Generic/Brand Comparison**

<b>Brand</b>		% Rx	% Paid	Avg Ing Cost/Rx
	Single Source	39.8%		
	Multiple Source	1.7%		
	All Brands	41.5%	82.4%	\$120.12
Generic		% Rx	% Paid	Avg Ing Cost/Rx
	All Generics	58.5%	17.6%	\$18.12
Group A	<u>verage</u>	% Rx	% Paid	Avg Ing Cost/Rx
	Overall			\$60.52

% Rx

Generic
58%

Brand
42%



This FFS aggregate drug summary excludes SeniorCare, BadgerCare and Family Planning waiver cost and utilization data that are not reflected in MA drug line of MARS financial reports. Dollar amounts reflect gross All Funds costs.

Source: DHFS Division of Health Care Financing

# Trends in Performance Summary Variables SFY04 vs. SFY05

	SFY04	SFY05	% Change
Total Expenditures	\$561,047,316	\$612,425,954	9.16%
Total Prescriptions	9,475,550	10,119,546	6.80%
Avg Recipients Per Week	65,036	69,957	7.57%
Avg Cost Per Recipient Per Week	\$165.90	\$168.35	1.48%
Average # of Rx's Per Recip/Week	2.80	2.78	-0.72%
Cost Per Prescription	\$59.21	\$60.52	2.21%
Cost Per Generic Prescription	\$17.51	\$18.12	3.48%
Cost Per Brand Prescription	\$105.62	\$120.12	13.73%
Copay Per Prescription	\$0.82	\$0.90	9.76%
% Generic Prescriptions	52.7%	58.5%	5.80%
% Brand Prescriptions	47.3%	41.5%	-5.80%
% Generic Paid	16.2%	17.6%	1.40%
% Brand Paid	83.8%	82.4%	-1.40%

#### **SUMMARY FINDING**

The 9.1% increase in SFY05 drug costs was caused by a 7.6% increase in recipients and 1.5% increase in the cost per recipient. The number of Rx's per recipient remained constant and was not a factor in the cost increase.


Annual Drug Cost Growth Rate declined from 13.1% in SFY04 to 9.1% in SFY05. This is due to the cost per recipeint growth rate falling from 6.1% to 1.5%, while recipient growth increased from 7.0% to 7.6%.

Source: Division of Health Care Financing

This FFS aggregate drug summary excludes BadgerCare and Family Planning waiver cost and utilization data, but includes Family Planning non-waiver, FQHC and Enteral Nutrition drug costs that are not reflected in MA drug line of MARS financial reports. This summary is also claims-based, not disbursement based as are the MARS financial reports.

REATEST S FY03 Rank)   (1) (2) (4) (3)	ges to C SFY05 HARE OF E FY04 Rank	ost Per I	test Share of Total \$\$\$ a							
REATEST S (1) (2) (4) (3)	SFY05 HARE OF E FY04 Rank		TX 101 tilese classes							
REATEST S FY03 Rank)   (1) (2) (4) (3)	HARE OF E FY04 Rank	XPENDITUR								
(1) (2) (4) (3)	FY04 Rank	XPENDITUR								
(1) (2) (4) (3)	FY04 Rank	XPENDITUR	<u> </u>							Cost Per R
(1) (2) (4) (3)	1									% Change
(2) (4) (3)						FY05 % \$\$				Since FY0
(4)		1	Antipsychotics - Atypicals	15.7%		18.0%	\$194.92	\$215.28	\$226.80	16.36
(3)	2	2	Anticonvulsants	8.3%			\$97.02	\$109.72	\$115.19	
	3	3	Analgesics - Narcotics	5.4%			\$49.60	\$56.64	\$56.74	14.40
	4	4	Proton Pump Inhibitors	6.8%			\$127.51	\$94.94	\$70.02	-45.09
(5)	5	5	Antidepressants - SSRI's	5.3%			\$67.44	\$67.15	\$54.56	
(6)	6	6	Lipotropes - Statins	3.4%	3.4%		\$84.58	\$85.12	\$83.72	
(7)	7	7	Asthma - Preventative	2.7%	2.9%		\$89.45	\$102.22	\$112.24	25.48
(11)	10	8	Stimulants (Including Strattera)	1.6%			\$69.70	\$83.35	\$88.03	
(8)	8	9	Diabetes - Oral	2.2%	2.2%	2.0%	\$44.32	\$46.73	\$45.03	
(16)	14	10	Agents for Alzheimers	1.2%	1.4%		\$118.97	\$119.52	\$120.00	
(12)	11	11	Diabetes - Insulins	1.4%	1.5%	1.7%	\$50.29	\$59.39	\$64.06	
(15)	13	12	Antidpressants - SNRI's	1.2%	1.4%		\$100.59	\$115.77	\$121.03	
(10)	12	13	Calcium Channel Blockers	1.7%	1.5%	1.4%	\$43.05	\$43.45	\$43.29	0.56
(18)	15	14	Antiplatelets - Agg Inhibitors	1.1%	1.2%	1.4%	\$99.99	\$107.07	\$111.20	
(14)	17	15	Antiretrovirals	1.2%	1.2%	1.3%	\$415.20	\$449.43	\$480.16	
(17)	16	16	Agents for Osteoporosis	1.2%	1.2%	1.3%	\$63.48	\$68.04	\$74.45	
(19)	18	17	Agents for Multiple Sclerosis	1.1%	1.2%	1.3%		\$1,079.40		34.3
(9)	9	18	NSAIDS/COX2 Inhibitors	2.1%	2.0%	1.3%	\$87.20	\$92.02	\$94.16	7.98
(20)	19	19	Agents for Urinary Spasms	1.0%	1.1%	1.1%	\$66.76	\$73.67	\$76.56	14.6
()	20	20	Asthma - Rescue Top 20 Total % of Drug Spend	1.0% <b>65.8%</b>	1.1% <b>66.5</b> %		\$28.82	\$32.38	\$34.26	18.88
		es were #13 in F	FY03 cost and are not							
Top 20 for FY05	5									
DE 4 TE 0 T 0										Cost Per I
REATEST S			01	EV00.0/ D	EV04.0/ B	EVOE 0/ D.:	E\(000/D	EV0.46/D	EV056/D	% Chang
Y03 Rank)						FY05 % Rx				Since FY
(1)	1	1	Analgesics - Narcotics	6.0%	6.3%	6.4%	\$49.60	\$56.64	\$56.74	14.40
(3)	3	2	Antipsychotics - Atypicals	4.4%			\$194.92	\$215.28	\$226.80	16.3
(2)	2	3	Anticonvulsants	4.7%	4.7%		\$97.02	\$109.72	\$115.19	18.7
(4)	4	4	Antidepressants - SSRI's	4.3%	4.3%		\$67.44	\$67.15	\$54.56	
(8)	6	5	Proton Pump Inhibitors	3.0%	3.1%		\$127.51	\$94.94	\$70.02	-45.0
(5)	5 9	6	Anxiety - Benzodiazepines	3.2%			\$13.14	\$12.61	\$10.44	-20.5
(10)	7	7	Beta Blockers	2.7%	2.8%		\$13.58	\$14.19	\$14.86	
(7)		8	Ace Inhibitors	2.9%			\$19.18	\$16.16	\$13.48	-29.7
(9)	10	10	Diabetes - Oral	2.7%	2.7%		\$44.32	\$46.73	\$45.03	
(6)	8	9	Diuretics - Loop	2.9%			\$7.33	\$6.86	\$6.67	
(12)	11	11	Lipotropes - Statins	2.2%			\$84.58	\$85.12	\$83.72	
(11)	12	12	Thyroid Replacement	2.2%			\$13.91	\$14.08	\$13.16	
(14)	14	13	Asthma - Rescue	2.0%			\$28.82	\$32.38	\$34.26	
(13)	13	14	Calcium Channel Blockers	2.1%			\$43.05	\$43.45	\$43.29	
(16)	16	15	Asthma - Preventative	1.6%			\$89.45	\$102.22	\$112.24	
(15)	15	16	Potassium	1.8%		1.6%	\$15.55	\$12.97	\$13.56	
(18)	17	17	Diabetes - Insulins	1.6%	1.5%		\$50.29	\$59.39	\$64.06	
(19)	18	18	Anticoagulants	1.5%			\$24.19	\$27.76	\$29.24	20.88
()	()	19	NSAIDS/Non COX-2 Inhibitors	1.3%			\$17.85	\$16.44	\$17.23	-3.47
()	()	20	Stimulants (Including Strattera)	1.3%		1.5%	\$69.70	\$83.35	\$88.03	26.30
			Top 20 Total % of Rx's	54.4%	54.9%	54.9%				
ource: Division			top 20 for SFY05.		<b></b>	1				<u> </u>

#### WI Medicaid FFS Generic vs Brand Fill Rate by Month July 2002-June 2005



#### 50 Highest Cost Drugs

#### **Medicaid Fee-for-Service**

SFY05 Final

Red = Greatest Cost Growth

Blue = Greatest Cost Decline

(FY04)				Primary	Gross	%		%	\$\$\$	Cost
Rank	Rank	Generic Name	Brand Name(s)	Therapy Class	\$\$\$	\$\$\$	Rx's	Rx's	Per Rx	PMPM
(1)	1	OLANZAPINE	ZYPREXA	Antipsychotic-Atypical	\$37,593,930.	6.03%	116,210.	1.12%	\$323.50	\$20.76
(2)	2	RISPERIDONE	RISPERDAL	Antipsychotic-Atypical	\$28,988,695.	4.65%	140,579.	1.35%	\$206.21	\$16.01
(3)	3	QUETIAPINE	SEROQUEL	Antipsychotic-Atypical	\$25,145,074.	4.03%	125,169.	1.20%	\$200.89	\$13.89
(4)	4	OXYCODONE	PERCODAN	Narcotic	\$17,217,560.	2.76%	161,385.	1.55%	\$106.69	\$9.51
(5)	5	DIVALPROEX SODIUM		Anticonvulsant	\$15,748,034.	2.52%	119,942.	1.15%	\$131.30	\$8.70
(8)	6	FLUTICASONE	ADVAIR	Asthma (Preventative)	\$13,994,160.	2.24%	123,024.	1.18%	\$113.75	\$7.73
(13)	7	ARIPIPRAZOLE	ABILIFY	Antipsychotic-Atypical	\$13,680,755.	2.19%	42,796.	0.41%	\$319.67	\$7.55
(10)	8	ATORVASTATIN	LIPITOR	Lipotrope - Statin	\$12,606,286.	2.02%	152,214.	1.46%	\$82.82	\$6.96
(7)	9	FENTANYL	DURAGESIC	Narcotic	\$11,938,941.	1.91%	60,776.	0.58%	\$196.44	\$6.59
(6)	10	GABAPENTIN	NEURONTIN	Anticonvulsant	\$11,732,176.	1.88%	104,351.	1.00%	\$112.43	\$6.48
(9)	11	SERTRALINE	ZOLOFT	Antidepressant (SSRI)	\$10,422,306.	1.67%	115,653.	1.11%	\$90.12	\$5.76
(20)	12	LAMOTRIGINE	LAMICTAL	Anticonvulsant	\$9,230,597.	1.48%	40,933.	0.39%	\$225.51	\$5.10
(14)	13	VENLAFAXINE	EFFEXOR	Antidepressant (SNRI)	\$9,146,954.	1.47%	73,828.	0.71%	\$123.90	\$5.05
(22)	14	CLOPIDOGREL	PLAVIX	Antiplatelet	\$8,040,564.	1.29%	69,622.	0.67%	\$115.49	\$4.44
(16)	15	TOPIRAMATE	TOPAMAX	Anticonvulsant	\$7,974,365.	1.28%	38,020.	0.37%	\$209.74	\$4.40
(22)	16	SIMVASTATIN	ZOCOR	Lipotrope - Statin	\$6,919,470.	1.11%	59,590.	0.57%	\$116.12	\$3.82
(28)	17	ZIPRASIDONE	GEODON	Antipsychotic-Atypical	\$6,761,931.	1.08%	28,095.	0.27%	\$240.68	\$3.73
(19)	18	LANSOPRAZOLE	PREVACID	Proton Pump Inhibitor	\$6,734,418.	1.08%	45,933.	0.44%	\$146.61	\$3.72
(11)	19	OMEPRAZOLE	Generic (Prilosec)	Proton Pump Inhibitor	\$6,627,149.	1.06%	217,401.	2.09%	\$30.48	\$3.66
(23)	20	AMLODIPINE	NORVASC	Calcium Channel Blocker	\$6,612,601.	1.06%	115,993.	1.11%	\$57.01	\$3.65
(26)	21	DONEPEZIL	ARICEPT	Agent for Alzheimers	\$6,595,112.	1.06%	51,747.	0.50%	\$127.45	\$3.64
(25)	22	ALBUTEROL	Generic - Various	Asthma (Rescue)	\$6,247,296.	1.00%	200,416.	1.92%	\$31.17	\$3.45
(21)	23	BUPROPION	WELLBUTRIN	Antidepressant (NDRI)	\$5,872,786.	0.94%	68,716.	0.66%	\$85.46	\$3.24
(27)	24	ZOLPIDEM	AMBIEN	Sedative Hypnotic	\$5,748,901.	0.92%	66,672.	0.64%	\$86.23	\$3.17
(17)	25	CELECOXIB	CELEBREX	Cox2 Inhibitor	\$5,655,021.	0.91%	58,637.	0.56%	\$96.44	\$3.12
(30)	26	AMPHETAMINE	ADDERALL	Stimulant	\$5,453,042.	0.87%	60,481.	0.58%	\$90.16	\$3.01
(31)	27	ESCITALOPRAM	LEXAPRO	Antidepressant (SSRI)	\$5,251,364.	0.84%	76,835.	0.74%	\$68.35	\$2.90
(12)	28	PANTOPRAZOLE	PROTONIX	Proton Pump Inhibitor	\$4,578,178.	0.73%	39,240.	0.38%	\$116.67	\$2.53
(35)	29	MONTELUKAST	SINGULAIR	Asthma (Preventative)	\$4,547,334.	0.73%	53,665.	0.52%	\$84.74	\$2.51
(36)	30	METHYLPHENIDATE	Generic (Ritalin, etc.)		\$4,489,938.	0.72%	62,803.	0.60%	\$71.49	\$2.48
(32)	31	PIOGLITAZONE	ACTOS	Diabetes (Oral)	\$4,474,221.	0.72%	31,426.	0.30%	\$142.37	\$2.47
(37)	32	ESOMEPRAZOLE	NEXIUM	Proton Pump Inhibitor	\$4,463,952.	0.72%	29,478.	0.28%	\$151.43	\$2.47
(38)	33	MORPHINE	Generic	Narcotic	\$4,452,060.	0.71%	40,984.	0.39%	\$108.63	\$2.46
(34)	34	TOLTERODINE	DETROL	Agent for Urinary Spasm	\$4,447,464.	0.71%	49,501.	0.48%	\$89.85	\$2.46
(24)	35	CLOZAPINE	Generic (Clozaril)	Antipsychotic-Atypical	\$4,402,686.	0.71%	58,756.	0.56%	\$74.93	\$2.43
(39)	36	ROSIGLITAZONE	AVANDIA	Diabetes (Oral)	\$4,069,057.	0.65%	35,174.	0.34%	\$115.68	\$2.25
(15)	37	PAROXETINE	PAXIL	Antidepressant (SSRI)	\$4,059,873.	0.65%	78,410.	0.75%	\$51.78	\$2.24
()	38	PALIVIZUMAB	SYNAGIS	Viral Respitory (RSV)	\$3,772,834.	0.60%	2,716.	0.03%	\$1,389.11	\$2.08
(45)	39	ONDANSETRON	ZOFRAN	Antiemetic/Antivertigo	\$3,743,946.	0.60%	6,079.	0.06%	\$615.88	\$2.07
(41)	40	INTERFER BETA-1A	AVONEX/REBIF	Multiple Sclerosis	\$3,727,670.	0.60%	3,174.	0.03%	\$1,174.44	\$2.06
()	41	LEVETIRACETAM	KEPPRA	Anticonvulsant	\$3,565,484.	0.57%	17,996.	0.17%	\$198.13	\$1.97
()	42	AZITHROMYCIN	ZITHROMAX	Macrolides	\$3,541,590.	0.57%	74,358.	0.71%	\$47.63	\$1.96
(46)	43	ALENDRONIC ACID	FOSAMAX	Osteoporosis	\$3,409,779.	0.55%	48,929.	0.47%	\$69.69	\$1.88
()	44	ANTIHEMOPHILIC F8	Factor VIII	Antihemophelic	\$3,308,446.	0.53%	185.	0.00%	\$17,883.49	\$1.83
()	45	INSULIN GLARGINE	LANTUS	Agents for Diabetes-Ins.	\$3,241,638.	0.52%	41,075.	0.39%	\$78.92	\$1.79
()	46	ETANERCEPT	ENBREL	Agent for Rheuma Arth	\$3,100,832.	0.50%	2,436.	0.02%	\$1,272.92	\$1.71
()	47	LEVOFLOXACIN	LEVAQUIN	Quinolones	\$3,090,956.	0.50%	38,867.	0.37%	\$79.53	\$1.71
(49)	48	GLATIRAMER	COPAXONE	Multiple Sclerosis	\$3,089,153.	0.50%	2,515.	0.02%	\$1,228.29	\$1.71
()	49	METOPROLOL	Generic	Beta Blocker	\$3,084,137.	0.49%	150,425.	1.44%	\$20.50	\$1.70
(43)	50	INSULIN ISOPHANE	HUMULIN	Diabetes (Insulin)	\$3,055,067.	0.49%	61,608.	0.59%	\$49.59	\$1.69
Totals 1	or Top	50			\$395,655,783	63.41%	3,464,818	33.26%	\$114.19	\$145.66

(--) signifies drug that was not in the Top 50 Highest Cost for SFY04.

SFY04 Top 50 Drugs (SFY04 Rank) not in SFY05 Top 50: Celexa (29), Vioxx (33), Synagis (40), Remeron (42), L-Thyroxine (44), amoxicillan (47), Copaxone (49), O

Prepared by DHFS Division of Health Care Financing

Highest Cost MA FFS Drugs SFY05 - Final

#### **50 Most Frequently Prescribed Drugs**

#### **Medicaid Fee-for-Service**

SFY05 Final

Red = Greatest Utilization Growth

Blue = Greatest Utilization Decline

(FY04)	FY05			Primary	Gross	%		%	\$\$\$	Cost
Rank	Rank	Generic Name	Brand Name	Therapy Class	\$\$\$	\$\$\$	Rx's	Rx's	Per Rx	PMPM
(1)	1	FUROSEMIDE	Generic	Diuretic	\$1,576,345.	0.25%	271,024.	2.60%	\$5.82	\$0.58
(3)	2	HYDROCODONE	Generic	Narcotic	\$2,982,203.	0.48%	237,226.	2.28%	\$12.57	\$1.10
(2)	3	L-THYROXINE	Generic	Thyroid Replacement	\$2,949,948.	0.47%	223,545.	2.15%	\$13.20	\$1.09
(6)	4	OMEPRAZOLE	Generic (Prilosec)	Proton Pump Inhibitor	\$6,627,149.	1.06%	217,401.	2.09%	\$30.48	\$2.44
(4)	5	ALBUTEROL	Generic	Asthma - Rescue	\$6,247,296.	1.00%	200,416.	1.92%	\$31.17	\$2.30
(5)	6	POTASSIUM	Generic	Potassium	\$2,353,387.	0.38%	173,082.	1.66%	\$13.60	\$0.87
(7)	7	OXYCODONE	Percodan	Narcotic	\$17,217,560.	2.76%	161,385.	1.55%	\$106.69	\$6.34
(9)	8	LISINOPRIL	Generic	Ace Inhibitor	\$1,405,741.	0.23%	156,830.	1.51%	\$8.96	\$0.52
(8)	9	WARFARIN	Generic	Anticoagulant	\$1,699,956.	0.27%	154,624.	1.48%	\$10.99	\$0.63
(12)	10	ATORVASTATIN	LIPITOR	Lipotrope - Statin	\$12,606,286.	2.02%	152,214.	1.46%	\$82.82	\$4.64
(11)	11	METOPROLOL	Generic	Beta Blocker	\$3,084,137.	0.49%	150,425.	1.44%	\$20.50	\$1.14
(13)	12	RISPERIDONE	RISPERDAL	Antipsychotic-Atypical	\$28,988,695.	4.65%	140,579.	1.35%	\$206.21	\$10.67
(21)	13	QUETIAPINE	SEROQUEL	Antipsychotic-Atypical	\$25,145,074.	4.03%	125,169.	1.20%	\$200.89	\$9.26
(22)	14	FLUTICASONE	ADVAIR	Asthma - Preventative	\$13,994,160.	2.24%	123,024.	1.18%	\$113.75	\$5.15
(15)	15	DIVALPROEX SODIUM	DEPAKOTE	Anticonvulsant	\$15,748,034.	2.52%	119,942.	1.15%	\$131.30	\$5.80
(16)		ATENOLOL	Generic	Beta Blocker	\$743,716.	0.12%	118,028.	1.13%	\$6.30	\$0.27
(14)	17	OLANZAPINE	ZYPREXA	Antipsychotic-Atypical	\$37,593,930.	6.03%	116,210.	1.12%	\$323.50	\$13.84
(20)	18	AMLODIPINE	NORVASC	Calcium Channel Blocker	\$6,612,601.	1.06%	115,993.	1.11%	\$57.01	\$2.43
(10)	19	SERTRALINE	ZOLOFT	Antidepressant (SSRI)	\$10,422,306.	1.67%	115,653.	1.11%	\$90.12	\$3.84
(18)	20	LORAZEPAM	Generic	Anti-Anxiety	\$1,076,865.	0.17%	112,873.	1.08%	\$9.54	\$0.40
(19)	21	AMOXICILLIN	Generic	Penicillin	\$2,424,476.	0.39%	111,642.	1.07%	\$21.72	\$0.89
(32)	22	FLUOXETINE	Generic (Prozac)	Antidepressant (SSRI)	\$1,692,595.	0.27%	106,115.	1.02%	\$15.95	\$0.62
(23)	23	GABAPENTIN	NEURONTIN	Anticonvulsant	\$11,732,176.	1.88%	104,351.	1.00%	\$112.43	\$4.32
(17)	24	RANITIDINE	Generic	Agent for Ulcers	\$1,397,087.	0.22%	99,512.	0.96%	\$14.04	\$0.51
(25)	25	HYDROCHLOROTHIAZIDE	Generic	Diuretic	\$606,477.	0.10%	97,907.	0.94%	\$6.19	\$0.22
(26)	26	CLONAZEPAM	Generic	Anti-Anxiety	\$1,024,113.	0.16%	96,319.	0.92%	\$10.63	\$0.38
(29)	27	METFORMIN	Generic	Diabetes (Oral)	\$1,328,351.	0.21%	91,718.	0.88%	\$14.48	\$0.49
(28)		TRAZODONE	Generic	Antidepressant (SARI)	\$580,824.	0.09%	88,825.	0.85%	\$6.54	\$0.43
(50)	29	LORATADINE	Generic (Claritin)	Non-Sedating Antihist.	\$962,272.	0.05%	79,969.	0.77%	\$12.03	\$0.21
(31)	30	CODEINE	CODEINE	Narcotic	\$790,320.	0.13%	79,875.	0.77%	\$9.89	\$0.29
(33)	31	ALPRAZOLAM	Generic	Anti-Anxiety	\$1,010,027.	0.16%	79,373.	0.76%	\$12.73	\$0.23
(27)	32	DIGOXIN	Generic	Digitalis Glycosides	\$634,218.	0.10%	78,793.	0.76%	\$8.05	\$0.37
(24)	33	PAROXETINE	PAXIL	Antidepressant (SSRI)	\$4,059,873.	0.65%	78,410.	0.75%	\$51.78	\$0.23 \$1.49
(39)	34	ESCITALOPRAM	LEXAPRO	Antidepressant (SSRI)	\$5,251,364.	0.84%	76,410.	0.74%	\$68.35	\$1. <del>4</del> 9 \$1.93
()	35	AZITHROMYCIN	ZITHROMAX	Macrolides	\$3,541,590.	0.57%	74,358.	0.74%	\$47.63	\$1.30
	36	VENLAFAXINE	EFFEXOR		\$9,146,954.	1.47%	73,828.	0.71%	\$123.90	\$3.37
(34)	37	PREDNISONE	Generic	Antidepressant (SNRI)	\$395,752.	0.06%	73,064.	0.71%	\$123.90 \$5.42	\$3.37 \$0.15
(40)	38	CLOPIDOGREL	PLAVIX	Glucocorticoid	\$8,040,564.	1.29%	69,622.	0.70%		\$0.15 \$2.96
(47)	39	MIRTAZAPINE	REMERON	Antiplatelet Antidepressant (A2RA)	\$1,888,673.	0.30%	69,095.	0.66%	\$115.49 \$27.33	\$0.70
(36) (44)	39 40	BUPROPION	WELLBUTRIN	Antidepressant (AZRA) Antidepressant (NDRI)	\$5,872,786.	0.94%	68,716.	0.66%	\$85.46	\$0.70 \$2.16
` '	40	ZOLPIDEM	AMBIEN	' '	\$5,748,901.	0.94%	66,672.	0.64%		\$2.10 \$2.12
(45)		ASPIRIN		Sedative Hypnotic	\$209,758.	0.92 %	65,619.	0.63%	\$86.23	
(48)	42		Generic	Analgesic		0.39%	65,258.	0.63%	\$3.20	\$0.08
(38)	43	CARBAMAZEPINE	Generic	Anticonvulsant	\$2,424,970.				\$37.16	\$0.89
(37)	44	PHENYTOIN	Generic	Anticonvulsant	\$1,591,930. \$712.591	0.26% 0.11%	64,183. 63,294.	0.62% 0.61%	\$24.80	\$0.59
(42)	45	PROPOXYPHENE	Generic	Narcotic	\$713,581. \$448,175.	0.11%	63,294.	0.61%	\$11.27	\$0.26
(43)	46	ENALAPRILAT	Generic	Ace Inhibitor	. ,				\$7.09	\$0.16
()	47	METHYLPHENIDATE	Generic Ritalin	Stimulant	\$4,489,938.	0.72% 0.49%	62,803.	0.60% 0.59%	\$71.49	\$1.65
(41)	48	INSULIN ISOPHANE	HUMULIN	Diabetes (Insulin)	\$3,055,067. \$11,938,941.	1.91%	61,608.	0.59%	\$49.59	\$1.12
()	49	FENTANYL	DURAGESIC	Narcotic			60,776.		\$196.44	\$4.40
() <b>-</b>	50	AMPHETAMINE	ADDERALL	Stimulant	\$5,453,042.	0.87%	60,481.	0.58%	\$90.16	\$2.01
Totals	ror I op	5 50			\$297,530,184	47.68%	5,517,853	52.97%	\$53.92	\$109.53

<sup>(--)</sup> signifies drug that was not in the Top 50 Most Frequently Prescribed for SFY04.

SFY04 Top 50 Drugs not in SFY05 Top 50: Citalopram (Celexa), Clozapine (Clozaril), Pantoprazole (Protonix) and Celecoxib (Celebrex).

# Part Two

# SFY 2005 Cost and Utilization by Drug and Therapy Class

ACE INHIBITORS							<u> </u>
Share of FFS Rx's: 2.84%	1						
Per Member SFY05: \$13.22	MAC'd?	Brand/Innovator	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LISINOPRIL	V	Prinivil/Zestril					
	1		Merck/AstraZeneca	\$1,369,029	153,653	51.9%	\$8.91
RAMIPRIL	N	Altace	Monarch	\$704,353	13,015	4.4%	\$54.12
QUINAPRIL	Υ	Accupril	Parke-Davis	\$465,111	11,350	3.8%	\$40.98
ENALAPRILAT	Υ	Vasotec	Biovail	\$438,622	62,696	21.2%	\$7.00
TRANDOLAPRIL	N	Mavik	Abbott	\$291,345	7,913	2.7%	\$36.82
FOSINOPRIL	Υ	Monopril	BMS	\$240,422	9,835	3.3%	\$24.45
BENAZEPRIL	Υ	Lotensin	Novartis	\$188,471	18,827	6.4%	\$10.01
MOEXIPRIL	Y	Univasc	Schwarz	\$161,033	5,005	1.7%	\$32.17
CAPTOPRIL	· ·	Capoten	Par Pharmaceuticals	\$98,812	13,024	4.4%	\$7.59
	<u>.</u>						
PERINDOPRIL	N	Aceon	Solvay	\$32,409	650	0.2%	\$49.86
Total	<u> </u>			\$3,989,608	295,968	100.0%	\$13.48
ACE INHIBITORS/CCB COMBINATION	<b>VS</b>						
Share of FFS Rx's: 0.13%							
Per Member SFY05 YTD: \$3.54	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMLODIPINE	N N	Lotrel	Novartis/Pfizer		13,054	93.6%	\$77.44
				\$1,010,965			-
TRANDOLAPRIL	N	Tarka	Abbott	\$54,599	842	6.0%	\$64.84
ENALAPRILAT	Υ	Vaseretic	Biovail	\$3,103	57	0.4%	\$54.45
Total				\$1,068,667	13,953	100.0%	\$76.59
ACETAMINOPHEN PRODUCTS					T		·
Share of FFS Rx's: 0.35%	1						
Per Member SFY05 YTD: \$0.81	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
		Brand	Manufacturer				
ACETAMINOPHEN	Υ	Tylenol	McNeil	\$243,929	36,523	100.0%	\$6.68
AGENTS FOR ACNE							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$0.78	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CLINDAMYCIN	Y	Cleocin	Pharmacia	\$191,171	2,238	76.3%	\$85.42
AZELAIC ACID	N N	Azelex/Finacea	Allergen/Berlex	\$32,431	580	19.8%	\$55.92
SULFACETAMIDE	N	Klaron	Dermik	\$11,636	115	3.9%	\$101.18
Total	+	Ttiaion	DOMINIK	\$235,238	2,933	100.0%	\$80.20
Total	+			φ <b>2</b> 33,230	2,333	100.076	φου.20
	+						
AGENTS FOR ALS - RILUZOLE							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.67	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
RILUZOLE	N	Rilutek	Aventis	\$201,005	282	100.0%	\$712.78
1.1.2.0.2.2	· ·	T till dion	717071110	<b>\$20.,000</b>			<b>V</b>
ACENTO FOR ALTUEIMER DICEAGE	+						
AGENTS FOR ALZHEIMER DISEASE							
Share of FFS Rx's: 0.98%							
Per Member SFY05 YTD: \$40.70	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DONEPEZIL	N	Aricept	Eisai/Pfizer	\$6,683,038	52,584	51.4%	\$127.09
MEMANTINE	N	Namenda	Forest	\$2,473,119	25,787	25.2%	\$95.91
GALANTAMINE	N	Reminyl	Janssen	\$1,800,179	14,133	13.8%	\$127.37
RIVASTIGMINE	N	Exelon	Novartis	\$1,327,181	9,858	9.6%	\$134.63
TACRINE	N	Cognex	Parke-Davis	\$622	2	0.0%	\$311.00
Total				\$12,284,139	102,364	100.0%	\$120.00
AGENTS FOR ANAPHYLAXIS	1						
	+						
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$0.66	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
EPINEPHRINE	N	EpiPen	Dey	\$199,438	2,834	100.0%	\$70.37
AGENTS FOR ASTHMA - PREVENTIV	E						
Share of FFS Rx's: 1.65%	<del>-</del> -				-		
	1446:10	D	Manuelant	T-1-1 AA	T-1-1-	Mandant Ci	66 D
Per Member SFY05 YTD: \$63.88	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
FLUTICASONE	N	Flovent	GlaxoSmithKline	\$11,015,200	81,565	47.5%	\$135.05
MONTELUKAST	N	Singulair	Merck	\$4,233,902	50,231	29.2%	\$84.29
BUDESONIDE	N	Rhinocort	AstraZeneca	\$1,964,903	10,997	6.4%	\$178.68
SALMETEROL	N	Serevent	GlaxoSmithKline	\$717,684	7,894	4.6%	\$90.92
OMALIZUMAB TUE ORUMA LINE	N Y	Xolair	Genentech	\$504,541	278	0.2%	\$1,814.90 \$22.59
THEOPHYLLINE	· ·	Theo-Dur	Schering-Plough	\$297,766	13,183	7.7%	
7A FIDI LIKA OT	N	Accolate	AstraZeneca	\$199,800	2,830	1.6%	\$70.60
ZAFIRLUKAST		Nasalide	Ivax	\$112,248	1,367	0.8%	\$82.11
FLUNISOLIDE	Y		0-1				
FLUNISOLIDE FORMOTEROL	N	Foradil	Schering-Plough	\$80,588	953	0.6%	
FLUNISOLIDE FORMOTEROL BECLOMETHASONE	N N	Foradil Qvar Inhalation	IVAX	\$68,414	1,095	0.6%	\$62.48
FLUNISOLIDE FORMOTEROL BECLOMETHASONE CROMOLYN	N N Y	Foradil Qvar Inhalation Intal		\$68,414 \$52,836	1,095 1,229	0.6% 0.7%	\$62.48 \$42.99
FLUNISOLIDE FORMOTEROL BECLOMETHASONE CROMOLYN CAFFEINE	N N Y	Foradil Qvar Inhalation Intal Various	IVAX Monarch	\$68,414 \$52,836 \$27,699	1,095 1,229 38	0.6% 0.7% 0.0%	\$62.48 \$42.99 \$728.91
FLUNISOLIDE FORMOTEROL BECLOMETHASONE CROMOLYN CAFFEINE NEDOCROMIL	N N Y N	Foradil Qvar Inhalation Intal Various Tilade	IVAX Monarch Monarch	\$68,414 \$52,836 \$27,699 \$2,466	1,095 1,229 38 38	0.6% 0.7% 0.0% 0.0%	\$62.48 \$42.99 \$728.91 \$64.90
FLUNISOLIDE FORMOTEROL BECLOMETHASONE CROMOLYN CAFFEINE NEDOCROMIL DYPHYLLINE	N N Y N N	Foradil Qvar Inhalation Intal Various	IVAX Monarch	\$68,414 \$52,836 \$27,699 \$2,466 \$717	1,095 1,229 38 38 13	0.6% 0.7% 0.0% 0.0% 0.0%	\$62.48 \$42.99 \$728.91 \$64.90 \$55.15
FLUNISOLIDE FORMOTEROL BECLOMETHASONE CROMOLYN CAFFEINE NEDOCROMIL DYPHYLLINE AMINOPHYLLINE	N N Y N	Foradil Qvar Inhalation Intal Various Tilade	IVAX Monarch Monarch	\$68,414 \$52,836 \$27,699 \$2,466 \$717 \$435	1,095 1,229 38 38 13 56	0.6% 0.7% 0.0% 0.0% 0.0% 0.0%	\$84.56 \$62.48 \$42.99 \$728.91 \$64.90 \$55.15
FLUNISOLIDE FORMOTEROL BECLOMETHASONE CROMOLYN CAFFEINE NEDOCROMIL DYPHYLLINE	N N Y N N	Foradil Qvar Inhalation Intal Various Tilade	IVAX Monarch Monarch	\$68,414 \$52,836 \$27,699 \$2,466 \$717	1,095 1,229 38 38 13	0.6% 0.7% 0.0% 0.0% 0.0%	\$62.48 \$42.99 \$728.91 \$64.90 \$55.15

METAPROPERION   Y   Alignet   Soleringer   \$1,200   \$3.5   \$3.5   \$3.4	AGENTS FOR ASTHMA - RESCUE							
ALBUTEROL   Y   Processed   Scheming Pilotoph   Social 1,000   199, 344   36, 25   5317, 250   199, 344   36, 25   5317, 250   199, 344   36, 25   5317, 250   199, 344   36, 25   5317, 250   199, 344   36, 25   5317, 250   199, 344   36, 25   5317, 250   199, 344   36, 25   5317, 250   199, 344   36, 25   5317, 250   199, 344   36, 250   199, 341								
EVALUATION   No.		MAC'd?						
PRESIDENCY   N   November   N   November   N   November   N   November   N   N   November   N   N   N   N   N   N   N   N   N		Y						
TERBUTANE   Y   Somfrive   AAI Finama   \$37.718   672   0.256   \$30.000     Total   N   Santra of FFR (27. 0.276   0.256   0.256   0.256     SA, 229, 985   199, 271   100,076   \$3.4.21     Santra of FFR (27. 0.276   0.256   0.256   0.256   0.256   0.256     SA, 229, 985   199, 271   100,076   \$3.4.22     Santra of FFR (27. 0.276   0.256								
Section								\$30.83
AGENTS FOR BENIGN PROSTATIC HYPERROPHY  Share of FFR Rx*: 0.21%  AGENTS FOR CHF - ALPHA/BETA BLOCKES  Share of FFR Rx*: 0.25%  AGENTS FOR CHF - ALPHA/BETA BLOCKES  Share of FFR Rx*: 0.25%  Per Member SYYOS YTD: 8.46  MAC97  Brand  Manufacturer  N		Υ					0.2%	\$36.47
Share of FFR R's: 0.21%	Total				\$6,829,985	199,371	100.0%	\$34.26
Per Member SYTOS YTO: 58.86   NAC-97   Brand   Manufacturer   Total St   Total Rx   Market Share   St Per Rx		HYPERT	ROPHY					
TAMSLILOSIN   N								
PRINSTERIOR   N   Proposed   Merck   S202.410   3,908   1,23%   3,770.00   2,000   2								
DUTASTRICE								
S2,089,946   32,030   100,0%   S44,63								\$73.60
### AGENTS FOR CATAPLEXY ### Share of FFS fix's 0.00% ### Manufacturer ### Total \$5    Total Rx   Market Share   SP er Rx	ALFUZOSIN	N	Uroxatral	Sanofi-Synthelabo	\$93,940	2,037	6.4%	\$46.12
Share of FFS Rx's 0.00%	Total				\$2,069,946	32,030	100.0%	\$64.63
Per Member SP109 \text{TDI: \$0.01}								
AGENTS FOR CHF - ALPHA/BETA BLOCKERS   Share of FFS Rts: 0.29%   Per Member 5FV05 YTD: \$2.64   MACd2   Brand   Manufacturer   Total \$\$   Total Rt   Market Share   SFP Rt   STALE								
AGENTS FOR CHF - ALPHABETA BLOCKERS		MAC'd?	Brand	Manufacturer			Market Share	\$\$ Per Rx
Share of FFS RX's 0.25%	HYDROXYBUTERATE	N	Xyrem	Orphan	\$1,880	6	100.0%	\$313.33
Share of FFS RX's 0.25%	ACENTS FOR CUE ALBUA/DETA D	LOCKET						
Per Member SPY05 YTD: \$6.46		LOCKER	3					
CARVEDIOL   N   Coreg   GlaxoSmirkline   \$1,00.061   19,044   74,995   \$9,227   \$1,00.061   \$13,09.061   \$13,09.061   \$13,09.061   \$13,09.061   \$13,09.061   \$13,09.061   \$13,09.061   \$1,04.075   \$13,09.061   \$1,04.075		MACITO	Brand	Monufecture	Total or	Total Do	Market Char-	éé Bau Ba
AGENTS FOR CHRONIC INFLAMMATION OF COLON   Share of FFS Rx's: 0.02%   Mac'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$ Per Rx								
Total								* * *
Share of FFS Rx*s: 0.02%			, tolliodyllo	Concining 1 loagi.				\$73.58
Share of FFS Rx*s: 0.02%	ACENTS FOR CURONIC INC. AMMA	FION OF	COLON					
Per Member SFV05 YTD: \$2.64   MAC'd?   Brand   Manufacturer   Total \$\$ Total RX   Market Share   \$\$ \$PER RX		TION OF	COLON					
MESALAMINE         N         Assoc/Pentasa         PRG/Shire         \$739,157         4.391         93,7%         \$168,11           BALSALAZIDE         N         Colazal         Salik         \$44,843         201         4.3%         \$22,0%         \$155,00           OLSALAZINE         N         Dipentum         Celitech/Phr-Upin         \$14,266         92         2.0%         \$150,00           Total         N         Dipentum         Celitech/Phr-Upin         \$14,266         92         2.0%         \$150,00           AGENTS FOR COPD         Share of FFS Rx's: 0.12%         ST012%         ST012%         ST012%         Market Share         \$100,00%         \$170,21           Per Member SFY05 YTD: \$2.39         MAC'd7         Brand         Manufacturer         Total \$\$         Total Rx         Market Share         \$\$ Per Rx           PEATROPIUM         N         Spiriva         Boohringer         \$687,944         6.372         23.7%         \$\$100,00%         \$\$2.41           AGENTS FOR CYSTIC FIBROSIS         Share of FFS Rx's: 0.02%         \$1,407,801         26,840         100.0%         \$\$2.44           AGENTS FOR DIABETES - GLUCOSE         Brand         Manufacturer         Total \$\$         Market Share         \$\$ \$Per Rx		MVCi43	Brand	Manufacturor	Total \$\$	Total Pv	Market Share	\$\$ Dor Dy
BALSALAZIDE N Colazal Salik \$44,843 201 4.3% \$223.10 CLSALAZINE N Depentum Celltech/Phr-Upin \$1.266 62 2.0% \$150.05 Total \$797,266 4.684 100.0% \$710.2% \$797,266 4.684 100.0% \$710.2% \$797,266 4.684 100.0% \$710.2% \$797,266 4.684 100.0% \$710.2% \$797,266 4.684 100.0% \$710.2% \$710.2% \$797,266 4.684 100.0% \$710.2%								
Total						-		\$223.10
### AGENTS FOR COPD  ### Altrovent Boehringer \$719.857 20.468 76.3% \$35.17   ### Doehringer \$719.857 20.468 76.3% \$35.17   ### TOTAL N	OLSALAZINE	N	Dipentum	Celltech/Phr-Upjn	\$14,266	92	2.0%	\$155.06
Share of FFS Rx's: 0.12%	Total				\$797,266	4,684	100.0%	\$170.21
Share of FFS Rx's: 0.12%   MAC'd?   Brand   Manufacturer   Total \$\$ Total Rx   Market Share   \$\$ Per Rx   \$\$ Per Rx   \$\$ Total \$\$ Total \$\$ Total \$\$ \$\$ Per Rx   \$\$ Per Rx								
Per Member SFY05 YTD: \$2.39	ACENTS FOR COPD							
PRATEOPLIM   Y	AGENTS FOR COPD							
TOTROPIUM	Share of FFS Rx's: 0.12%							
Total	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	
AGENTS FOR CYSTIC FIBROSIS  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$2.96  MAC'd? Brand  Manufacturer  Total \$\$  Total Rx  Market Share \$\$ Per Rx  DORNASE ALFA  N Pulmozyme Genentech \$833,188 593 31.1% \$1,405.04 \$68.9% \$45.57  Total  \$\$893,109 1,908 100.0% \$468.05  AGETYLCYSTEINE Y Mucomyst Sandoz \$893,109 1,908 100.0% \$468.05  AGENTS FOR DIABETES - GLUCOSE ELEVATING AGENTS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98  MAC'd? Brand Manufacturer Manufacturer Manufacturer Manufacturer Manufacturer Total \$\$  Total Rx  Market Share \$\$ Per Rx  GLUCAGON N GlucaGen Bedford \$279,972 2,557 80.0% \$109.4% \$199.45  DIAZOXIDE Y Proglycem Ivax \$4,949 12 0.4% \$412.46  Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 MAC'd? Brand Manufacturer Manufacturer Manufacturer Manufacturer Total \$\$  Total \$\$  Total Rx  Market Share \$\$ Per Rx  \$4,949 12 0.4% \$412.46  Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 MAC'd? Brand Manufacturer Manufacturer Manufacturer Total \$\$  Total \$\$  Total \$\$  Total \$\$  Total \$\$  N Lantus Aventis \$3,072,569 39,412 24.7% \$77.99  INSULIN ISOPHANE NPH N Humulin Lilly \$30,09,598 61,508 38.5% \$48.93  INSULIN ISPRO, HUMAN REC.ANLOG N Novolin Novo Nordisk \$1,942,77 12.2% \$99.36  INSULIN ISPRO, HUMAN REC.ANLOG N Humulin Lilly \$654,757 22,673 14.2% \$99.36  INSULIN ISPRO, HUMAN REC.ANLOG N Humulin Lilly \$654,757 5,546 3.77  INSULIN ISPRO, HUMAN N Novolog Novo Nordisk \$788,598 7,417 4,6% \$106.32  INSULIN ISPRO (PIL) N Humulin Lilly \$13,507 5,546 3.77 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,542 5,543 5,546 5,546 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,746 5,747 5,	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM	Υ	Atrovent	Boehringer	\$719,857	20,468	76.3%	\$35.17
Share of FFS Rx's: 0.02%	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM	Υ	Atrovent	Boehringer	\$719,857 \$687,944	20,468 6,372	76.3% 23.7%	\$35.17 \$107.96
Per Member SFY05 YTD: \$2.96	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM	Υ	Atrovent	Boehringer	\$719,857 \$687,944	20,468 6,372	76.3% 23.7%	\$35.17
DORNASE ALFA	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total	Υ	Atrovent	Boehringer	\$719,857 \$687,944	20,468 6,372	76.3% 23.7%	\$35.17 \$107.96
ACETYLCYSTEINE   Y   Mucomyst   Sandoz   \$59,921   1,315   68.9%   \$45.57	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS	Υ	Atrovent	Boehringer	\$719,857 \$687,944	20,468 6,372	76.3% 23.7%	\$35.17 \$107.96
Total	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02%	Y	Atrovent Spiriva	Boehringer Boehringer	\$719,857 \$687,944 <b>\$1,407,801</b>	20,468 6,372 <b>26,840</b>	76.3% 23.7% 100.0%	\$35.17 \$107.96 \$52.45
AGENTS FOR DIABETES - GLUCOSE ELEVATING AGENTS   Share of FFS Rx's: 0.03%	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA	Y N MAC'd?	Atrovent Spiriva  Brand Pulmozyme	Boehringer Boehringer  Manufacturer Genentech	\$719,857 \$687,944 <b>\$1,407,801</b> Total <b>\$</b> \$833,188	20,468 6,372 <b>26,840</b> Total Rx 593	76.3% 23.7% 100.0% Market Share 31.1%	\$35.17 \$107.96 \$52.45 \$Per Rx \$1,405.04
Share of FFS Rx's: 0.03%	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE	Y N MAC'd?	Atrovent Spiriva  Brand Pulmozyme	Boehringer Boehringer  Manufacturer Genentech	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921	20,468 6,372 <b>26,840</b> Total Rx 593 1,315	76.3% 23.7% 100.0% Market Share 31.1% 68.9%	\$35.17 \$107.96 \$52.45 \$Per Rx \$1,405.04 \$45.57
Per Member SFY05 YTD: \$0.98   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$ Per Rx	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE	Y N MAC'd?	Atrovent Spiriva  Brand Pulmozyme	Boehringer Boehringer  Manufacturer Genentech	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921	20,468 6,372 <b>26,840</b> Total Rx 593 1,315	76.3% 23.7% 100.0% Market Share 31.1% 68.9%	\$35.17 \$107.96 \$52.45 \$Per Rx \$1,405.04 \$45.57
GLUCAGON   N   GlucaGen   Bedford   \$279,972   2,557   80.0%   \$109.4%     DEXTROSE   N	Share of FFS Rx's: 0.12%  Per Member SFY05 YTD: \$2.39  IPRATROPIUM  TIOTROPIUM  Total  AGENTS FOR CYSTIC FIBROSIS  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$2.96  DORNASE ALFA  ACETYLCYSTEINE  Total	MAC'd?	Atrovent Spiriva  Brand Pulmozyme Mucomyst	Boehringer Boehringer  Manufacturer Genentech	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921	20,468 6,372 <b>26,840</b> Total Rx 593 1,315	76.3% 23.7% 100.0% Market Share 31.1% 68.9%	\$35.17 \$107.96 \$52.45 \$Per Rx \$1,405.04 \$45.57
DEXTROSE	Share of FFS Rx's: 0.12%  Per Member SFY05 YTD: \$2.39  IPRATROPIUM  TIOTROPIUM  Total  AGENTS FOR CYSTIC FIBROSIS  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$2.96  DORNASE ALFA  ACETYLCYSTEINE  Total  AGENTS FOR DIABETES - GLUCOSI  Share of FFS Rx's: 0.03%	MAC'd? N Y EELEVA	Atrovent Spiriva  Brand Pulmozyme Mucomyst  TING AGENTS	Boehringer Boehringer  Manufacturer Genentech Sandoz	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109	20,468 6,372 26,840 Total Rx 593 1,315 1,908	76.3% 23.7% 100.0% Market Share 31.1% 68.9% 100.0%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09
DIAZOXIDE   Y   Proglycem   Ivax   \$4,949   12   0.4%   \$412.40	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98	MAC'd? N Y MAC'd? MAC'd?	Brand Pulmozyme Mucomyst  TING AGENTS Brand	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109	20,468 6,372 26,840 Total Rx 593 1,315 1,908	76.3% 23.7% 100.0% Market Share 31.1% 68.9% 100.0%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09
Total	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON	MAC'd? N Y  MAC'd? N Y  MAC'd? N	Brand Pulmozyme Mucomyst  TING AGENTS Brand	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$	20,468 6,372 26,840 Total Rx 593 1,315 1,908	76.3% 23.7% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$Per Rx \$109.49
AGENTS FOR DIABETES - INSULINS  Share of FFS Rx's: 1.53%  Per Member SFY05 YTD: \$35.73  MAC'd? Brand  Manufacturer  N Lantus  Aventis  \$3,072,569  39,412  24.7%  \$77.96  INSULIN ISOPHANE NPH  INSULIN LISPRO, HUMAN REC.ANLOG  N Novolin  Novo Nordisk  \$1,934,273  19,467  12.2%  \$99.38  INSULIN REGULAR  N Humulin  Lilly  \$854,757  22,673  14.2%  \$37.77  INSULIN ASPART  N NovoLog  Novo Nordisk  \$788,598  7,417  4.6%  \$106.32  INSULIN LISPRO (NPL)  N Humalog  Lilly  \$762,375  5,846  3.7%  \$130.41  INSULIN ASPART PROTAMINE HUMAN  N NovoLog  Novo Nordisk  \$31,931,213  1,427  1,426  \$10.30  1,427  1,426  1,427  1,427  1,426  1,426  1,427  1,426  1,426  1,427  1,426  1,427  1,426  1,427  1,426  1,427  1,426  1,427  1,426  1,426	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE	MAC'd? N Y  MAC'd? N Y  MAC'd? N N N	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629	76.3% 23.7% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$\$ Per Rx \$109.49 \$15.12
Share of FFS Rx's: 1.53%         MAC'd?         Brand         Manufacturer         Total \$\$         Total Rx         Market Share         \$Per Rx           INSULIN GLARGINE         N         Lantus         Aventis         \$3,072,569         39,412         24.7%         \$77.96           INSULIN ISOPHANE NPH         N         Humulin         Lilly         \$3,009,598         61,508         38.5%         \$48.93           INSULIN LISPRO, HUMAN REC.ANLOG         N         Novolin         Novo Nordisk         \$1,934,273         19,467         12.2%         \$99.37           INSULIN REGULAR         N         Humulin         Lilly         \$854,757         22,673         14.2%         \$37.70           INSULIN ASPART         N         Novo Log         Novo Nordisk         \$788,598         7,417         4.6%         \$106.32           INSULIN LISPRO (NPL)         N         Humallog         Lilly         \$762,375         5,846         3.7%         \$130.4*           INSULIN ASPART PROTAMINE HUMAN         N         NovoLog         Novo Nordisk         \$316,112         2,421         1.5%         \$130.4*           INSULIN ZINC         N         Humulin         Lilly         \$30,735         706         0.4%         \$43.5*	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE	MAC'd? N Y  MAC'd? N Y  MAC'd? N N N	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629	76.3% 23.7% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$\$ Per Rx \$109.49 \$15.12 \$412.40
Per Member SFY05 YTD: \$35.73         MAC'd?         Brand         Manufacturer         Total \$\$         Total Rx         Market Share         \$\$ Per Rx           INSULIN GLARGINE         N         Lantus         Aventis         \$3,072,569         39,412         24.7%         \$77.96           INSULIN ISOPHANE NPH         N         Humulin         Lilly         \$3,009,598         61,508         38.5%         \$48.93           INSULIN LISPRO, HUMAN REC.ANLOG         N         Novolin         Novo Nordisk         \$1,934,273         19,467         12.2%         \$99.36           INSULIN REGULAR         N         Humulin         Lilly         \$854,757         22,673         14.2%         \$37.70           INSULIN ASPART         N         NovoLog         Novo Nordisk         \$788,598         7,417         4.6%         \$106.32           INSULIN LISPRO (NPL)         N         Humalog         Lilly         \$762,375         5,846         3.7%         \$130.41           INSULIN ASPART PROTAMINE HUMAN         N         NovoLog         Novo Nordisk         \$316,112         2,421         1.5%           INSULIN ZINC         N         Humulin         Lilly         \$30,735         706         0.4%         \$43.55           INSULIN ZIN	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE	MAC'd? N Y  MAC'd? N Y  MAC'd? N N N	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629	76.3% 23.7% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$\$ Per Rx \$109.49 \$15.12 \$412.40
NSULIN GLARGINE   N   Lantus   Aventis   \$3,072,569   39,412   24.7%   \$77.96	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total	MAC'd? N Y  MAC'd? N Y  MAC'd? N Y  MAC'd? N N Y	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629	76.3% 23.7% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$\$ Per Rx \$109.49 \$15.12
NSULIN ISOPHANE NPH   N   Humulin   Lilly   \$3,009,598   61,508   38.5%   \$48.93	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total  AGENTS FOR DIABETES - INSULINS	MAC'd? N Y  MAC'd? N Y  MAC'd? N Y  MAC'd? N N Y	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629	76.3% 23.7% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$\$ Per Rx \$109.49 \$15.12 \$412.40
NSULIN LISPRO,HUMAN REC.ANLOG   N Novolin Novo Nordisk   \$1,934,273   19,467   12.2%   \$99.36	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73	MAC'd?  MAC'd?  MAC'd?	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen  Proglycem  Brand	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share	\$35.17 \$107.96 \$52.45 \$52.45 \$1,405.04 \$45.57 \$468.09 \$15.12 \$412.40 \$92.07
NSULIN REGULAR	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE	MAC'd? N  MAC'd? N  MAC'd? N  MAC'd? N  MAC'd?	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen  Proglycem  Brand Lantus	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Aventis	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7%	\$35.17 \$107.96 \$52.45 \$\$Per Rx \$1,405.04 \$45.57 \$468.09 \$\$Per Rx \$109.49 \$15.12 \$412.40 \$92.07
NSULIN ASPART   N NovoLog Novo Nordisk   \$788,598   7,417   4.6%   \$106.32	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM TOTAI  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE TOTAI  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE TOTAI  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE INSULIN ISOPHANE NPH	MAC'd? N Y  MAC'd? N Y  MAC'd? N N Y  MAC'd? N N N N N	Atrovent Spiriva  Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen  Proglycem  Brand Lantus Humulin	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Aventis Lilly	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$ \$3,072,569 \$3,009,598	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx 39,412 61,508	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7% 38.5%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$\$ Per Rx \$109.49 \$15.12 \$412.40 \$92.07
INSULIN LISPRO (NPL)         N         Humalog         Lilly         \$762,375         5,846         3.7%         \$130.41           INSULIN ASPART PROTAMINE HUMAN         N         NovoLog         Novo Nordisk         \$316,112         2,421         1.5%         \$130.57           INSULIN ZINC         N         Humulin L         Lilly         \$30,735         706         0.4%         \$43.53           INSULIN ZINC EXTENDED         N         Humulin U         Lilly         \$13,591         323         0.2%         \$42.08	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM TOTAI  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE TOTAI  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE TOTAI  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE INSULIN ISOPHANE NPH INSULIN ISOPHANE NPH INSULIN LISPRO,HUMAN REC.ANLOG	MAC'd? N Y  MAC'd? N Y  MAC'd? N N N N N N N N N N N N	Brand GlucaGen Proglycem  Brand	Boehringer Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Aventis Lilly Novo Nordisk	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$ \$3,072,569 \$3,009,598 \$1,934,273	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx 39,412 61,508 19,467	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7% 38.5% 12.2%	\$35.17 \$107.96 \$52.45 \$52.45 \$1,405.04 \$45.57 \$468.09 \$15.12 \$412.40 \$92.07 \$Per Rx \$77.96 \$48.93 \$99.36
INSULIN ASPART PROTAMINE HUMAN   N   NovoLog   Novo Nordisk   \$316,112   2,421   1.5%   \$130.57   \$185ULIN ZINC   N   Humulin L   Lilly   \$30,735   706   0.4%   \$43.53   \$185ULIN ZINC EXTENDED   N   Humulin U   Lilly   \$13,591   323   0.2%   \$42.08   \$42.08   \$42.08   \$42.08   \$43.53   \$4	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE INSULIN ILSPRO,HUMAN REC.ANLOG INSULIN REGULAR	MAC'd? N Y  MAC'd? N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen  Proglycem  Brand Lantus Humulin Novolin Humulin	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Aventis Lilly Novo Nordisk Lilly	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$ \$3,072,569 \$3,009,598 \$1,934,273 \$884,757	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx 39,412 61,508	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7% 38.5% 12.2% 14.2%	\$35.17 \$107.96 \$52.45 \$52.45 \$1,405.04 \$45.57 \$468.09 \$15.12 \$412.40 \$92.07 \$\$ Per Rx \$77.96 \$48.93 \$99.36 \$37.70
INSULIN ZINC         N         Humulin L         Lilly         \$30,735         706         0.4%         \$43.53           INSULIN ZINC EXTENDED         N         Humulin U         Lilly         \$13,591         323         0.2%         \$42.08	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM TOTAI  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE INSULIN ISOPHANE NPH INSULIN ISOPHANE NPH INSULIN REGULAR INSULIN REGULAR	MAC'd? N Y  MAC'd? N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Proglycem  Brand Brand GlucaGen  Proglycem  Brand Humulin Novolin Humulin NovoLog	Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Aventis Lilly Novo Nordisk Lilly Novo Nordisk	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$ \$3,072,569 \$3,009,598 \$1,934,273 \$854,757 \$788,598	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx 39,412 61,508 19,467 22,673 7,417	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7% 38.5% 12.2% 14.2% 4.6%	\$35.17 \$107.96 \$52.45 \$\$2.45 \$\$Per Rx \$1,405.04 \$45.57 \$468.09 \$15.12 \$412.40 \$92.07 \$\$Per Rx \$77.96 \$48.93 \$93.06 \$37.70 \$106.32
	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM TOTAI  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE TOTAI  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE TOTAI  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE INSULIN ISOPHANE NPH INSULIN ISOPHANE NPH INSULIN LISPRO, (NPL)	MAC'd? N Y  MAC'd? N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand GlucaGen Proglycem Brand Lantus Humulin Novolin Humulin NovoLog Humalog	Boehringer Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Betford  Lily Novo Nordisk Lilly Novo Nordisk Lilly Novo Nordisk Lilly	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$ \$3,072,569 \$3,009,598 \$1,934,273 \$854,757 \$788,598 \$762,375	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx 39,412 61,508 19,467 22,673 7,417 5,846	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7% 38.5% 12.2% 14.2% 4.6% 3.7%	\$35.17 \$107.96 \$52.45 \$52.45 \$1,405.04 \$45.57 \$468.09 \$15.12 \$412.40 \$92.07 \$Per Rx \$77.96 \$48.93 \$99.36 \$37.70 \$106.32 \$130.41 \$130.57
Total \$10,782,607 159,773 100.0% \$67.49	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE INSULIN ISOPHANE NPH INSULIN LISPRO, HUMAN REC.ANLOG INSULIN ASPART INSULIN LISPRO (NPL) INSULIN ASPART PROTAMINE HUMAN INSULIN ZINC	MAC'd? N Y  MAC'd? N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen  Proglycem  Brand Lantus Humulin Novolin Humulin NovoLog Humalog NovoLog Humulin L	Boehringer Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Aventis Lilly Novo Nordisk Lilly	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$ \$3,072,569 \$3,072,569 \$3,095,998 \$1,934,273 \$854,757 \$788,598 \$762,375 \$316,112 \$30,735	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx 39,412 61,508 19,467 22,673 7,417 5,846 2,421 706	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7% 38.5% 12.2% 14.2% 4.6% 3.7% 1.5% 0.4%	\$35.17 \$107.96 \$52.45 \$52.45 \$1,405.04 \$45.57 \$468.09 \$15.12 \$412.40 \$92.07 \$\$ Per Rx \$77.96 \$48.93 \$99.36 \$37.70 \$106.32 \$130.41 \$130.57 \$43.53
	Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$2.39 IPRATROPIUM TIOTROPIUM Total  AGENTS FOR CYSTIC FIBROSIS Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.96 DORNASE ALFA ACETYLCYSTEINE Total  AGENTS FOR DIABETES - GLUCOSI Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.98 GLUCAGON DEXTROSE DIAZOXIDE Total  AGENTS FOR DIABETES - INSULINS Share of FFS Rx's: 1.53% Per Member SFY05 YTD: \$35.73 INSULIN GLARGINE INSULIN ISOPHANE NPH INSULIN LISPRO, HUMAN REC.ANLOG INSULIN ASPART INSULIN LISPRO (INPL) INSULIN ZINC EXTENDED	MAC'd? N Y  MAC'd? N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Pulmozyme Mucomyst  TING AGENTS  Brand GlucaGen  Proglycem  Brand Lantus Humulin Novolin Humulin NovoLog Humalog NovoLog Humulin L	Boehringer Boehringer Boehringer  Manufacturer Genentech Sandoz  Manufacturer Bedford  Ivax  Manufacturer Aventis Lilly Novo Nordisk Lilly	\$719,857 \$687,944 \$1,407,801 Total \$\$ \$833,188 \$59,921 \$893,109 Total \$\$ \$279,972 \$9,511 \$4,949 \$294,432 Total \$\$ \$3,072,569 \$3,009,598 \$1,934,273 \$854,757 \$788,598 \$762,375 \$316,112 \$30,735 \$113,591	20,468 6,372 26,840 Total Rx 593 1,315 1,908 Total Rx 2,557 629 12 3,198 Total Rx 39,412 61,508 19,467 22,673 7,417 5,846 2,421 706 323	76.3% 23.7% 100.0% 100.0%  Market Share 31.1% 68.9% 100.0%  Market Share 80.0% 19.7% 0.4% 100.0%  Market Share 24.7% 38.5% 12.2% 14.2% 4.6% 3.7% 1.5% 0.4% 0.2%	\$35.17 \$107.96 \$52.45 \$\$ Per Rx \$1,405.04 \$45.57 \$468.09 \$\$ Per Rx \$109.49 \$15.12 \$412.40 \$92.07 \$\$ Per Rx \$77.96 \$48.93 \$99.36 \$37.70 \$106.32 \$130.41 \$130.57 \$48.93

AGENTS FOR DIABETES - ORAL		+					
Share of FFS Rx's: 2.73%	MACIAO	Draw d	Manufacturar	Total ff	Tetal Dv	Market Share	ff Des Dy
PIOGLITAZONE	MAC'd?	Brand Actos	Manufacturer Takeda	Total \$\$ \$4,329,049	Total Rx 30,517	Market Snare	\$\$ Per Rx \$141.86
ROSIGLITAZONE	N	Avandia	GlaxoSmithKline	\$3,936,711	34,176	12.0%	\$115.19
METFORMIN	Υ	Glucophage	BMS	\$1,279,699	88,854	31.3%	\$14.40
GLYBURIDE	Υ	Micronase/Glynase		\$966,201	48,042	16.9%	\$20.11
GLIPIZIDE	Υ	Glucotrol	Pfizer	\$945,670	55,013	19.4%	\$17.19
GLIMEPIRIDE	N	Amaryl	Aventis	\$688,175	19,917	7.0%	\$34.55
REPAGLINIDE	N	Prandin	Novo Nordisk	\$314,917	3,244	1.1%	\$97.08
NATEGLINIDE ACARBOSE	N N	Starlix Precose	Novartis Bayer	\$216,608 \$94,698	2,448 1,385	0.9% 0.5%	\$88.48 \$68.37
MIGLITOL	N	Glyset	Pharm & Upjohn	\$22.509	346	0.1%	\$65.06
TOLAZAMIDE	Y	Tolinase	Pharmacia	\$2,307	114	0.0%	\$20.24
CHLORPROPAMIDE	Y	Diabinese	Pfizer	\$1,846	141	0.0%	\$13.09
TOLBUTAMIDE	Y	Orinase	Pfizer	\$1,036	73	0.0%	\$14.19
ACETOHEXAMIDE	N	Dymelor	Lilly	\$23	2	0.0%	\$11.48
Total		-		\$12,799,449	284,272	100.0%	\$45.03
AGENTS FOR GALL STONES							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$0.77	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
URSODIOL	Y	Actigall	Watson	\$233,668	2,869	100.0%	\$81.45
AGENTS FOR GLAUCOMA							
Share of FFS Rx's: 0.68%							
Per Member SFY05 YTD: \$11.72	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LATANOPROST	N N	Xalatan	Pharm & Upjohn	\$1,179,208	21,809	30.7%	\$\$ Per RX \$54.07
TIMOLOL	Y	Timoptic	Merck	\$1,179,208	16,549	23.3%	\$36.38
BRIMONIDINE	Y	Alphagan	Allergan	\$575.868	10,549	14.8%	\$54.79
TRAVOPROST	N	Travatan	Alcon	\$411,167	6,899	9.7%	\$59.60
BIMATOPROST	N	Lumigan	Allergan	\$357,633	4,428	6.2%	\$80.77
BETAXOLOL	N	Travatan	Alcon	\$176,819	3,481	4.9%	\$50.80
DORZOLAMIDE	N	Cosopt/Trusopt	Merck	\$99,786	2,472	3.5%	\$40.37
BRINZOLAMIDE	N	Azopt	Alcon	\$73,624	1,440	2.0%	\$51.13
PILOCARPINE	N	Salagen	MGI	\$26,914	1,873	2.6%	\$14.37
APRACLONIDINE	N	Lopidine	Alcon	\$14,674	166	0.2%	\$88.40
LEVOBUNOLOL	Υ	Betagan	Allergan	\$8,547	975	1.4%	\$8.77
CARTEOLOL	Υ	Ocupress	Novartis	\$6,687	373	0.5%	\$17.93
ECHOTHIOPHATE	N	Phospholine	Wyeth	\$2,379	43	0.1%	\$55.33
METIPRANOLOL	N	Various		\$1,585	89	0.1%	\$17.81
CARBACHOL	N	Isopto Carbachol	Alcon	\$1,498	40	0.1%	\$37.46
UNOPROSTONE	N	Rescula	Novartis	\$284	6	0.0%	\$47.36
Total				\$3,538,793	71,154	100.0%	\$49.73
AGENTS FOR GOUT							
Share of FFS Rx's: 0.41%							
Per Member SFY05 YTD: \$1.10	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ALLOPURINOL	Y	Zvloprim	Prometheus	\$215,221	32,971	78.1%	\$6.53
COLCHICINE	N	Colchicine	Watson	\$89,455	8,290	19.6%	\$10.79
PROBENECID	Υ	Benemid	Merck	\$25,772	956	2.3%	\$26.96
SULFINPYRAZONE	Υ	Anturane	Novartis	\$203	10	0.0%	\$20.28
Total				\$330,651	42,227	100.0%	\$7.83
AGENTS FOR HEPATITIS							
Share of FFS Rx's: 0.02%							
Per Member SFY05 YTD: \$7.38	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PEGINTERFERON ALFA-2A	N	Pegasys	Roche	\$820,552	517	23.3%	\$1,587.14
RIBAVIRIN	Y	Rebetol/Rebetron	Schering	\$586,740	736	33.2%	\$797.20
PEGINTERFERON ALFA-2B	N	PEG-Intron	Schering	\$571,719	437	19.7%	\$1,308.28
INTERFERON ALFACON-1	N	Infergen	Intermune	\$115,105	62	2.8%	\$1,856.53
ADEFOVIR	N	Hepsera	Gilead	\$94,216	212	9.6%	\$444.41
LAMIVUDINE	N	Epivir	GlaxoSmithKline	\$39,711	254	11.5%	\$156.34
Total				\$2,228,043	2,218	100.0%	\$1,004.53
AGENTS FOR HYPERTHYROIDISM							
Share of FFS Rx's: 0.04%				Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Per Member SFY05 YTD: \$0.21	MAC'd?	Brand	Manufacturer				-
	Υ	Tapazole	Monarch	\$55,572	2,851	77.5%	\$19.49
METHIMAZOLE	1/		Various	\$8,818	828	22.5%	\$10.65
PROPYLTHIOURACIL	Υ			\$64,390	3,679	100.0%	\$17.50
-	Y			φ04,330	3,079	100.0%	
PROPYLTHIOURACIL	Y			<b>Ф</b> 04,330	3,079	100.0%	
PROPYLTHIOURACIL Total	Υ			ф0 <del>4</del> ,390	3,079	100.0%	•
PROPYLTHIOURACIL Total AGENTS FOR IMPOTENCY	MAC'd?	Brand	Manufacturer	\$64,330 Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PROPYLTHIOURACIL Total  AGENTS FOR IMPOTENCY Share of FFS Rx's: 0.00%		Brand Elmiron	Manufacturer Ortho-McNeil		,		

Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.44	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PENTOSAN POLYSULFATE SODIUM	N	Elmiron	Ortho-McNeil	\$133,562	605	100.0%	\$220.76
AGENTS FOR LEPROSY							
Share of FFS Rx's: 0.01%	*** 61.10						**
Per Member SFY05 YTD: \$0.96 THALIDOMIDE	MAC'd?	Brand Thalomid	Manufacturer Celgene	Total \$\$ \$282,073	Total Rx 133	Market Share 11.9%	\$\$ Per Rx \$2,120.85
DAPSONE	N	Dapsone	Jacobus	\$8,555	986	87.9%	\$8.68
CLOFAZIMINE	N	Clofozine	AstraZeneca	\$36	3	0.3%	\$12.12
Total				\$290,664	1,122	100.0%	\$259.06
AGENTS FOR MIGRAINE - NON TRIP	TANS						
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.19	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DIHYDROERGOTAMINE	N N	Cafergot Midrin	Novartis Women First	\$41,379 \$8,582	245 543	25.6% 56.7%	\$168.89 \$15.81
ISOMETHEPTENE ERGOTAMINE	N	Ergostat	Pfizer	\$8,582 \$8,138	170	17.7%	\$15.81
Total		Ligodiai	T HZGI	\$58,099	958	100.0%	\$60.65
							•
AGENTS FOR MIGRAINE - TRIPTANS							
Share of FFS Rx's: 0.18%							
Per Member SFY05 YTD: \$11.54	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SUMATRIPTAN	N	Imitrex	GlaxoSmithKiline	\$2,434,115	12,380	66.1%	\$196.62
RIZATRIPTAN	N	Maxalt MLT	Merck	\$257,175	1,580	8.4%	\$162.77
NARATRIPTAN	N	Amerge	GlaxoSmithKiline	\$233,950	1,195	6.4%	\$195.77
ALMOTRIPTAN	N	Axert	Ortho-McNeil	\$218,343	1,469	7.8%	\$148.63
ZOLMITRIPTAN	N	Zomig	AstraZeneca	\$174,164	955	5.1%	\$182.37
ELETRIPTAN	N	Relpax	Pfizer	\$129,265	957	5.1%	\$135.07
FROVATRIPTAN	N	Frova	Elan	\$35,660	196	1.0%	\$181.94
Total				\$3,482,672	18,732	100.0%	\$185.92
AGENTS FOR MULTIPLE SCLEROSIS Share of FFS Rx's: 0.06%							
Per Member SFY05 YTD: \$23.92 INTERFERON BETA-1A	MAC'd? N	Brand Avonex/Rebif	Manufacturer Biogen/Pfizer	Total \$\$ \$3,371,991	Total Rx 2,899	Market Share 48.0%	\$\$ Per Rx \$1,163.16
GLATIRAMER	N	Copaxone	Teva	\$2,649,266	2,203	36.5%	\$1,202.57
INTERFERON BETA-1B	N	Betaseron	Berlex	\$1,199,676	937	15.5%	\$1,280.34
Total				\$7,220,934	6,039	100.0%	\$1,195.72
AGENTS FOR OSTEOPOROSIS							
Share of FFS Rx's: 1.09%	MAC'd?	Brand	Manufacturer	Tatal 66	Total Dv	Market Chara	ff Day Dy
Per Member SFY05 YTD: \$28.13 ALENDRONIC ACID	N N	Fosamax	Manufacturer Merck	Total \$\$ \$3,392,622	Total Rx 48,747	Market Share 42.7%	\$\$ Per Rx \$69.60
RISEDRONIC ACID	N	Actonel	Proctor & Gamble	\$2,290,424	34,157	30.0%	\$67.06
CALCITONIN	N	Miacalcin	Novartis	\$1,481,905	17,979	15.8%	\$82.42
RALOXIFENE	N	Evista	Lilly	\$552,188	7,204	6.3%	\$76.65
TERIPARATIDE	N	Forteo	Lilly	\$439,691	775	0.7%	\$567.34
CALCITRIOL ZOLEDRONIC ACID	N N	Rocaltrol Aredia	Roche Novartis	\$280,974 \$20,818	5,011 24	4.4% 0.0%	\$56.07 \$867.44
ETIDRONIC ACID	N	Didronel	Proctor & Gamble	\$15,841	111	0.1%	\$142.71
PAMIDRONIC ACID	N	Zometa	Novartis	\$14,724	23	0.0%	\$640.17
IBANDRONIC ACID				\$654	9	0.0%	\$72.62
Total				\$8,489,841	114,040	100.0%	\$74.45
ACENTS FOR RABINISONIS							
AGENTS FOR PARKINSON'S							
Share of FFS Rx's: 1.17%	MACINO	Brand	Manufacture	T-4-1 **	Total Dir	Mauket Oli	ee Dan Dir
Per Member SFY05 YTD: \$12.59 LEVODOPA	MAC'd?	Brand Sinemet	Manufacturer BMS	Total \$\$	Total Rx 30,589	Market Share 25.0%	\$\$ Per Rx \$43.96
PRAMIPEXOLE	N N	Mirapex	Pharm & Upiohn	\$1,344,823 \$874.670	30,589 8,804	25.0% 7.2%	\$43.96 \$99.35
BENZTROPINE	Y	Cogentin	Merck	\$480,577	50,750	41.5%	\$9.47
ROPINIROLE	N	Requip	GlaxoSmithKline	\$323,524	2,378	1.9%	\$136.05
ENTACAPONE	N	Comtan	Novartis	\$216,553	1,325	1.1%	\$163.44
AMANTADINE TRILLEYARDI ENIDAL	Y	Symmetrel	Endo	\$191,149	11,968	9.8%	\$15.97
TRIHEXYPHENIDYL PERGOLIDE	Y	Artane Permax	Lederle Valeant	\$143,667 \$117,601	12,576 830	10.3% 0.7%	\$11.42 \$141.69
PROCYCLIDINE PROCYCLIDINE	N	Kemadrin	Monarch	\$66,286	1,505	1.2%	\$44.04
SELEGILINE	Y	Eldepryl	Somerset	\$11,976	781	0.6%	\$15.33
BIPERIDEN	N	Akineton	Par	\$11,405	377	0.3%	\$30.25
CARBIDOPA	N	Stalevo	Novartis	\$9,328	249	0.2%	\$37.46
TOLCAPONE Total	N	Tasmar	Roche	\$7,088 <b>\$3,798,645</b>	34 <b>122,166</b>	0.0% <b>100.0%</b>	\$208.46 <b>\$31.0</b> 9
AGENTS FOR PCP					,		
AULITIOIONIOI	1						
Share of FFS Rx's: 0.00%							
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.31	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
	MAC'd? N	Brand Mepron/Malarone NeuTrexin		Total \$\$ \$85,286 \$6,033	Total Rx	Market Share 81.8% 0.7%	\$\$ Per Rx \$728.94 \$6,033.48

DENTAMBLE INSTITUTONATE	N	Danton 200 Inicati	- Tuiiseus	£4.000	25	17.5%	<b>₹70 F0</b>
PENTAMIDINE ISETHIONATE  Total	IN	Pentam 300 Injection	on Fujisawa	\$1,838 <b>\$93,158</b>	25 <b>143</b>	100.0%	\$73.53 <b>\$651.45</b>
1044				ψου, ιου	1-10	100.070	ψ001.40
AGENTS FOR PSORIASIS							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$2.03	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CALCIPOTRIENE	N N	Dovonex	Warner Chilcott	\$297,977	1,794	62.4%	\$166.10
ACITRETIN	N	Soriatane	Roche	\$166,539	361	12.6%	\$461.33
TAZAROTENE	N	Tazorac	Allergan	\$71,095	623	21.7%	\$114.12
EFALIZUMAB	N	Raptiva	Genentech	\$51,431	41	1.4%	\$1,254.42
ALEFACEPT	N	Amevive	Biogen Idec	\$13,856	4		
METHOXSALEN	N	Oxsoralen	ICN	\$10,234	39	1.4%	\$262.41
ANTHRALIN	N	Psoriatec	Sirius	\$679	12	0.4%	\$56.57
Total				\$611,812	2,874	100.0%	\$212.88
AGENTS FOR PULMONARY HYPER	TENSION						
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$3.56	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
BOSENTAN	N	Tracleer	Actelion	\$655,510	244	73.1%	\$2,686.52
TREPROSTINIL	N	Remodulin	United Therapeutics	\$303,055	43	12.9%	\$7,047.80
EPOPROSTENOL .	N	Flolan	GlaxoSmithKline	\$115,502	47	14.1%	\$2,457.50
Total				\$1,074,068	334	100.0%	\$3,215.77
AGENTS FOR RA AND CROHN'S - IN	IFLIXIMA	В					
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.01	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
INFLIXIMAB	N	Remicade	Centocor	\$4,518	13	100.0%	\$347.54
AGENTS FOR RHEUMATOID ARTHR	ITIS						<del></del>
Share of FFS Rx's: 0.05%							
Per Member SFY05 YTD: \$17.20	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ETANERCEPT	N	Enbrel	Amgen	\$2,719,786	2,170	42.7%	\$1,253.36
ADALIMUMAB	N	Humira Injection	Abbott	\$1,820,332	1,273	25.0%	\$1,429.95
LEFLUNOMIDE	N	Arava	Aventis	\$531,926	1,400	27.5%	\$379.95
ANAKINRA	N	Kineret	Amgen	\$98,960	109	2.1%	\$907.89
AURANOFIN	N	Ridaura	Yamanouchi	\$13,410	72	1.4%	\$186.25
PENICILLAMINE	N	DI .	0: 1	\$5,719	49	2.00/	<b>*</b> 40.00
METHOTREXATE	Υ	Rheumatrex	Stada	\$168	14	0.3%	\$12.00
Total				\$5,190,301	5,087	100.0%	\$1,020.31
AGENTS FOR RSV - PALIVISUMAB							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$13.14	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PALIVIZUMAB	N	Synagis	MedImmune	\$3,966,564	2,879	100.0%	\$1,377.76
İ							
AGENTS FOR SMOKING CESSATION	V						
	V						
Share of FFS Rx's: 0.09%		Brand	Manufacturer	Total \$\$	Total Ry	Market Share	\$\$ Per Ry
Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$4.12	MAC'd?	Brand Nicoderm	Manufacturer GlaxoSmithKline	Total \$\$ \$1,130,063	Total Rx	Market Share	\$\$ Per Rx \$137.44
Share of FFS Rx's: 0.09%		Brand Nicoderm Zyban	Manufacturer GlaxoSmithKline GlaxoSmithKline	\$1,130,063	8,222	Market Share 87.4% 12.6%	\$137.44
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE	MAC'd?	Nicoderm	GlaxoSmithKline			87.4%	
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE  BUPROPION	MAC'd?	Nicoderm	GlaxoSmithKline	\$1,130,063 \$112,220	8,222 1,184	87.4% 12.6%	\$137.44 \$94.78
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE  BUPROPION  Total	MAC'd? N Y	Nicoderm Zyban	GlaxoSmithKline	\$1,130,063 \$112,220	8,222 1,184	87.4% 12.6%	\$137.44 \$94.78
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T	MAC'd? N Y	Nicoderm Zyban	GlaxoSmithKline	\$1,130,063 \$112,220	8,222 1,184	87.4% 12.6%	\$137.44 \$94.78
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T  Share of FFS Rx's: 0.00%	MAC'd? N Y	Nicoderm Zyban	GlaxoSmithKline GlaxoSmithKline	\$1,130,063 \$112,220 <b>\$1,242,282</b>	8,222 1,184 <b>9,406</b>	87.4% 12.6% <b>100.0%</b>	\$137.44 \$94.78 <b>\$132.07</b>
Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.40	MAC'd? N Y TREATME	Nicoderm Zyban ENT Brand	GlaxoSmithKline GlaxoSmithKline  Manufacturer	\$1,130,063 \$112,220 <b>\$1,242,282</b> Total \$\$	8,222 1,184 <b>9,406</b> Total Rx	87.4% 12.6% 100.0% Market Share	\$137.44 \$94.78 <b>\$132.07</b> \$\$ Per Rx
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T  Share of FFS Rx's: 0.00%	MAC'd? N Y	Nicoderm Zyban	GlaxoSmithKline GlaxoSmithKline	\$1,130,063 \$112,220 <b>\$1,242,282</b>	8,222 1,184 <b>9,406</b>	87.4% 12.6% <b>100.0%</b>	\$137.44 \$94.78 <b>\$132.07</b>
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE  BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER	MAC'd? N Y  FREATME MAC'd? N	Nicoderm Zyban  ENT  Brand Prevpac	GlaxoSmithKline GlaxoSmithKline  Manufacturer	\$1,130,063 \$112,220 <b>\$1,242,282</b> Total \$\$	8,222 1,184 <b>9,406</b> Total Rx	87.4% 12.6% 100.0% Market Share	\$137.44 \$94.78 <b>\$132.07</b> \$\$ Per Rx
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT	MAC'd? N Y  FREATME MAC'd? N	Nicoderm Zyban  ENT  Brand Prevpac	GlaxoSmithKline GlaxoSmithKline  Manufacturer	\$1,130,063 \$112,220 <b>\$1,242,282</b> Total \$\$	8,222 1,184 <b>9,406</b> Total Rx	87.4% 12.6% 100.0% Market Share	\$137.44 \$94.78 <b>\$132.07</b> \$\$ Per Rx
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS	GlaxoSmithKline GlaxoSmithKline  Manufacturer  Tap	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549	8,222 1,184 9,406 Total Rx 463	87.4% 12.6% 100.0% Market Share 100.0%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE  BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT  Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78	MAC'd? N Y  FREATME MAC'd? N	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand	GlaxoSmithKline GlaxoSmithKline  Manufacturer  Tap  Manufacturer	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549	8,222 1,184 9,406 Total Rx 463	87.4% 12.6% 100.0% Market Share 100.0%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT  Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78  RANITIDINE	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac	GlaxoSmithKline GlaxoSmithKline  Manufacturer Tap  Manufacturer GlaxoSmithKline	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669	8,222 1,184 9,406 Total Rx 463	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78  RANITIDINE FAMOTIDINE	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid	Manufacturer Tap Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid	Manufacturer GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Merck  Reliant	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0% 1.2%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79 \$48.02
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid	Manufacturer Tap Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0% 1.2% 2.9%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79 \$48.02 \$8.87
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid	Manufacturer GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Merck  Reliant	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0% 1.2%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79 \$48.02
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT  Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78  RANITIDINE FAMOTIDINE CIMETIDINE  Total	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid	Manufacturer GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Merck  Reliant	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0% 1.2% 2.9%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79 \$48.02 \$8.87
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78  RANITIDINE FAMOTIDINE FAMOTIDINE CIMETIDINE TOTAL  AGENTS FOR ULCERS - OTHER	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid	Manufacturer GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Merck  Reliant	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0% 1.2% 2.9%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79 \$48.02 \$8.87
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT  Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78  RANITIDINE FAMOTIDINE CIMETIDINE  Total	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid	Manufacturer GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Merck  Reliant	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0% 1.2% 2.9%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79 \$48.02 \$8.87
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12  NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40  ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78  RANITIDINE FAMOTIDINE FAMOTIDINE CIMETIDINE TOTAL  AGENTS FOR ULCERS - OTHER	MAC'd? N Y  FREATME MAC'd? N  TOR ANTA	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid	Manufacturer GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Manufacturer  GlaxoSmithKline  Merck  Reliant	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671	87.4% 12.6% 100.0% Market Share 100.0% Market Share 77.9% 18.0% 1.2% 2.9%	\$137.44 \$94.78 \$132.07 \$\$ Per Rx \$260.37 \$\$ Per Rx \$14.15 \$10.79 \$48.02 \$8.87
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE Total  AGENTS FOR ULCERS - OTHER Share of FFS Rx's: 0.07%  Per Member SFY05 YTD: \$0.79 SUCRALFATE	MAC'd? N Y  FREATME  MAC'd? N  MAC'd? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid Tagamet  Brand  Carafate	Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck Reliant GlaxoSmithKline Manufacturer Axcan	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671 126,554	87.4% 12.6% 100.0% 100.0%  Market Share 100.0%  Market Share 77.9% 18.0% 1.2% 2.9% 100.0%	\$137.44 \$94.78 \$132.07 \$132.07 \$\$ Per Rx \$260.37 \$\$10.79 \$48.02 \$8.87 \$13.80 \$\$ Per Rx
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE Total  AGENTS FOR ULCERS - OTHER Share of FFS Rx's: 0.07%  Per Member SFY05 YTD: \$0.79 SUCRALFATE MISOPROSTOL	MAC'd? N Y  FREATME  MAC'd? N  FOR ANT.  MAC'd? Y Y Y Y	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid Tagamet  Brand	Manufacturer Tap  Manufacturer GlaxoSmithKline  Manufacturer GlaxoSmithKline Merck Reliant GlaxoSmithKline Manufacturer Manufacturer	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671 126,554 Total Rx 6,561 603	87.4% 12.6% 100.0% 100.0%  Market Share 100.0%  18.0% 1.2% 2.9% 100.0%  Market Share 91.6% 8.4%	\$137.44 \$94.78 \$132.07 \$132.07 \$\$ Per Rx \$260.37 \$10.79 \$48.02 \$8.87 \$13.80 \$\$ Per Rx \$41.92
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE Total  AGENTS FOR ULCERS - OTHER Share of FFS Rx's: 0.07%  Per Member SFY05 YTD: \$0.79 SUCRALFATE	MAC'd? N Y  FREATME  MAC'd? N  MAC'd? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid Tagamet  Brand  Carafate	Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck Reliant GlaxoSmithKline Manufacturer Axcan	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671 126,554	87.4% 12.6% 100.0% 100.0%  Market Share 100.0%  Market Share 77.9% 18.0% 1.2% 2.9% 100.0%	\$137.44 \$94.78 \$132.07 \$132.07 \$\$ Per Rx \$260.37 \$\$10.79 \$48.02 \$8.87 \$13.80 \$\$ Per Rx
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE Total  AGENTS FOR ULCERS - OTHER Share of FFS Rx's: 0.07%  Per Member SFY05 YTD: \$0.79 SUCRALFATE MISOPROSTOL	MAC'd? N Y  FREATME  MAC'd? N  MAC'd? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid Tagamet  Brand  Carafate	Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck Reliant GlaxoSmithKline Manufacturer Axcan	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671 126,554 Total Rx 6,561 603	87.4% 12.6% 100.0% 100.0%  Market Share 100.0%  18.0% 1.2% 2.9% 100.0%  Market Share 91.6% 8.4%	\$137.44 \$94.78 \$132.07 \$132.07 \$\$ Per Rx \$260.37 \$\$14.15 \$10.79 \$48.02 \$8.87 \$13.80 \$\$13.80
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21%  Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE Total  AGENTS FOR ULCERS - OTHER Share of FFS Rx's: 0.07%  Per Member SFY05 YTD: \$0.79 SUCRALFATE MISOPROSTOL	MAC'd? N Y  FREATME  MAC'd? N  MAC'd? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid Tagamet  Brand Carafate Cytotec	Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck Reliant GlaxoSmithKline Manufacturer Axcan	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671 126,554 Total Rx 6,561 603	87.4% 12.6% 100.0% 100.0%  Market Share 100.0%  18.0% 1.2% 2.9% 100.0%  Market Share 91.6% 8.4%	\$137.44 \$94.78 \$132.07 \$132.07 \$\$ Per Rx \$260.37 \$\$14.15 \$10.79 \$48.02 \$8.87 \$13.80 \$\$13.80
Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21% Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE Total  AGENTS FOR ULCERS - OTHER Share of FFS Rx's: 0.07% Per Member SFY05 YTD: \$0.79 SUCRALFATE MISOPROSTOL Total	MAC'd? N Y  FREATME  MAC'd? N  MAC'd? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid Tagamet  Brand Carafate Cytotec	Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck Reliant GlaxoSmithKline Manufacturer Axcan	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671 126,554 Total Rx 6,561 603	87.4% 12.6% 100.0% 100.0%  Market Share 100.0%  18.0% 1.2% 2.9% 100.0%  Market Share 91.6% 8.4%	\$137.44 \$94.78 \$132.07 \$132.07 \$\$ Per Rx \$260.37 \$10.79 \$48.02 \$8.87 \$13.80 \$\$ Per Rx \$41.92
Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$4.12 NICOTINE BUPROPION  Total  AGENTS FOR ULCERS - H PYLORI T Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.40 ANTI-ULCER-H.PYLORI AGENTS CLASSIFIER  AGENTS FOR ULCERS - H2 RECEPT Share of FFS Rx's: 1.21% Per Member SFY05 YTD: \$5.78 RANITIDINE FAMOTIDINE NIZATIDINE CIMETIDINE TOtal  AGENTS FOR ULCERS - OTHER Share of FFS Rx's: 0.07% Per Member SFY05 YTD: \$0.79 SUCRALFATE MISOPROSTOL  Total  AGENTS FOR ULCERS - PROTON PICE  MAGENTS FOR ULCERS - PROTON PICE  MISOPROSTOL  Total	MAC'd? N Y  FREATME  MAC'd? N  MAC'd? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Nicoderm Zyban  ENT  Brand Prevpac  AGONISTS  Brand Zantac Pepcid Axid Tagamet  Brand Carafate Cytotec	Manufacturer GlaxoSmithKline Manufacturer Tap Manufacturer GlaxoSmithKline Merck Reliant GlaxoSmithKline Manufacturer Axcan	\$1,130,063 \$112,220 \$1,242,282 Total \$\$ \$120,549 Total \$\$ \$1,394,669 \$246,330 \$72,411 \$32,546 \$1,745,956	8,222 1,184 9,406 Total Rx 463 Total Rx 98,556 22,819 1,508 3,671 126,554 Total Rx 6,561 603	87.4% 12.6% 100.0% 100.0%  Market Share 100.0%  18.0% 1.2% 2.9% 100.0%  Market Share 91.6% 8.4%	\$137.44 \$94.78 \$132.07 \$132.07 \$\$ Per Rx \$260.37 \$14.15 \$10.79 \$48.02 \$8.87 \$13.80 \$\$ Per Rx \$13.80

Display	1.4NOODD 4.7OLE	lNI .	Dravasid	Ton	C 470 000	44.500	42.20/	€4.4E.40
PARTOPHE ADDRESS OF THE STATE O	LANSOPRAZOLE	N	Prevacid	Tap Astro-Zonoso	\$6,472,009	44,503	13.2%	\$145.43
Resident   Administration   Administra		I NI						
Page								
AGENTS FOR URINARY SPASM		IN	Acipnex	Eisai				
Share of FFS RY to 0.00%   Part Member SY 70 YTD: \$2.17   MAC'07   Brand   Manufacturer   Total St   Total Rx   Market Share   \$5 Per Rx   \$6 Per Rx	Iotal				\$23,542,930	336,242	100.0%	\$70.02
Post Member SPY05 YTD: \$23.71	AGENTS FOR URINARY SPASM							
No.   Dietre   Phore   Augine   S44.11.03   40.297   50.776   50								
OXTEDITYPINN	*							
ROSPILIAN   N   Sanchura   Opyssey   566.505   760   0.9%   580.   580								\$89.50
FLAVORATE   N   Uniques   GlaroSimenKine   \$48.405   4.69   0.5%   \$88.60mFFRANCIN   N   \$20.70   279   0.79%   \$81.60mFFRANCIN   \$80.018   \$111   0.19%   \$85.60mFFRANCIN   \$80.018   \$10.00%   \$1.60mFFRANCIN   \$80.018   \$1.00mFFRANCIN   \$80.018   \$177.300   \$1.00mFFRANCIN   \$80.018   \$177.300   \$1.00mFFRANCIN   \$1.00mFFRAN		·						\$61.52
DARPENNICK								\$62.97
SOLIFEMANICH   SOLIFICATION   SOLIFICATION   STEEL   ST,156,532   33,472   100.09%   STEEL   ST,156,532   33,472   100.09%   STEEL   ST,156,532   33,472   100.09%   STEEL   ST,156,532   33,472   100.09%   STEEL   ST,156,532			Urispas	GlaxoSmithKline				\$98.98
S7,156,532   93,472   100,0%   S76.		N						\$81.39
AGENTS FOR WEIGHT LOSS   Share of FFS fix's 0.09%   Significant   Natural State   National State   Nationa								\$85.75
Share of FFS fix's 0.09%	Total				\$7,156,532	93,472	100.0%	\$76.56
Post Member SPY05 YTD: \$2.02   MAC 97   Brand	AGENTS FOR WEIGHT LOSS							
Post Member SPY05 YTD: \$2.02   MAC 97   Brand								
RRISTATA  N		MVCida	Drand	Manufacturer	Total ¢¢	Total Dv	Market Chare	¢¢ Dor Dy
SIBUTHANNE	*							
PRENTERNINE   Y   Asignex   Gate   \$45,549   1,468   24,37%   \$31,757   \$35,757   \$40,775   \$4								
DIETHYLPROPROPORT   Y   Tenuste   Aventis   \$2.238   85   1.5%   \$25.								
PHENDMETRAZINE   Y   Pregine   Wyeth   \$1.051   50   0.5%   \$3.05   53.0   53		T V						\$31.03
Se10,785   G.031   100.0%   S101.		T V						\$25.15
AGENTS FOR WOUND HEALING Share of FFS RX's: 0.29%  PAPAPA  NAC'07  Granulax		Y	rieginė	vvyetn				\$36.03
Share of FFS Rx's: 0.25%   Per Member SPY0S YTD: \$5.77   MAC'd?   Brand   Manufacturer   Total SS   Total Rx   Market Share   SP Per Rx	Iotai				\$610,785	6,031	100.0%	\$101.27
Per Member SPV0S YTD: \$5.77	AGENTS FOR WOUND HEALING							
Per Member SPV0S YTD: \$5.77	Share of FFS Rx's: 0.25%							
TRYPSIN		MAC'42	Brand	Manufacturer	Total \$\$	Total Ry	Market Share	\$\$ Per Ry
PAPAIN   N   Accuryme   HealthPoint   \$456.097   6.400   24.7%   \$77.								\$55.94
BECAPLERMIN   N   Regranex   Janssen   \$216,060   448   1.7%   \$482     Total   N   Santyl   Koll   \$31,742,752   26,025   100.0%   \$66.   ALPHA BLOCKERS   Share of FFS Rx's: 0.22%								\$71.04
COLLAGENASE   N   Santyl   Knol   S33.470   616   2.4%   S54.								
St.742,752   26,025   100.0%   \$66.								
ALPHA BLOCKERS Share of FFS Rx's: 0.22% Per Member SFY05 YTD: \$0.65 MAC'd? Brand Manufacturer DOXAZOSIN Y Cardura Pitzer \$89,347 12,750 56,5% 56,76 ERAZOSIN Y Hyfrin Abbott \$77,539 8,103 35,9% \$9. PRAZOSIN Y Hyfrin Abbott \$77,539 8,103 35,9% \$9. PRAZOSIN Y Minipress Pitzer \$39,232 1,707 7,76% \$17. Total \$100,0% \$8.  AMINOGLYCOSIDES Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$2.99 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per R Member SFY05 YTD: \$2.99 MAC'd? Parameter Section Schering-Plough \$13,036 1,536 51,0% \$9. ERNTAMICIN Y Amikin Sandoz \$15,047 80 2,2% \$755. MANUACIN Y Amikin Sandoz \$15,047 80 2,2% \$188. STREEPTOMYCIN N VARIOUS Spectrum \$99 2 0,1% \$49. KANAMYCIN N N Kantrex Sandoz \$57,04 9 0,3% \$3. Total \$\$ Antiex Sandoz \$57,04 9 0,3% \$3. Total \$\$ Total Rx Market Share \$\$ \$9.  ANALGESICS - BUTALBITAL Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9.  ANALGESICS - CLONIDINE PATCH Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ \$9. Per R Member SFY05 YTD: \$0.00 MAC'd? Brand Manufacturer \$\$ \$9. \$1. \$0.00 MAC'd? Brand Manufacturer \$\$ \$9. \$9. \$0. \$0. \$0. \$0. \$0. \$0. \$0. \$0. \$0. \$0		IN	Santyi	KIIOII				\$66.96
Share of FFS Rx's: 0.22%	Total				ψ1,7 <del>1</del> 2,7 02	20,023	100.070	ψ00.30
Per Member SPY05 YTD: \$0.65   MAC'd?   Brand   Manufacturer   Total \$\$   Total \$\$   Total \$\$   Seper Rx	ALPHA BLOCKERS							
DOXAZOSIN Y Cardura Pitzer \$88,347 12,750 56.5% 58 58 FERAZOSIN Y Hytrin Abbott \$77,539 8.103 35.9% \$9 PRAZOSIN Y Minipress Plizer \$30,232 1,707 7.6% \$17 Total \$196,118 22,560 100.0% \$8.  ### AMINOGLYCOSIDES	Share of FFS Rx's: 0.22%							
DOXAZOSIN Y Cardura Pitzer \$88,347 12,750 56.5% 58 58 FERAZOSIN Y Hytrin Abbott \$77,539 8.103 35.9% \$9 PRAZOSIN Y Minipress Plizer \$30,232 1,707 7.6% \$17 Total \$196,118 22,560 100.0% \$8.  ### AMINOGLYCOSIDES	Per Member SFY05 YTD: \$0.65	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
TERAZOSIN   Y	*	Y						\$6.93
PRAZOSIN   Y   Minipress   Pfizer   \$30,232   1,707   7,6%   \$17		Y						\$9.57
State   Stat		Y						\$17.71
Share of FFS Rx's: 0.03%	Total		iiiiiipreee	T HEO!				\$8.69
Share of FFS Rx's: 0.03%								
Per Member SFY05 YTD: \$2.39								
Nebcin   Lilly								
NEOMYCIN   Y		MAC'd?						
AMIKACIN Y Amikin Sandoz \$15,047 80 2.7% \$188.  GENTAMICIN Y Garamycin Schering-Plough \$13,036 1,536 51.0% \$8.  STREPTOMYCIN N Various Spectrum \$99 2 0.1.% \$49.  KANAMYCIN N KANTEX Sandoz \$27 9 0.3% \$3.  Total \$70 1,000 \$239.  ANALGESICS - BUTALBITAL  Share of FFS Rx's: 0.02%		Y	Nebcin	Lilly				\$755.19
Schering-Plough   \$13,036   1,536   51,0%   \$8.		Y						\$56.37
STREPTOMYCIN   N   Various   Spectrum   S99   2   0.1%   \$49		Y						\$188.09
N   Kantex   Sandoz   \$27   9   0.3%   \$3.	GENTAMICIN	Υ						\$8.49
Total					· ·	-		\$49.43
ANALGESICS - BUTALBITAL  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$0.20  MAC'd? Brand  N Various  S59,854  ANALGESICS - CLONIDINE PATCH  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.00  MAC'd? Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx  CLONIDINE  N  MAC'd? Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx  CLONIDINE  N  ANALGESICS - NARCOTIC ANESTHETICS  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$0.00  MAC'd? Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$0.00  MAC'd? Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$0.00  MAC'd? Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx  Share of FFS Rx's: 6.23%  Per Member SFY05 YTD: \$121.93  MAC'd?  Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx  Share of FFS Rx's: 6.23%  Per Member SFY05 YTD: \$121.93  MAC'd?  Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx  \$\$ 17.329,301  \$\$ 151,467  \$\$ 23.4%  \$\$ 103.  \$\$ 188.	KANAMYCIN	N	Kantrex	Sandoz				\$3.05
Share of FFS Rx's: 0.02%   Per Member SFY05 YTD: \$0.20   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$ Per Rx	Total				\$721,242	3,012	100.0%	\$239.46
Per Member SFY05 YTD: \$0.20	ANALGESICS - BUTALBITAL							
Per Member SFY05 YTD: \$0.20	Share of FFS Rx's: 0.02%							
State of FFS Rx's: 0.00%   State of FFS Rx's: 0.02%   State of FFS Rx's:		MACId2	Brand	Manufacturer	22 letoT	Total Ry	Market Share	\$\$ Par Ry
ANALGESICS - CLONIDINE PATCH  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.00  MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx CLONIDINE  ANALGESICS - NARCOTIC ANESTHETICS  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$0.00  MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx FENTANYL  Y Sublimaze Taylor \$870  ANALGESICS - NARCOTICS  Share of FFS Rx's: 6.23%  Per Member SFY05 YTD: \$121.93  MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS  Share of FFS Rx's: 6.23%  Per Member SFY05 YTD: \$121.93  MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS  Share of FFS Rx's: 6.23%  Per Member SFY05 YTD: \$121.93  MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS  Share of FFS Rx's: 6.23%  Per Member SFY05 YTD: \$121.93  MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS \$\$ Total Rx Market Share \$\$ Per Rx CANALGESICS - NARCOTICS - NARCOTICS - NARCOTICS - NARCOTICS - NARCOTICS - NARCOTICS - NARCOTI			+	Manuacture				
Share of FFS Rx's: 0.00%   Per Member SFY05 YTD: \$0.00   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$   Per Rx	BUTALBITAL	IN	various		<b>\$59,654</b>	2,193	100.0%	\$21.29
Per Member SFY05 YTD: \$0.00   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$   Per Rx	ANALGESICS - CLONIDINE PATCH							
Per Member SFY05 YTD: \$0.00   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$   Per Rx	Share of FFS Rx's: 0.00%							
ANALGESICS - NARCOTIC ANESTHETICS   Share of FFS Rx's: 0.02%   Per Member SFY05 YTD: \$0.00   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$ Per Rx   FENTANYL   Y Sublimaze   Taylor   \$870   40   100.0%   \$21.	Per Member SEY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Ry	Market Share	\$\$ Per Ry
Share of FFS Rx's: 0.02%	·							\$253.00
Share of FFS Rx's: 0.02%	ANALOESIOS NADOOTIO ANTOTI	ETICS						
Per Member SFY05 YTD: \$0.00   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$ Per Rx		LIIUS						
Sublimaze   Taylor   \$870   40   100.0%   \$21.		MACIAS	Brand	Manufacturer	Total \$¢	Total Pv	Market Share	\$\$ Per Pv
ANALGESICS - NARCOTICS  Share of FFS Rx's: 6.23%  Per Member SFY05 YTD: \$121.93  MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx  OXYCODONE N Percodan Endo \$15,601,920 151,467 23.4% \$103.  FENTANYL Y Duragesic Patches Janssen \$11,329,301 60,043 9.3% \$188.			+					\$\$ Per KX \$21.75
Share of FFS Rx's: 6.23%         MAC'd?         Brand         Manufacturer         Total \$\$         Total Rx         Market Share         \$\$ Per Rx           OXYCODONE         N         Percodan         Endo         \$15,601,920         151,467         23.4%         \$103.           FENTANYL         Y         Duragesic Patches         Janssen         \$11,329,301         60,043         9.3%         \$188.				-				
Per Member SFY05 YTD: \$121.93         MAC'd?         Brand         Manufacturer         Total \$\$         Total Rx         Market Share         \$\$ Per Rx           OXYCODONE         N         Percodan         Endo         \$15,601,920         151,467         23.4%         \$103.           FENTANYL         Y         Duragesic Patches         Janssen         \$11,329,301         60,043         9.3%         \$188.								
OXYCODONE         N         Percodan         Endo         \$15,601,920         151,467         23.4%         \$103.           FENTANYL         Y         Duragesic Patches         Janssen         \$11,329,301         60,043         9.3%         \$188.								
FENTANYL Y Duragesic Patches Janssen \$11,329,301 60,043 9.3% \$188.								
	OXYCODONE							\$103.01
MORPHINE   Y   MS Contin   Purdue   \$4,044,977   39,142   6.0%   \$103.								\$188.69
	MODDIUME	Υ	IMS Contin	Purdue	\$4 044 977	39 142	6.0%	\$103.34

HYDROCODONE	Υ	Vicodin	Abbott	\$2,287,020	203,602	31.4%	\$11.23
TRAMADOL	Υ	Ultram	McNeil	\$1,331,906	56,388	8.7%	\$23.62
PROPOXYPHENE	Υ	Darvon	AAI Pharma	\$681,886	60,273	9.3%	\$11.31
CODEINE	N	Codeine	Roxane	\$569,167	53,562	8.3%	\$10.63
METHADONE	Υ	Dolophine	Roxane	\$305,132	16,501	2.5%	\$18.49
HYDROMORPHONE	N	Dilaudid	Abbott	\$272,766	3,618	0.6%	\$75.39
BUPRENORPHINE	N	Suboxone	Reckitt	\$233,829	1,192	0.2%	\$196.17
BUTORPHANOL	-	Stadol	Sandoz	\$41,755	896	0.1%	\$46.60
MEPERIDINE	N	Demerol	Sanofi-Synthelabo	\$35,571	1,013	0.2%	\$35.11
OPIUM	N	B&O Supprettes	PolyMedica	\$27,335	518	0.1%	\$52.77
LEVORPHANOL	N	Levorphanol	Roxane	\$20,321	100	0.0%	\$203.21
PENTAZOCINE	N	Pentazocine	Watson	\$15,865	245	0.0%	\$64.76
DIHYDROCODEINE	N	Synalgos-DC	Women First	\$1,458	33	0.0%	\$44.17
NALBUPHINE	N	Nubain	Endo	\$599	16	0.0%	\$37.45
Total	+ -			\$36,800,808	648,609	100.0%	\$56.74
Total	+			\$30,000,000	040,003	100.070	ψ50.74
	1						
ANALGESICS - NSAIDS - COX2 INHIB	ITORS						
Share of FFS Rx's: 0.80%	1						
Per Member SFY05 YTD: \$26.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CELECOXIB	N	Celebrex	Pfizer	\$5,554,743	58,241	69.9%	\$95.38
VALDECOXIB	N	Bextra	Pfizer	\$1,306,190	13,738	16.5%	\$95.08
ROFECOXIB	N	Vioxx	Merck	\$984,980	11,348	13.6%	\$86.80
Total	1			\$7,845,913	83,327	100.0%	\$94.16
	+			Ţ1, <del>0-10,010</del>	33,027	. 30.0 /0	ψ3 <del>-1</del> .10
	<u> </u>	1					
ANALGESICS - NSAIDS - NON-COX2	INHIBITO	ORS					
Share of FFS Rx's: 1.33%							
		D	Manuel 1	T A4	T-4 1-	Manda + O	ee = =
Per Member SFY05 YTD: \$7.91	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MELOXICAM	N	Mobic	Boehringer Ingel.	\$502,782	4,642	3.4%	\$108.31
NABUMETONE	Υ	Relafen	GlaxoSmithKline	\$457,617	12,335	8.9%	\$37.10
IBUPROFEN	Υ	Motrin	McNeil	\$379,907	53,242	38.4%	\$7.14
NAPROXEN	Y	Naprosyn	Roche	\$344,349	33,269	24.0%	\$10.35
DICLOFENAC	Y	Voltaren	Novartis	\$333,881	12,535	9.0%	\$26.64
	\ <u>'</u>	Lodine	Wyeth		5,526	4.0%	\$25.92
ETODOLAC	T V			\$143,225			
SULINDAC	Υ	Clinoril	Merck	\$56,217	2,778	2.0%	\$20.24
INDOMETHACIN	Υ	Indocin	Merck	\$52,141	4,673	3.4%	\$11.16
OXAPROZIN	Υ	Daypro	Pharmacia	\$29,871	1,862	1.3%	\$16.04
PIROXICAM	Υ	Feldene	Pfizer	\$24,336	4,133	3.0%	\$5.89
KETOROLAC	Υ	Toradol	Roche	\$21,098	1,697	1.2%	\$12.43
KETOPROFEN	Υ	Orudis	Wyeth	\$19,940	1,221	0.9%	\$16.33
TOLMETIN	Y	Tolectin	McNeil	\$10,623	173	0.1%	\$61.41
	Y						
FLURBIPROFEN	•	Ansaid	Pharmacia	\$4,580	281	0.2%	\$16.30
MEFENAMIC ACID	N	Ponstel	First Horizon	\$3,821	57	0.0%	\$67.04
FENOPROFEN	Υ	Nalfon	Ranbaxy	\$1,342	77	0.1%	\$17.43
MECLOFENAMIC ACID	Υ	Meclomen	Pfizer	\$665	40	0.0%	\$16.63
Total				\$2,386,395	138,541	100.0%	\$17.23
	1			, ,,	,-		· · · · · · · · · · · · · · · · · · ·
ANALGESICS - SALICYLATES							
Share of FFS Rx's: 0.70%	MACIAO	Draud	Manufactura	Tatales	Total Dv	Market Chara	ff Des Dy
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN	Υ			\$210,876	66,591	91.9%	\$3.17
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE	MAC'd? Y	Disaclid	3M	\$210,876 \$97,780	66,591 4,744	91.9% 6.5%	\$3.17 \$20.61
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL	Y Y Y			\$210,876 \$97,780 \$24,568	66,591 4,744 563	91.9% 6.5% 0.8%	\$3.17 \$20.61 \$43.64
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE	Υ	Disaclid	3M	\$210,876 \$97,780	66,591 4,744	91.9% 6.5%	\$3.17 \$20.61 \$43.64
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE	Y Y Y	Disaclid	3M	\$210,876 \$97,780 \$24,568 \$23,103	66,591 4,744 563 556	91.9% 6.5% 0.8% 0.8%	\$3.17 \$20.61 \$43.64 \$41.55
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL	Y Y Y	Disaclid	3M	\$210,876 \$97,780 \$24,568	66,591 4,744 563	91.9% 6.5% 0.8%	\$3.17 \$20.61 \$43.64 \$41.55
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total	Y Y Y	Disaclid	3M	\$210,876 \$97,780 \$24,568 \$23,103	66,591 4,744 563 556	91.9% 6.5% 0.8% 0.8%	\$3.17 \$20.61 \$43.64 \$41.55
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE	Y Y Y	Disaclid	3M	\$210,876 \$97,780 \$24,568 \$23,103	66,591 4,744 563 556	91.9% 6.5% 0.8% 0.8%	\$3.17 \$20.61 \$43.64 \$41.55
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total	Y Y Y	Disaclid	3M	\$210,876 \$97,780 \$24,568 \$23,103	66,591 4,744 563 556	91.9% 6.5% 0.8% 0.8%	\$3.17 \$20.61 \$43.64 \$41.55
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%	Y Y Y N	Disaclid Dolobid	3M Merck	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327	66,591 4,744 563 556 <b>72,454</b>	91.9% 6.5% 0.8% 0.8% 100.0%	\$3.17 \$20.61 \$43.64 \$41.55 <b>\$4.92</b>
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82	Y Y Y N N MAC'd?	Disaclid Dolobid	3M	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327	66,591 4,744 563 556 <b>72,454</b> Total Rx	91.9% 6.5% 0.8% 0.8% 100.0%	\$3.17 \$20.61 \$43.64 \$41.55 <b>\$4.92</b>
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE	Y Y Y N N MAC'd?	Disaclid Dolobid  Brand Various	3M Merck	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8%	\$3.17 \$20.61 \$43.64 \$41.55 <b>\$4.92</b> \$Per Rx \$158.98
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE	Y Y Y N N MAC'd? N	Disaclid Dolobid  Brand Various Oxandrin	3M Merck Manufacturer	\$210,876 \$97,780 \$24,568 \$23,103 <b>\$356,327</b> Total <b>\$\$</b> \$385,695 \$149,605	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426 346	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8% 12.0%	\$3.17 \$20.61 \$43.64 \$41.55 <b>\$4.92</b> \$\$ Per Rx \$158.98 \$432.38
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE	Y Y Y N MAC'd? N N	Disaclid Dolobid  Brand Various	3M Merck	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695	66,591 4,744 563 556 <b>72,454</b> <b>Total Rx</b> 2,426 346	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8%	\$3.17 \$20.61 \$43.64 \$41.55 <b>\$4.92</b> \$\$ Per Rx \$158.98 \$432.38 \$268.50
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE	Y Y Y N N MAC'd? N	Disaclid Dolobid  Brand Various Oxandrin	3M Merck Manufacturer	\$210,876 \$97,780 \$24,568 \$23,103 <b>\$356,327</b> Total <b>\$\$</b> \$385,695 \$149,605	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426 346	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8% 12.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  OXANDROLONE  FLUOXYMESTERONE	Y Y Y N MAC'd? N N	Disaclid Dolobid  Brand Various Oxandrin Estratest	3M Merck Manufacturer Savient Solvay	\$210,876 \$97,780 \$24,568 \$23,103 <b>\$356,327</b> Total \$\$ \$385,695 \$149,605 \$9,129	66,591 4,744 563 556 <b>72,454</b> <b>Total Rx</b> 2,426 346	91.9% 6.5% 0.8% 100.0% Market Share 83.8% 12.0% 1.2%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.88 \$432.38 \$268.50 \$58.99
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE OXYMETHOLONE	Y Y Y N MAC'd? N N	Disaclid Dolobid  Brand Various Oxandrin Estratest	3M Merck Manufacturer Savient Solvay	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426 346 34 87	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8% 12.0% 1.2% 3.0% 0.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.83 \$268.50 \$58.99 \$448.10
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  OXANDROLONE  FLUOXYMESTERONE  METHYLITESTOSTERONE	Y Y Y N MAC'd? N N	Disaclid Dolobid  Brand Various Oxandrin Estratest	3M Merck Manufacturer Savient Solvay	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426 346 34	91.9% 6.5% 0.8% 100.0% Market Share 83.8% 12.0% 1.2% 3.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.83 \$268.50 \$58.99 \$448.10
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE OXYMETHOLONE	Y Y Y N MAC'd? N N	Disaclid Dolobid  Brand Various Oxandrin Estratest	3M Merck Manufacturer Savient Solvay	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426 346 34 87	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8% 12.0% 1.2% 3.0% 0.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.83 \$268.50 \$58.99 \$448.10
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE OXYMETHOLONE	Y Y N N MAC'd? N N N N N N	Disaclid Dolobid  Brand Various Oxandrin Estratest	3M Merck Manufacturer Savient Solvay	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426 346 34 87	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8% 12.0% 1.2% 3.0% 0.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.83 \$268.50 \$58.99 \$448.10
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE 0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE 0XYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER	Y Y N N MAC'd? N N N N N N	Disaclid Dolobid  Brand Various Oxandrin Estratest	3M Merck Manufacturer Savient Solvay	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448	66,591 4,744 563 556 <b>72,454</b> Total Rx 2,426 346 34 87	91.9% 6.5% 0.8% 0.8% 100.0% Market Share 83.8% 12.0% 1.2% 3.0% 0.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.83 \$268.50 \$58.99 \$448.10
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER  Share of FFS Rx's: 0.98%	Y Y Y N N MAC'd? N N N N N N R R	Disaclid Dolobid  Brand Various Oxandrin Estratest Anadrol	3M Merck Manufacturer Savient Solvay Unimed	\$210,876 \$97,780 \$24,568 \$23,103 <b>\$356,327</b> Total <b>\$\$</b> \$385,695 \$149,605 \$9,129 \$5,132 \$448 <b>\$550,008</b>	66,591 4,744 563 556 72,454 Total Rx 2,426 346 34 87 1 2,894	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% 100.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  OXANDROLONE  FLUOXYMESTERONE  METHYLTESTOSTERONE  OXYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER  Share of FFS Rx's: 0.98%  Per Member SFY05 YTD: \$1.9.14	Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Disaclid Dolobid  Brand Various Oxandrin Estratest Anadrol  Brand	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer	\$210,876 \$97,780 \$24,568 \$23,103 <b>\$356,327</b> Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008	66,591 4,744 563 556 72,454 Total Rx 2,426 346 34 87 1 2,894	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% Market Share	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  OXANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER  Share of FFS Rx's: 0.98%	MAC'd? N N N N N N N N N N N N N N N N N N N	Disaclid Dolobid  Brand Various Oxandrin Estratest Anadrol	3M Merck Manufacturer Savient Solvay Unimed	\$210,876 \$97,780 \$24,568 \$23,103 <b>\$356,327</b> Total <b>\$\$</b> \$385,695 \$149,605 \$9,129 \$5,132 \$448 <b>\$550,008</b>	66,591 4,744 563 556 72,454 Total Rx 2,426 346 34 87 1 2,894	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% 100.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  0XANDROLONE  FLUOXYMESTERONE  0XYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER  Share of FFS Rx's: 0.98%  Per Member SFY05 YTD: \$1.91.14	Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Disaclid Dolobid  Brand Various Oxandrin Estratest Anadrol  Brand	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer	\$210,876 \$97,780 \$24,568 \$23,103 <b>\$356,327</b> Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008	66,591 4,744 563 556 72,454 Total Rx 2,426 346 34 87 1 2,894	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% Market Share	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$156.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN LOSARTAN	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer  Novartis Merck	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,533	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% 100.0%  Market Share 43.3% 36.6%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE 0XYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98%  Per Member SFY05 YTD: \$19.14  VALSARTAN  LOSARTAN  IRBESARTAN	Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008	66,591 4,744 563 556 72,454 Total Rx 2,426 346 34 87 1 2,894 Total Rx 44,353 37,533 7,321	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% 100.0%  Market Share 43.3% 36.6% 7.1%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  0XANDROLONE  FLUOXYMESTERONE  0XYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER  Share of FFS Rx's: 0.98%  Per Member SFY05 YTD: \$19.14  VALSARTAN  LOSARTAN  IRBESARTAN  TELMISARTAN  TELMISARTAN  TELMISARTAN	Y Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel.	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440	66,591 4,744 563 556 72,454 Total Rx 2,426 346 34 87 1 2,894 Total Rx 44,353 37,533 7,321 4,665	91.9% 6.5% 0.8% 0.8% 100.0% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$132.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE 0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE 0XYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN LOSARTAN IRBESARTAN TELMISARTAN CANDESARTAN CANDESARTAN	Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440 \$229,194	66,591 4,744 563 556 72,454 Total Rx 2,426 346 34 87 1 2,894 Total Rx 44,353 37,533 7,321 4,665 4,145	91.9% 6.5% 0.8% 0.8% 100.0% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN LOSARTAN IRBESARTAN TELMISARTAN CANDESARTAN OLMESARTAN OLMESARTAN	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand Benicar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca Sankyo	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$2494,400 \$229,194 \$184,443	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,321 4,665 4,145 4,164	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0% 4.1%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE 0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE 0XYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN LOSARTAN IRBESARTAN TELMISARTAN CANDESARTAN CANDESARTAN	Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440 \$229,194	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,533 7,321 4,665 4,145 4,164 344	91.9% 6.5% 0.8% 0.8% 100.0% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 0.0% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE OXANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN LOSARTAN IRBESARTAN TELMISARTAN CANDESARTAN OLMESARTAN OLMESARTAN	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand Benicar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca Sankyo	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$2494,400 \$229,194 \$184,443	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,533 7,321 4,665 4,145 4,164 344	91.9% 6.5% 0.8% 0.8% 100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0% 4.1%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.55 \$58.99 \$448.10 \$190.05 \$\$ Per Rx \$56.29 \$58.96 \$54.07 \$55.29 \$44.22 \$44.22 \$44.22
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE 0XYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98%  Per Member SFY05 YTD: \$19.14  VALSARTAN LOSARTAN IRBESARTAN IRBESARTAN CANDESARTAN CANDESARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand Benicar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca Sankyo	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440 \$229,194 \$184,443 \$14,848	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,321 4,665 4,145 4,164	91.9% 6.5% 0.8% 0.8% 100.0%  100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 1.00% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0% 4.1% 0.3%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.55 \$58.99 \$448.10 \$190.05 \$\$ Per Rx \$56.29 \$58.96 \$54.07 \$55.29 \$44.22 \$44.22 \$44.22
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE 0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE OXYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN LOSARTAN IRBESARTAN TELMISARTAN CANDESARTAN CANDESARTAN OLMESARTAN OLMESARTAN TOtal	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand Benicar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca Sankyo	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440 \$229,194 \$184,443 \$14,848	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,533 7,321 4,665 4,145 4,164 344	91.9% 6.5% 0.8% 0.8% 100.0%  100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 1.00% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0% 4.1% 0.3%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.90 \$448.10 \$56.29 \$56.29 \$54.07 \$52.18 \$55.29 \$44.29
Share of FFS Rx's: 0.70%  Per Member SFY05 YTD: \$1.18  ASPIRIN  SALSALATE  DIFLUNISAL  SALICYLATE  Total  ANDROGENS/ANABOLIC STEROIDS  Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$1.82  TESTOSTERONE  0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE 0XYMETHOLONE  Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98%  Per Member SFY05 YTD: \$19.14  VALSARTAN LOSARTAN IRBESARTAN IRBESARTAN CANDESARTAN CANDESARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN EPROSARTAN	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand Benicar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca Sankyo	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440 \$229,194 \$184,443 \$14,848	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,533 7,321 4,665 4,145 4,164 344	91.9% 6.5% 0.8% 0.8% 100.0%  100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 1.00% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0% 4.1% 0.3%	\$3.17 \$20.61 \$43.64 \$41.55 \$4.92 \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.90 \$448.10 \$56.29 \$56.29 \$54.07 \$52.18 \$55.29 \$44.29
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE 0XANDROLONE FLUOXYMESTERONE METHYLTESTOSTERONE 0XYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN LOSARTAN IRBESARTAN TELMISARTAN CANDESARTAN CANDESARTAN OLMESARTAN TOTAL	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand Benicar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca Sankyo	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440 \$229,194 \$184,443 \$14,848	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,533 7,321 4,665 4,145 4,164 344	91.9% 6.5% 0.8% 0.8% 100.0%  100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 1.00% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0% 4.1% 0.3%	\$3.17 \$20.61 \$43.64 \$41.55 <b>\$4.92</b> <b>\$\$ Per Rx</b> \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 <b>\$190.05</b> <b>\$\$ Per Rx</b> \$56.29 \$58.96 \$55.18 \$55.18 \$55.18
Share of FFS Rx's: 0.70% Per Member SFY05 YTD: \$1.18 ASPIRIN SALSALATE DIFLUNISAL SALICYLATE Total  ANDROGENS/ANABOLIC STEROIDS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$1.82 TESTOSTERONE 0XANDROLONE FLUOXYMESTERONE METHYL'TESTOSTERONE OXYMETHOLONE Total  ANGIOTENSIN RECEPTOR BLOCKER Share of FFS Rx's: 0.98% Per Member SFY05 YTD: \$19.14 VALSARTAN IRBESARTAN IRBESARTAN TELMISARTAN CANDESARTAN OLMESARTAN DLMESARTAN TOTAL  ANORECTAL PREPARATIONS	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Various Oxandrin Estratest Anadrol  Brand Diovan Cozaar/Hyzaar Avalide/Avapro Micardis Atacand Benicar	3M Merck  Manufacturer  Savient Solvay Unimed  Manufacturer Novartis Merck Bristol-Myers Boehringer-Ingel. AstraZeneca Sankyo	\$210,876 \$97,780 \$24,568 \$23,103 \$356,327 Total \$\$ \$385,695 \$149,605 \$9,129 \$5,132 \$448 \$550,008 Total \$\$ \$2,496,605 \$2,213,026 \$395,821 \$243,440 \$229,194 \$184,443 \$14,848	66,591 4,744 563 556 72,454  Total Rx 2,426 346 34 87 1 2,894  Total Rx 44,353 37,533 7,321 4,665 4,145 4,164 344	91.9% 6.5% 0.8% 0.8% 100.0%  100.0%  Market Share 83.8% 12.0% 1.2% 3.0% 1.00% 100.0%  Market Share 43.3% 36.6% 7.1% 4.6% 4.0% 4.1% 0.3%	\$3.17 \$20.61 \$43.64 \$41.55 <b>\$4.92</b> \$\$ Per Rx \$158.98 \$432.38 \$268.50 \$58.99 \$448.10 \$190.05

MESCADINE   N. Accomplements   Section   255   5.776   3777   3		1	T-	1				
BISCOOPY    Y	HYDROCORTISONE	N	Cortenema	Solvay	\$134,227	3,995	84.8%	\$33.60
SIX-CENER								
PRINCEPURENCE		-						
Site		Υ	Fleet Laxatives	Fleet			2.6%	\$13.13
ANTACIDS Share of FSR RY: 0.00%, Per Member SY10'S Y10'S 0.14 MAC'07 Share of FSR RY: 0.00%, Per Member SY10'S Y10'S 0.14 MAC'07 Share of FSR RY: 0.00%, MAC'07 Manufacturer  Share of FSR RY: 0.00%, MAC'07 MANUFACTURE N MARC'07 M	PHENYLEPHRINE							
Share of PFR Nr. 9.0.09%	Total				\$183,699	4,710	100.0%	\$39.00
For Member 8790 YTC: 50.14   MACCYP   Total R   Total R   Total R   Section   Sectio	ANTACIDS							
CALCHIM CARRONATE   N   Tures   GSK Common   \$3,578   5.448   6.298   5.295   5.007   5.448	Share of FFS Rx's: 0.08%							
MACHESIMA SALT   Y   Philips Mile of Mapper Beyon   528, 146   5.056   6.575   5.145	Per Member SFY05 YTD: \$0.14	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SODIUM BICARROMATE   N   Corp.   Schwarz   \$19.094   2.45   29.45   \$9.45	CALCIUM CARBONATE	N	Tums	GSK Consumer	\$33,078	5,448	62.3%	\$6.07
SODIUM BICARBONATE   N   Copie   Schwarz   \$10,194   2.46   28.45   \$4.45   \$4.55   \$4.50   \$4.00   \$4.00   \$6.00   \$4.00   \$4.00   \$6.00	MAGNESIUM SALT	Υ	Phillips Milk of Magn	Bayer	\$28,143	5,855	66.9%	\$4.81
ALLIAMPANIAL HYDROXIDE   N	SODIUM BICARBONATE	N			\$10,194	2,482	28.4%	\$4.11
MAGALIDATE   N   Ropen   Wyeth   \$1.035   56.00   1.075   \$4.2   \$4.2   \$3.2   \$4.2   \$4.2   \$3.2   \$4.2			,				2.8%	\$10.92
Section		N				166		\$6.26
Share of FFS fix's .01%				,				\$4.81
Share of FFS fix's .01%	ANTUGUMINTIOS							
Per Member SFYEN TUD. \$3.05   MAC47   Brand   Manufacturer								
MESERDAZQUE   N   Vermonco   McNeel   S6,100   389   577%   \$15.0   Vermonco   Merck   S6,864   178   26.4   57.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.0   58.0   77.		MACIAS	Drand	Manufacturer	Total \$\$	Total Dv	Market Chara	ff Dor Dy
VERNECTTN   N   Stromedol   Merck   54.08   178   726.4%   \$25.5     ALBERDAZOLE   N   Billincide   Biyer   \$1.081   149   71.1%   \$35.5     ALBERDAZOLE   N   Alberaz   GlavoSmithKine   \$1.002   56   8.8%   \$25.1     Total   S   1.093   71.093   513.5     Total   S   1.094   71.093   513.5     Total   S   1.094   71.093   513.5     Total   S   1.094   71.093   513.5     ANTI-ANXIETY AGENTS - BENZODIAZEPINES   Share of FFS Rx: 3.19%   WC/07   Strand   Mc/07   M		_						
PRAZPIGUATEL   N   Billicide   Bayer   \$1.083   48   7.1%   \$3.55   \$3.28								
ALBERDAZOLE   N   Abenza								
THABERDAZOLE   N								
State   Stat			Albenza	GlaxoSmithKline				\$28.16
ANTI-ANXIETY AGENTS - BENZODIAZEPINES  Share of FFS Rx: 3.19%  Per Member SPYOS YTD: \$1.50  MAC d? Brand Manufacturer  Froat SS 984, 105  MAC d? Brand Manufacturer  Total SS 101al Rx Market Share SS Per Rx (CANAZEPIAM Y KAINON)  ALFRAZOLAM Y KAINON Roche SS84, 105  MAC d. Alivon Roche SS94, 105  MAC d. Market Share SS94, 105  MAC d. Market	IHIABENDAZOLE	N					1.0%	\$13.51
Share of FFS Rx: 5.19%   Per Member SFYOS YTD: 51.50   MAC'97   Market Share   MAC'97   Market Share   MAC'97   Market Share   MAC'97   Market Share   MAC'97   MAC	Total				\$14,134	674	100.0%	\$20.97
Share of FFS Rx: 5.19%   Per Member SFYOS YTD: 51.50   MAC'97   Market Share   MAC'97   Market Share   MAC'97   Market Share   MAC'97   Market Share   MAC'97   MAC	ANTI-ANXIETY AGENTS - RENZODIA	ZEDINE	S					
Per Member SP705 YTD: \$11.50			<u>,                                      </u>					
CORAZEPAM		MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CLONAZEPAM	· · · · · · · · · · · · · · · · · · ·	Υ						\$9.26
Author   A		V						
SAZERAM		1 2						
CURRAZEPICA CID		T V						
Serax   Faulding   S81,890   2,030   0.6%   \$43.3		I V						
CHLORIDIZEPOXIDE		Y						
Total		Y						
ANTI-ANXIETY AGENTS - BUSPIRONE  Share of FFS Rx*s: 0.32%  Per Member SFY05 YTD: \$2.36  MAC'd?  Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx.  S\$ 10,853  33,684  100,0%  \$\$ 21.1  ANTI-ANXIETY AGENTS - OTHER  Share of FFS Rx*s: 0.00%  Per Member SFY05 YTD: \$0.09  MAC'd?  Brand  Manufacturer  Total \$\$  Total Rx  Market Share  \$\$ Per Rx.  Market Share  \$\$ Per Rx.  Market Share  \$\$ Per Rx.  \$\$ 10,0%  \$\$ \$71.8  \$\$ 100,0%  \$\$ \$71.8  ANTI-ARXIETY AGENTS - OTHER		Υ	Librium	Valeant		-		
Share of FFS Rx's: 0.32%   MAC'd?   Brand   Manufacturer   Total S\$   Total Rx   Market Share   S\$ Per Rx	Total				\$3,472,114	332,545	100.0%	\$10.44
Share of FFS Rx's: 0.00%   MAC'd?   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$ Per Rx   MEPROBAMATE   Y   Equanil   Wyeth   \$27,231   379   100.0%   \$71.8	Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.36		+					\$\$ Per Rx \$21.10
Per Member SFY05 YTD: \$0.99								
MEPROBAMATE   Y   Equanil   Wyeth   \$27,231   379   100.0%   \$71.8		MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Ry
Share of FFS Rx's: 0.13%			+					\$71.85
Share of FFS Rx's: 0.13%	ANTIADDINTIMOS							
Per Member SFY05 YTD: \$1.09								
AMIODARONE   Y   Cordarone   Wyeth   \$157,271   10,336   76.5%   \$15.2	Share of FFS Rx's: 0.13%							
AMIODARONE   Y   Cordarone   Wyeth   \$157,271   10,336   76.5%   \$15.2	Per Member SFY05 YTD: \$1.09	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PROPAFENONE   Y   Rythmol   Reliant   \$46,391   603   4.5%   \$76.9								\$15.22
FLECAINIDE		Υ						\$76.93
DOFFILIDE   N   Tikosyn   Pfizer   \$32,766   301   2.2%   \$108.8	FLECAINIDE	Υ	Tambocor	3M	\$35,718	860	6.4%	\$41.53
DISOPYRAMIDE   Y   Norpace   Pharmacia   \$20,513   395   2.9%   \$51.9		N	Tikosyn	Pfizer		301	2.2%	\$108.86
MEXILETINE   Y   Mexitil   Boehringer   \$18,210   447   3.3%   \$40.7		Υ		Pharmacia		395	2.9%	\$51.93
QUINIDINE   Y   Quinaglute Dura-tabs   Berlex   \$10,797   341   2.5%   \$31.6		Y						\$40.74
PROCAINAMIDE   Y		1.1	INICVIIII		\$18,210			
MORICIZINE		Y		Ū			2.5%	\$31,66
LIDOCAINE   \$113	QUINIDINE	Y Y	Quinaglute Dura-tabs	Berlex	\$10,797	341		\$31.66 \$31.20
Total	QUINIDINE PROCAINAMIDE	Y	Quinaglute Dura-tabs	Berlex	\$10,797 \$6,582	341 211	1.6%	\$31.20
ANTICOAGULANTS - HEPARIN/RELATED  Share of FFS Rx's: 0.13%  Per Member SFY05 YTD: \$10.76  MAC'd? Brand Manufacturer Total \$\$ Total Rx  ENOXAPARIN N Lovenox Aventis \$2,841,310  DALTEPARIN,PORCINE N Fragmin Pharm & Upjohn \$158,819 373 2.8% \$425.7  HEPARIN,PORCINE N ?? \$158,620 6,930 52.7% \$22.8  TINZAPARIN,PORCINE N Innohep Dupont \$61,489 25 0.2% \$2,459.5  FONDAPARINUX N Arixtra Organon-Sanofit \$25,846 35 0.3% \$738.4  Total \$\$3,246,084 13,143 100.0% \$246.9  ANTICOAGULANTS - ORAL  Share of FFS Rx's: 1.49%  Per Member SFY05 YTD: \$5.57 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE	Y	Quinaglute Dura-tabs	Berlex	\$10,797 \$6,582 \$1,286	341 211	1.6% 0.1%	\$31.20 \$107.16
Share of FFS Rx's: 0.13%   Brand   Manufacturer   Total \$\$   Total Rx   Market Share   \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE	Y	Quinaglute Dura-tabs	Berlex	\$10,797 \$6,582 \$1,286 \$113	341 211 12 1	1.6% 0.1% 0.0%	\$31.20
Per Member SFY05 YTD: \$10.76         MAC'd?         Brand         Manufacturer         Total \$\$         Total Rx         Market Share         \$\$ Per Rx           ENOXAPARIN         N         Lovenox         Aventis         \$2,841,310         5,780         44.0%         \$491.5           DALTEPARIN,PORCINE         N         Fragmin         Pharm & Upjohn         \$158,819         373         2.8%         \$425.7           HEPARIN,PORCINE         N         ??         \$158,620         6,930         52.7%         \$22.8           INIZAPARIN,PORCINE         N         Innohep         Dupont         \$61,489         25         0.2%         \$2,459.5           FONDAPARINUX         N         Arixtra         Organon-Sanofit         \$25,846         35         0.3%         \$738.4           Total         \$3,246,084         13,143         100.0%         \$246.9           ANTICOAGULANTS - ORAL         \$3,246,084         13,143         100.0%         \$246.9           Share of FFS Rx's: 1.49%         \$3,246,084         Total Rx         Market Share         \$\$ Per Rx           Per Member SFY05 YTD: \$5.57         MAC'd?         Brand         Manufacturer         Total \$\$         Total Rx         Market Share         \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE	Y	Quinaglute Dura-tabs	Berlex	\$10,797 \$6,582 \$1,286 \$113	341 211 12 1	1.6% 0.1% 0.0%	\$31.20 \$107.16 \$113.18
ENOXAPARIN   N   Lovenox   Aventis   \$2,841,310   5,780   44.0%   \$491.5	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/RELI	Y	Quinaglute Dura-tabs	Berlex	\$10,797 \$6,582 \$1,286 \$113	341 211 12 1	1.6% 0.1% 0.0%	\$31.20 \$107.16 \$113.18
DALTEPARIN,PORCINE         N         Fragmin         Pharm & Upjohn         \$158,819         373         2.8%         \$425.7           HEPARIN,PORCINE         N         ??         \$158,620         6,930         52.7%         \$22.8           TINZAPARIN,PORCINE         N         Innohep         Dupont         \$61,489         25         0.2%         \$2,459.5           FONDAPARINUX         N         Arixtra         Organon-Sanofit         \$25,846         35         0.3%         \$738.4           Total         \$3,246,084         13,143         100.0%         \$246.9           ANTICOAGULANTS - ORAL         Share of FFS Rx's: 1.49%         Share of FFS Rx's: 1.49%         Total \$\$         Total Rx         Market Share         \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13%	ATED	Quinaglute Dura-tabs Procanbid	Berlex Monarch	\$10,797 \$6,582 \$1,286 \$113 \$329,647	341 211 12 1 1 13,507	1.6% 0.1% 0.0% 100.0%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b>
HEPARIN,PORCINE	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76	ATED  MAC'd?	Quinaglute Dura-tabs Procanbid  Brand	Berlex Monarch	\$10,797 \$6,582 \$1,286 \$113 \$329,647	341 211 12 1 1 13,507	1.6% 0.1% 0.0% 100.0%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b> \$\$ Per Rx
TINZAPARIN,PORCINE         N         Innohep         Dupont         \$61,489         25         0.2%         \$2,459.5           FONDAPARINUX         N         Arixtra         Organon-Sanofit         \$25,846         35         0.3%         \$738.4           Total         \$3,246,084         13,143         100.0%         \$246.9           ANTICOAGULANTS - ORAL         Share of FFS Rx's: 1.49%         Total \$\$         Total Rx         Market Share         \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORCIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/RELA Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN	ATED  MAC'd?	Quinaglute Dura-tabs Procanbid  Brand Lovenox	Berlex Monarch  Manufacturer Aventis	\$10,797 \$6,582 \$1,286 \$113 \$329,647 Total \$\$ \$2,841,310	341 211 12 13,507 Total Rx 5,780	1.6% 0.1% 0.0% 100.0% Market Share 44.0%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b> \$Per Rx \$491.58
FONDAPARINUX   N   Arixtra   Organon-Sanofit   \$25,846   35   0.3%   \$738.4	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE	ATED  MAC'd?  N	Quinaglute Dura-tabs Procanbid  Brand Lovenox Fragmin	Berlex Monarch  Manufacturer Aventis	\$10,797 \$6,582 \$1,286 \$113 <b>\$329,647</b> Total \$\$ \$2,841,310 \$158,819	341 211 12 1 13,507 Total Rx 5,780 373	1.6% 0.1% 0.0% 100.0% Market Share 44.0% 2.8%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b> \$Per Rx \$491.58 \$425.79
FONDAPARINUX   N   Arixtra   Organon-Sanofit   \$25,846   35   0.3%   \$738.4	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE	ATED  MAC'd?  N  N	Quinaglute Dura-tabs Procanbid  Brand Lovenox Fragmin	Berlex Monarch  Manufacturer Aventis	\$10,797 \$6,582 \$1,286 \$113 <b>\$329,647</b> Total \$\$ \$2,841,310 \$158,819	341 211 12 1 13,507 Total Rx 5,780 373	1.6% 0.1% 0.0% 100.0% Market Share 44.0% 2.8% 52.7%	\$31.20 \$107.16 \$113.18 \$24.41 \$\$ Per Rx \$491.58 \$425.79 \$22.89
Total \$3,246,084 13,143 100.0% \$246.9  ANTICOAGULANTS - ORAL  Share of FFS Rx's: 1.49%  Per Member SFY05 YTD: \$5.57 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/RELJ Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE HEPARIN,PORCINE	ATED  MAC'd?  N  N	Quinaglute Dura-tabs Procanbid  Brand Lovenox Fragmin ??	Manufacturer Aventis Pharm & Upjohn	\$10,797 \$6,582 \$1,286 \$113 <b>\$329,647</b> Total \$\$ \$2,841,310 \$158,819 \$158,620	341 211 12 1 13,507 Total Rx 5,780 373 6,930	1.6% 0.1% 0.0% 100.0% Market Share 44.0% 2.8% 52.7%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b> \$\$ Per Rx \$491.58 \$425.79 \$22.89 \$2,459.57
Share of FFS Rx's: 1.49%  Per Member SFY05 YTD: \$5.57  MAC'd? Brand  Manufacturer  Total \$\$ Total Rx  Market Share \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE HEPARIN,PORCINE TINZAPARIN,PORCINE	ATED  MAC'd?  N  N  N	Brand Lovenox Fragmin ??	Manufacturer Aventis Pharm & Upjohn Dupont	\$10,797 \$6,582 \$1,286 \$113 \$329,647 Total \$\$ \$2,841,310 \$158,620 \$61,489	341 211 12 1 13,507 Total Rx 5,780 373 6,930 25	1.6% 0.1% 0.0% 100.0% Market Share 44.0% 2.8% 52.7% 0.2%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b> \$\$ Per Rx \$491.58 \$425.79 \$22.88 \$2,459.57
Share of FFS Rx's: 1.49%  Per Member SFY05 YTD: \$5.57  MAC'd? Brand  Manufacturer  Total \$\$ Total Rx  Market Share \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE HEPARIN,PORCINE TINZAPARIN,PORCINE FONDAPARINUX	ATED  MAC'd?  N  N  N	Brand Lovenox Fragmin ??	Manufacturer Aventis Pharm & Upjohn Dupont	\$10,797 \$6,582 \$1,286 \$113 <b>\$329,647</b> Total \$\$ \$2,841,310 \$158,819 \$158,620 \$61,489 \$25,846	341 211 12 1 13,507 Total Rx 5,780 373 6,930 25 35	1.6% 0.1% 0.0% 100.0% Market Share 44.0% 2.8% 52.7% 0.2% 0.3%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b> \$\$ Per Rx \$491.58 \$425.79 \$22.89 \$2,459.57 \$738.44
Per Member SFY05 YTD: \$5.57 MAC'd? Brand Manufacturer Total \$\$ Total Rx Market Share \$\$ Per Rx	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE HEPARIN,PORCINE HIDARIN,PORCINE TINZAPARIN,PORCINE FONDAPARINUX Total	ATED  MAC'd?  N  N  N	Brand Lovenox Fragmin ??	Manufacturer Aventis Pharm & Upjohn Dupont	\$10,797 \$6,582 \$1,286 \$113 <b>\$329,647</b> Total \$\$ \$2,841,310 \$158,819 \$158,620 \$61,489 \$25,846	341 211 12 1 13,507 Total Rx 5,780 373 6,930 25 35	1.6% 0.1% 0.0% 100.0% Market Share 44.0% 2.8% 52.7% 0.2% 0.3%	\$31.20 \$107.16 \$113.18 <b>\$24.41</b> \$\$ Per Rx \$491.58 \$425.79 \$22.89 \$2,459.57 \$738.44
	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/RELA Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE HEPARIN,PORCINE HINZAPARIN,PORCINE FONDAPARINUX Total  ANTICOAGULANTS - ORAL	ATED  MAC'd?  N  N  N	Brand Lovenox Fragmin ??	Manufacturer Aventis Pharm & Upjohn Dupont	\$10,797 \$6,582 \$1,286 \$113 <b>\$329,647</b> Total \$\$ \$2,841,310 \$158,819 \$158,620 \$61,489 \$25,846	341 211 12 1 13,507 Total Rx 5,780 373 6,930 25 35	1.6% 0.1% 0.0% 100.0% Market Share 44.0% 2.8% 52.7% 0.2% 0.3%	\$31.20 \$107.16 \$113.18 \$24.41 \$\$ Per Rx \$491.58 \$425.79 \$22.89
WARFARIN Y Coumadin DuPont \$1,681,669 155,392 100.0% \$10.8	QUINIDINE PROCAINAMIDE MORICIZINE LIDOCAINE Total  ANTICOAGULANTS - HEPARIN/REL Share of FFS Rx's: 0.13% Per Member SFY05 YTD: \$10.76 ENOXAPARIN DALTEPARIN,PORCINE HEPARIN,PORCINE HEPARIN,PORCINE TINZAPARIN,PORCINE FONDAPARINUX Total  ANTICOAGULANTS - ORAL Share of FFS Rx's: 1.49%	Y  ATED  MAC'd?  N  N  N  N	Brand Lovenox Fragmin ?? Innohep Arixtra	Manufacturer Aventis Pharm & Upjohn Dupont Organon-Sanofit	\$10,797 \$6,582 \$1,286 \$113 \$329,647 Total \$\$ \$2,841,310 \$158,819 \$158,620 \$61,489 \$25,846 \$3,246,084	341 211 12 1 13,507 Total Rx 5,780 373 6,930 25 35 13,143	1.6% 0.1% 0.0% 100.0%  Market Share 44.0% 2.8% 52.7% 0.2% 0.3% 100.0%	\$31.20 \$107.16 \$113.18 \$24.41 \$24.41 \$491.58 \$425.79 \$22.89 \$2,459.57 \$738.44 \$246.98

Total							
ANTICONVULSANTS							
Share of FFS Rx's: 4.83%							
Per Member SFY05 YTD: \$191.98	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DIVALPROEX SODIUM	N	Depakote	Abbott	\$15,749,188	120,275	23.9%	\$130.9
GABAPENTIN	Υ	Neurontin	Parke-Davis	\$11,199,693	101,339	20.1%	\$110.5
LAMOTRIGINE	N	Lamictal	GlaxoSmithKline	\$8,834,442	39,178	7.8%	\$225.4
TOPIRAMATE LEVETIRACETAM	N N	Topamax Keppra	Ortho-McNeil UCB	\$7,620,110 \$3,512,145	36,610 17,827	7.3% 3.5%	\$208.1 \$197.0
OXCARBAZEPINE	N	Trileptal	Novartis	\$2,965,045	19,316	3.8%	\$157.0
CARBAMAZEPINE	Y	Tegretol	Novartis	\$2,392,410	65,325	13.0%	\$36.62
PHENYTOIN	Υ	Dilantin	Pfizer	\$1,593,409	64,526	12.8%	\$24.69
ZONISAMIDE	N	Zonegran	Elan	\$1,383,566	8,265	1.6%	\$167.40
TIAGABINE DIAZEPAM	N	Gabitril Valium	Sephalon Roche	\$657,275 \$633,706	5,312 2,441	1.1% 0.5%	\$123.73 \$259.6
FELBAMATE	N	Felbatol	MedPointe	\$589,357	2,376	0.5%	\$248.0
PRIMIDONE	Y	Mysoline	Xcel	\$349,570	8,820	1.8%	\$39.63
VALPROIC ACID	Υ	Depakene	Abbott	\$311,781	9,541	1.9%	\$32.68
ETHOSUXIMIDE	N	Zarontin	Parke-Davis	\$56,522	818	0.2%	\$69.10
MEPHOBARBITAL	N	Mebaral	Ovation	\$46,248	700	0.1%	\$66.07
FOSPHENYTOIN	N N	Peganone	Ovation Parke-Davis	\$20,834	31 124	0.0%	\$672.05 \$133.01
ETHOTOIN METHSUXIMIDE	N	Celontin Cerebyx	Parke-Davis Parke-Davis	\$16,494 \$12,447	209	0.0%	\$133.0
Total	IN	Celebyx	r aike-Davis	\$57,944,241	503,033	100.0%	\$115.19
Total				ψ01,544,241	303,033	100.070	ψιιο.ι.
ANTIDEPRESSANTS - A2RAS							
Share of FFS Rx's: 0.67%		1					
Per Member SFY05 YTD: \$6.27	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MIRTAZAPINE	Υ	Remeron	Organon	\$1,893,482	70,189	100.0%	\$26.98
ANTIDEPRESSANTS - MAO INHIBITO	DRS						
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.10	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PHENELZINE	N	Nardil	Parke-Davis	\$19,923	291	72.9%	\$68.46
TRANYLCYPROMINE	N	Parnate	GlaxoSmithKline	\$10,929	108	27.1%	\$101.19
Total				\$30,852	399	100.0%	\$77.32
ANTIDEDDECCANTE NODIC							
ANTIDEPRESSANTS - NDRIS							
Share of FFS Rx's: 0.58%							
Per Member SFY05 YTD: \$16.84	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
BUPROPION	Υ	Wellbutrin	GlaxoSmithKline	\$5,083,973	60,719	100.0%	\$83.73
41/7/200000000000000000000000000000000000							
ANTIDEPRESSANTS - OTHER							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.06	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMITRIPTYLINE	Υ	Elavil	AstraZeneca	\$18,812	1,208	100.0%	\$15.57
ANTIDEDDECCANTO CADIO							
ANTIDEPRESSANTS - SARIS							
Share of FFS Rx's: 0.87%	MA 01:10	D	N f t	T-1-1-00	Tatal Day	Manhat Obana	** D D
Per Member SFY05 YTD: \$2.20 TRAZODONE	MAC'd?	Brand	Manufacturer	Total \$\$ \$563,299	Total Rx	Market Share 95.5%	\$\$ Per Rx
NEFAZODONE NEFAZODONE	Y	Desyrel Serzone	Apothecon BMS	\$100,573	86,254 4,019	4.5%	\$6.53 \$25.02
Total		CCIZOTIC	DIVIO	\$663,872	90.273	100.0%	\$7.35
				<b>4000,0.2</b>	00,2.0	1001070	<b>4</b>
ANTIDEPRESSANTS - SNRIS		1					
Share of FFS Rx's: 0.73%		1					
Per Member SFY05 YTD: \$27.72	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
VENLAFAXINE	N	Effexor	Wyeth	\$8,367,410	68,548	89.8%	\$122.07
DULOXETINE	N	Cymbalta	Lilly	\$867,361	7,754	10.2%	\$111.86
Total				\$9,234,771	76,302	100.0%	\$121.03
ANTIDEPRESSANTS - SSRIS							
Share of FFS Rx's: 4.00%							
Per Member SFY05 YTD: \$75.29	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SERTRALINE	N	Zoloft	Pfizer	\$10,025,281	111,867	26.9%	\$89.62
ESCITALOPRAM	N	Lexapro	Forest	\$4,940,882	72,951	17.5%	\$67.73
PAROXETINE	Y	Paxil	GlaxoSmithKline	\$3,899,281	76,309	18.3%	\$51.10
CITALOPRAM FLUOXETINE	Y	Celexa Prozac	Forest Lilly	\$1,947,490 \$1,596,834	45,345 99,940	10.9% 24.0%	\$42.95 \$15.98
FLUVOXAMINE	Y	Luvox	Solvay	\$1,596,834 \$313,295	10,061	24.0%	\$15.98
Total	1			\$22,723,063	416,473	100.0%	\$54.56
		1		,,.	,	1 2 2 . 2 7 0	,
ANTIDEPRESSANTS - TRICYCLICS		1					
Share of FFS Rx's: 0.90%	+	+					
Per Member SFY05 YTD: \$3.05	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx

IMIPRAMINE	Υ	Tofranil	Mallinkrodt	\$228,412	10,848	11.6%	\$21.06
NORTRIPTYLINE	Υ	Aventyl	Lilly	\$150,079	17,168	18.4%	\$8.74
DOXEPIN	Υ	Sinequan	Pfizer	\$73,872	9,118	9.8%	\$8.10
CLOMIPRAMINE	Υ	Anafranil	Mallinkrodt	\$70,027	5,113	5.5%	\$13.70
TRIMIPRAMINE	Υ	Surmontil	Odyssey	\$43,079	425	0.5%	\$101.36
PROTRIPTYLINE	N	Vivactil	Odyssey, Merck	\$38,743	420	0.4%	\$92.24
DESIPRAMINE	Y	Norpramin	Aventis	\$38,663	1,961	2.1%	\$19.72
AMOXAPINE	Y	Asendin	Lederle	\$11,544	329	0.4%	\$35.09
MAPROTILINE	Υ	Ludiomil	Novartis	\$7,009	248	0.3%	\$28.26
Total	-			\$920,786	93,377	100.0%	\$9.86
Total				ψ320,700	33,311	100.070	ψ3.00
ANTIDIARRHEALS							
Share of FFS Rx's: 0.20%							
Per Member SFY05 YTD: \$0.60	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DIPHENOXYLATE	V	Lomotil	Pharmacia	\$89,924		46.0%	
LOPERAMIDE	T V		McNeil		9,739		\$9.23
	Y	Imodium	MCNell	\$77,448	10,817	51.1%	\$7.16
PAREGORIC	N	Paregoric		\$6,619	77	0.4%	\$85.97
DIFENOXIN	N	Motofen	Amarin	\$5,375	93	0.4%	\$57.80
BISMUTH SUBSALICYLATE	Y	Various		\$2,689	458	2.2%	\$5.87
Total				\$182,055	21,184	100.0%	\$8.59
ANTIDOTES							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$1.45	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DEFEROXAMINE	N	Desferal	Novartis	\$424,764	1,134	92.6%	\$374.57
SUCCIMER	N	Chemet	Ovation	\$4,300	12	1.0%	\$358.34
ZINC ACETATE	N	Various	0.0001	\$3,983	43	3.5%	\$92.63
TRIENTINE	N	Syprine	Merck	\$3,370	34	2.8%	\$99.11
METHYLENE BLUE	IN	Зурине	INICION	\$3,370 \$53	34	2.0%	φ <del>99</del> .11
	-	+				400.007	<b>#</b> 0.50.50
Total				\$436,471	1,224	100.0%	\$356.59
ANTIEMETIC/ANTIVERTIGO - ANTIS	<b>EROTON</b>	IN AGENTS					
Share of FFS Rx's: 0.06%							
Per Member SFY05 YTD: \$13.38	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ONDANSETRON	N	Zofran	GlaxoSmithKline	\$3,641,152	5,962	91.9%	\$610.73
DOLASETRON	N	Anzemet	Aventis	\$232,198	292	4.5%	\$795.20
GRANISETRON	N	Kytril	Roche	\$164,974	236	3.6%	\$699.04
Total				\$4,038,324	6,490	100.0%	\$622.24
1				<b>+</b> 1,000,000	-,		**
ANTIEMETIC/ANTIVERTIGO - DRON	ABINOL						
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$2.32	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DRONABINOL	N N	Marinol		\$698,797	1,274	100.0%	\$548.51
DRONABINOL	IN	Iviannoi	Unimed	\$090,191	1,214	100.076	\$340.3 I
ANTIEMETIC/ANTIVERTIGO - MISCE	LLANEO	US					
	LLANEO	us					
Share of FFS Rx's: 0.31%							
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.31%		Brand Compazine	Manufacturer GlaxoSmithKline	Total \$\$ \$223,753	Total Rx 12,073	Market Share 36.9%	\$\$ Per Rx \$18.53
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19		Brand					
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE	MAC'd?	Brand Compazine Transderm Scop	GlaxoSmithKline Novartis	\$223,753 \$208,049	12,073 4,763	36.9% 14.6%	\$18.53 \$43.68
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE	MAC'd? Y N	Brand Compazine	GlaxoSmithKline	\$223,753	12,073	36.9%	\$18.53
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE	MAC'd? Y N Y	Brand Compazine Transderm Scop Phenergan	GlaxoSmithKline Novartis Wyeth Pfizer	\$223,753 \$208,049 \$91,303 \$78,088	12,073 4,763 2,021 13,282	36.9% 14.6% 6.2% 40.6%	\$18.53 \$43.68 \$45.18 \$5.88
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT	MAC'd? Y N Y Y N	Brand Compazine Transderm Scop Phenergan Antivert Emend	GlaxoSmithKline Novartis Wyeth Pfizer Merck	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063	12,073 4,763 2,021 13,282 193	36.9% 14.6% 6.2% 40.6% 0.6%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE	MAC'd? Y N Y Y N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457	12,073 4,763 2,021 13,282 193 301	36.9% 14.6% 6.2% 40.6% 0.6% 0.9%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE	MAC'd? Y N Y Y N Y Y Y N N Y Y	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264	12,073 4,763 2,021 13,282 193 301 70	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE	MAC'd? Y N Y Y N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91	12,073 4,763 2,021 13,282 193 301 70 6	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 0.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE	MAC'd? Y N Y Y N Y Y Y N N Y Y	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264	12,073 4,763 2,021 13,282 193 301 70	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total	MAC'd? Y N Y Y N Y Y Y N N Y Y	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91	12,073 4,763 2,021 13,282 193 301 70 6	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 0.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE	MAC'd? Y N Y Y N Y Y Y N N Y Y	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91	12,073 4,763 2,021 13,282 193 301 70 6	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 0.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total  ANTIFUNGALS	MAC'd? Y N Y Y N Y Y Y N N Y Y	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91	12,073 4,763 2,021 13,282 193 301 70 6	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 0.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  ANTIFUNGALS Share of FFS Rx's: 0.00%	MAC'd? Y N Y Y Y N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 0.0% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31	MAC'd? Y N Y Y N N N N N N M M M M M M M M M M	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  ANTIFUNGALS Share of FFS Rx's: 0.00%	MAC'd? Y N Y Y Y N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 0.0% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31	MAC'd? Y N Y Y N N N N N N M M M M M M M M M M	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE	MAC'd? Y N Y Y N N N N N N M M M M M M M M M M	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE TOIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES	MAC'd? Y N Y Y N N N N N N M M M M M M M M M M	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE	MAC'd? Y N Y Y N N N N N N M M M M M M M M M M	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33%	MAC'd? Y N Y Y N N N N N N M M M M M M M M M M	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068	12,073 4,763 2,021 13,282 193 301 70 6 32,709	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE  SCOPOLAMINE  PROMETHAZINE  MECLIZINE  MECLIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  TRIMETHOBENZAMIDE  DIMENHYDRINATE  THIETHYLPERAZINE  Total  ANTIFUNGALS  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$1.31  VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES  Share of FFS Rx's: 0.33%  Per Member SFY05 YTD: \$7.75	MAC'd? Y N Y Y N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 <b>\$660,068</b> Total \$\$ \$395,693	12,073 4,763 2,021 13,282 193 301 70 6 32,709 Total Rx 271	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$Per Rx \$1,460.12
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE	MAC'd? Y N N Y Y N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068 Total \$\$ \$395,693	12,073 4,763 2,021 13,282 193 301 70 6 32,709 Total Rx 271	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0%  Market Share 100.0%  Market Share 6.2%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$Per Rx \$1,460.12
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE	MAC'd? Y N Y Y N N N N N MAC'd? N MAC'd? N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068 Total \$\$ \$395,693	12,073 4,763 2,021 13,282 193 301 70 6 32,709 Total Rx 271	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0%  100.0%  Market Share 100.0%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$Per Rx \$1,460.12 \$Per Rx \$250.25 \$25.09
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MERLITHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31  VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN	MAC'd? Y N N Y N N N N MAC'd? N MAC'd? N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 <b>\$660,068</b> Total \$\$ \$395,693	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147	36.9% 14.6% 6.2% 40.6% 0.9% 0.2% 100.0% 100.0%  Market Share 100.0% 6.2% 57.0% 0.4%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 <b>\$20.18</b> \$Per Rx \$1,460.12 \$Per Rx \$250.25 \$25.029 \$2,311.37
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE  SCOPOLAMINE  PROMETHAZINE  MECLIZINE  MECLIZINE  MERCIZINE  MERCIZINE  MERCIZINE  MERCIZINE  MERCIZINE  MERCIZINE  MERCIZINE  MERCIZINE  MERCIZINE  MIMENTHOBENZAMIDE  DIMENHYDRINATE  THIETHYLPERAZINE  Total  ANTIFUNGALS  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$1.31  VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES  Share of FFS Rx's: 0.33%  Per Member SFY05 YTD: \$7.75  TERBINAFINE  FLUCONAZOLE  CASPOFUNGIN  AMPHOTERICIN B	MAC'd? Y N Y Y N N N N N MAC'd? N MAC'd? N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 <b>\$660,068</b> Total \$\$ \$395,693	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0% 100.0%  Market Share 100.0%  Market Share 6.2% 57.0% 0.4% 0.7%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$Per Rx \$1,460.12 \$\$ Per Rx \$250.25 \$250.25 \$25.25 \$25.25 \$25.25
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MECLIZINE MECLIZINE MECLIZINE MECLIZINE METHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN	MAC'd? Y N N Y Y N N N N N MAC'd? N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon	\$223,753 \$208,049 \$91,303 \$78,088 \$44,063 \$10,457 \$264 \$91 <b>\$660,068</b> Total \$\$ \$395,693 Total \$\$ \$533,034 \$487,522 \$339,771 \$260,647 \$249,461	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823	36.9% 14.6% 6.2% 40.6% 0.9% 0.2% 100.0% 100.0%  Market Share 100.0%  Market Share 6.2% 57.0% 0.4% 0.7% 22.9%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ Per Rx \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN ITRACONAZOLE	MAC'd? Y N N Y Y N N N N N MAC'd? N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 <b>\$660,068</b> <b>Total \$\$</b> \$395,693 <b>Total \$\$</b> \$533,034 \$487,522 \$339,771 \$260,647 \$249,461	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0% 100.0%  Market Share 100.0%  Market Share 6.2% 57.0% 0.4% 0.7% 22.9% 1.6%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$Per Rx \$1,460.12 \$\$Per Rx \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89 \$423.71
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN	MAC'd? Y N N Y Y N N N N N MAC'd? N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen	\$223,753 \$208,049 \$91,303 \$78,088 \$44,063 \$10,457 \$264 \$91 <b>\$660,068</b> Total \$\$ \$395,693 Total \$\$ \$533,034 \$487,522 \$339,771 \$260,647 \$249,461	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823	36.9% 14.6% 6.2% 40.6% 0.9% 0.2% 100.0% 100.0%  Market Share 100.0%  Market Share 6.2% 57.0% 0.4% 0.7% 22.9%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$Per Rx \$1,460.12 \$\$Per Rx \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89 \$423.71
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE APREPITANT TRIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE  Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN ITRACONAZOLE	MAC'd? Y N N Y Y N N N N N MAC'd? N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox Fulvicin	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 \$660,068 Total \$\$ \$395,693 Total \$\$ \$395,693	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0% 100.0%  Market Share 100.0%  Market Share 6.2% 57.0% 0.4% 0.7% 22.9% 1.6%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ \$250.25 \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89 \$423.71 \$86.46
Share of FFS Rx's: 0.31%  Per Member SFY05 YTD: \$2.19  PROCHLORPERAZINE  SCOPOLAMINE  PROMETHAZINE  MECLIZINE  MECLIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MERCHIZINE  MINIMITHOBENZAMIDE  DIMENHYDRINATE  THIETHYLPERAZINE  Total  ANTIFUNGALS  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$1.31  VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES  Share of FFS Rx's: 0.33%  Per Member SFY05 YTD: \$7.75  TERBINAFINE  FLUCONAZOLE  CASPOFUNGIN  AMPHOTERICIN B  NYSTATIN  ITRACONAZOLE  GRISEOFULVIN  CLOTRIMAZOLE	MAC'd? Y N N Y Y N N N N N N MAC'd? N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox Fulvicin Mycelex	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen Schering-Plough McNeil	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 <b>\$660,068</b> Total \$\$ \$395,693 Total \$\$ \$533,034 \$487,522 \$339,771 \$260,647 \$249,461 \$227,531 \$136,866 \$97,900	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537 1,583 1,489	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0% 100.0%  Market Share 100.0%  Market Share 6.2% 57.0% 0.4% 0.7% 22.9% 1.6% 4.4%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ \$Per Rx \$250.25 \$250.25 \$250.25 \$31.89 \$423.71 \$86.46 \$65.75
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MERCHIZINE TOTAI  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN ITRACONAZOLE GRISEOFULVIN CLOTRIMAZOLE KETOCONAZOLE	MAC'd? Y N N Y Y N N N N MAC'd? N  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox Fulvicin	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen Schering-Plough	\$223,753 \$208,049 \$91,303 \$78,088 \$44,063 \$10,457 \$264 \$91 <b>\$660,068</b> <b>Total \$\$</b> \$395,693 <b>Total \$\$</b> \$533,034 \$487,522 \$339,771 \$260,647 \$249,461 \$227,531 \$136,866 \$97,900	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537 1,583 1,489 712	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0% 100.0%  Market Share 100.0% 57.0% 0.7% 22.9% 1.6% 4.6% 4.4% 2.1%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ Per Rx \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89 \$423.71 \$86.75 \$10.95
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MINIMITER TOTAL  MINIMITER TOTAL  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN ITRACONAZOLE GRISEOFULVIN CLOTRIMAZOLE	MAC'd? Y N N Y Y N N N N N MAC'd? N  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox Fulvicin Mycelex	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen Schering-Plough McNeil	\$223,753 \$208,049 \$91,303 \$78,088 \$48,063 \$10,457 \$264 \$91 <b>\$660,068</b> Total \$\$ \$395,693 Total \$\$ \$533,034 \$487,522 \$339,771 \$260,647 \$249,461 \$227,531 \$136,866 \$97,900	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537 1,583 1,489	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 0.2% 100.0% 100.0%  Market Share 100.0%  Market Share 6.2% 57.0% 0.4% 0.7% 22.9% 1.6% 4.4%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ Per Rx \$250.25 \$250.25 \$31.89 \$423.71 \$86.46 \$65.75
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE TIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN ITRACONAZOLE GRISEOFULVIN CLOTRIMAZOLE KETOCOONAZOLE TOTAL	MAC'd? Y N N Y Y N N N N N MAC'd? N  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox Fulvicin Mycelex	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen Schering-Plough McNeil	\$223,753 \$208,049 \$91,303 \$78,088 \$44,063 \$10,457 \$264 \$91 <b>\$660,068</b> <b>Total \$\$</b> \$395,693 <b>Total \$\$</b> \$533,034 \$487,522 \$339,771 \$260,647 \$249,461 \$227,531 \$136,866 \$97,900	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537 1,583 1,489 712	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0% 100.0%  Market Share 100.0% 57.0% 0.7% 22.9% 1.6% 4.6% 4.4% 2.1%	\$18.53 \$43.68 \$43.68 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ Per Rx \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89 \$423.71 \$86.75 \$10.95
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MERCHIZINE TOTAI  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN ITRACONAZOLE GRISEOFULVIN CLOTRIMAZOLE KETOCONAZOLE	MAC'd? Y N N Y Y N N N N N MAC'd? N  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox Fulvicin Mycelex	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen Schering-Plough McNeil	\$223,753 \$208,049 \$91,303 \$78,088 \$44,063 \$10,457 \$264 \$91 <b>\$660,068</b> <b>Total \$\$</b> \$395,693 <b>Total \$\$</b> \$533,034 \$487,522 \$339,771 \$260,647 \$249,461 \$227,531 \$136,866 \$97,900	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537 1,583 1,489 712	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0% 100.0%  Market Share 100.0% 57.0% 0.7% 22.9% 1.6% 4.6% 4.4% 2.1%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ Per Rx \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89 \$423.71 \$86.75 \$10.95
Share of FFS Rx's: 0.31% Per Member SFY05 YTD: \$2.19 PROCHLORPERAZINE SCOPOLAMINE PROMETHAZINE MECLIZINE MECLIZINE MECLIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE MERCHIZINE TIMETHOBENZAMIDE DIMENHYDRINATE THIETHYLPERAZINE Total  ANTIFUNGALS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$1.31 VORICONAZOLE  ANTIFUNGALS ANTI-INFECTIVES Share of FFS Rx's: 0.33% Per Member SFY05 YTD: \$7.75 TERBINAFINE FLUCONAZOLE CASPOFUNGIN AMPHOTERICIN B NYSTATIN ITRACONAZOLE GRISEOFULVIN CLOTRIMAZOLE KETOCOONAZOLE TOTAL	MAC'd? Y N N Y Y N N N N N MAC'd? N  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Compazine Transderm Scop Phenergan Antivert Emend Tigan Dramamine Torecan  Brand VFEND  Brand Lamisil Diflucan Cancidas Amphotec Mycostatin Sporanox Fulvicin Mycelex	GlaxoSmithKline Novartis Wyeth Pfizer Merck Monarch Pharmacia Roxane  Manufacturer Pfizer  Manufacturer Novartis Pfizer Merck InterMune Apothecon Janssen Schering-Plough McNeil	\$223,753 \$208,049 \$91,303 \$78,088 \$44,063 \$10,457 \$264 \$91 <b>\$660,068</b> <b>Total \$\$</b> \$395,693 <b>Total \$\$</b> \$533,034 \$487,522 \$339,771 \$260,647 \$249,461 \$227,531 \$136,866 \$97,900	12,073 4,763 2,021 13,282 193 301 70 6 32,709  Total Rx 271  Total Rx 2,130 19,429 147 243 7,823 537 1,583 1,489 712	36.9% 14.6% 6.2% 40.6% 0.6% 0.9% 100.0% 100.0%  Market Share 100.0% 57.0% 0.7% 22.9% 1.6% 4.6% 4.4% 2.1%	\$18.53 \$43.68 \$45.18 \$5.88 \$249.03 \$34.74 \$3.77 \$15.23 \$20.18 \$\$ Per Rx \$1,460.12 \$\$ Per Rx \$250.25 \$25.09 \$2,311.37 \$1,072.62 \$31.89 \$423.71 \$86.75 \$10.95

		I					
Per Member SFY05 YTD: \$5.89	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NYSTATIN	Y	Mycostatin	Apothecon	\$531,166	28,910	38.1%	\$18.37
CLOTRIMAZOLE	Y	Lotrimin	Schering-Plough	\$437,089	22,950	30.3%	\$19.05
KETOCONAZOLE	Y	Nizoral	Janssen	\$325,406	11,077	14.6%	\$29.38
CICLOPIROX	N	Loprox	Medicis	\$263,281	3,141	4.1%	\$83.82
ECONAZOLE	Υ	Spectazole	Ortho	\$56,139	2,064	2.7%	\$27.20
OXICONAZOLE	N	Oxistat	GlaxoSmithKline	\$53,892	1,093	1.4%	\$49.31
NAFTIFINE	N	Naftin	Merz	\$34,438	722	1.0%	\$47.70
TERBINAFINE	N	Lamisil	Novartis	\$28,916	1,685	2.2%	\$17.16
MICONAZOLE	Υ	Monistat	Ortho	\$28,323	3,420	4.5%	\$8.28
BUTENAFINE	N	Mentax	Bertek	\$13,401	187	0.2%	\$71.66
TOLNAFTATE	Y	Tinactin	Schering-Plough	\$2,671	468	0.6%	\$5.71
SULCONAZOLE	N	Exelderm	Westwood	\$2,095	80	0.1%	\$26.19
SERTACONAZOLE	N						
		Ertaczo	Neutrogena	\$2,090	32	0.0%	\$65.30
FORMALDEHYDE	N	Formalyde	Pedinol	\$29	1	0.0%	\$29.38
Total				\$1,778,937	75,830	100.0%	\$23.46
ANTIHEMOPHILIC FACTORS							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$18.84	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ANTIHEMOPHILIC FACTOR VIII	N	Alphanate	Alpha	\$4,025,697	198	75.6%	\$20,331.80
FACTOR VIIA,RECOMB(BHK CELLS)	N	NovoSeven	Novo Nordisk	\$1,303,502	27	10.3%	\$48,277.84
FACTOR IX	N	AlphaNine	Alpha	\$355,641	37	14.1%	\$9,611.91
Total				\$5,684,840	262	100.0%	\$21,697.86
				Ç,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		. 30.0 /0	,,,,,,,,,
ANTIHISTAMINES - NON-SEDATING		1					
Share of FFS Rx's: 1.14%	+	+					
	MA 01 10	D		T. ( 1.60	T-1 1-	Marila 4 O	** -
Per Member SFY05 YTD: \$11.91	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CETIRIZINE	N	Zyrtec	Pfizer	\$1,300,033	23,071	19.3%	\$56.35
FEXOFENADINE	N	Allegra	Aventis	\$1,075,432	15,750	13.2%	\$68.28
LORATADINE	Υ	Claritin	Schering	\$913,380	75,884	63.6%	\$12.04
DESLORATADINE	N	Clarinex	Schering	\$305,380	4,530	3.8%	\$67.41
Total				\$3,594,225	119,235	100.0%	\$30.14
				, -, , -	-,		•
ANTIHISTAMINES - NON-SEDATING	COMBIN	ATION					
Share of FFS Rx's: 0.11%	COMBIN	711014					
Per Member SFY05 YTD: \$1.89	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PSEUDOPHEDRINE		Various		\$569,998	11,568	100.0%	\$49.27
					-		
ANTIHOTAMINEC CEDATINO							
ANTIHISTAMINES - SEDATING							
Share of FFS Rx's: 0.52%							
Per Member SFY05 YTD: \$2.36		Down d	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
. cermenom actuatiu: 37.30	MAC'd?	Brand					
-	MAC'd?	Brand Ataray					
HYDROXYZINE	MAC'd?	Atarax	Pfizer	\$442,057	20,724	38.1%	\$21.33
HYDROXYZINE PROMETHAZINE	MAC'd?	Atarax Phenergan	Pfizer Wyeth	\$442,057 \$129,404	20,724 8,329	38.1% 15.3%	\$21.33 \$15.54
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE	Y Y	Atarax Phenergan Benadryl	Pfizer Wyeth Pfizer	\$442,057 \$129,404 \$98,240	20,724 8,329 22,206	38.1% 15.3% 40.9%	\$21.33 \$15.54 \$4.42
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE	Y Y Y	Atarax Phenergan Benadryl Periactin	Pfizer Wyeth Pfizer Merck	\$442,057 \$129,404 \$98,240 \$31,169	20,724 8,329 22,206 2,377	38.1% 15.3% 40.9% 4.4%	\$21.33 \$15.54 \$4.42 \$13.11
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE	Y Y Y Y	Atarax Phenergan Benadryl Periactin Tavist	Pfizer Wyeth Pfizer Merck Novartis	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174	20,724 8,329 22,206 2,377 402	38.1% 15.3% 40.9% 4.4% 0.7%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE	Y Y Y	Atarax Phenergan Benadryl Periactin	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169	20,724 8,329 22,206 2,377	38.1% 15.3% 40.9% 4.4%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE	Y Y Y Y	Atarax Phenergan Benadryl Periactin Tavist	Pfizer Wyeth Pfizer Merck Novartis	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174	20,724 8,329 22,206 2,377 402	38.1% 15.3% 40.9% 4.4% 0.7%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE	Y Y Y Y N	Atarax Phenergan Benadryl Periactin Tavist Balamine	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787	20,724 8,329 22,206 2,377 402 83	38.1% 15.3% 40.9% 4.4% 0.7% 0.2%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE	Y Y Y Y N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516	20,724 8,329 22,206 2,377 402 83 232	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE	Y Y Y Y N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136	20,724 8,329 22,206 2,377 402 83 232	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE	Y Y Y Y N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$136	20,724 8,329 22,206 2,377 402 83 232 2	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total	Y Y Y Y Y Y Y N Y	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$136	20,724 8,329 22,206 2,377 402 83 232 2	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME	Y Y Y Y Y Y Y N Y	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$136	20,724 8,329 22,206 2,377 402 83 232 2	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04%	Y Y Y Y N Y S S S S S S S S S S S S S S	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.54 \$15.47 \$13.09
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30	Y Y Y Y Y Y Y N Y	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various V	Pfizer Wyeth Pfizer Merck Novartis Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04%	Y Y Y Y N Y S S S S S S S S S S S S S S	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30	Y Y Y Y N Y S S S S S S S S S S S S S S	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various V	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE	Y Y Y Y N Y S S S S S S S S S S S S S S	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  V  Brand Various Various Various Various	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 <b>\$711,499</b> Total \$\$ \$58,312 \$32,098	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE	Y Y Y Y Y N Y MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  Various Various Various Various Phenergan	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0% 0.2%	\$21.33 \$15.54 \$4.54 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE	Y Y Y Y N Y S S S S S S S S S S S S S S	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  V  Brand Various Various Various Various	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748 8	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE	Y Y Y Y Y N Y MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  Various Various Various Various Phenergan	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0% 0.2%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total	Y Y Y Y Y N Y MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  Various Various Various Various Phenergan	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748 8	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC	Y Y Y Y Y N Y MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  Various Various Various Various Phenergan	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748 8	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total	Y Y Y Y Y N Y MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  Various Various Various Various Phenergan	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748 8	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC	Y Y Y Y Y N Y MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  Various Various Various Various Phenergan	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748 8	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09%	Y Y Y Y Y N N Y  MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  V  Brand Various Various Various Phenergan Balamine	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 <b>\$711,499</b> Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 402 83 232 2 2 1 54,356 Total Rx 2,982 748 8 1 3,739	38.1% 15.3% 40.9% 4.4.4% 0.7% 0.2% 0.4% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.19
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE	Y Y Y Y Y N N Y  MAC'd?  MAC'd?  N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Various Phenergan Balamine Balamine Brand Patanol	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%	\$21.33 \$15.54 \$4.54 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.19
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN	Y Y Y Y Y N N Y	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various  Various  Various Phenergan Balamine  Brand Patanol Zaditor	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 402 83 232 2 1 54,356 Total Rx 2,982 748 8 1 3,739	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.19
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE	Y Y Y Y Y N N Y  MAC'd?  MAC'd?  N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine Brand Patanol Zaditor Optivar	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 <b>\$711,499</b> Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356 Total Rx 2,982 748 8 1 3,739	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0% 100.0% 3.1%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.19
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE	Y Y Y Y Y N N Y  MAC'd? N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Various Phenergan Balamine Brand Patanol Zaditor Optivar Elestat	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 <b>\$711,499</b> Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 402 83 232 2 2 1 54,356 Total Rx 2,982 748 8 1 3,739 Total Rx 8,420 620 296	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%  Market Share 88.1% 6.5% 3.1% 1.9%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$21.53 \$6.54 \$68.02 \$15.47 \$13.09 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.19
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE LEVOCABASTINE	Y Y Y Y Y N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine Balamine Brand Patanol Zaditor Optivar Elestat Livostin	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$65.21,53 \$68.02 \$15.47 \$13.09 \$\$Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.19 \$59.85 \$68.41 \$66.85 \$59.85
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE	Y Y Y Y Y N N Y  MAC'd? N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Various Phenergan Balamine Brand Patanol Zaditor Optivar Elestat	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 <b>\$711,499</b> Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 402 83 232 2 2 1 54,356 Total Rx 2,982 748 8 1 3,739 Total Rx 8,420 620 296	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$68.02 \$15.47 \$13.05 \$Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.15 \$59.85 \$68.44 \$66.85
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE LEVOCABASTINE	Y Y Y Y Y N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine Balamine Brand Patanol Zaditor Optivar Elestat Livostin	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.88 \$21.53 \$68.02 \$115.41 \$13.05 \$\$ Per Rx \$19.55 \$42.91 \$4.84 \$6.16 \$24.15 \$59.86 \$68.41 \$66.86 \$59.86 \$68.47
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE EPINASTINE EMEDASTINE	Y Y Y Y Y N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine Balamine Brand Patanol Zaditor Optivar Elestat Livostin	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454 Total \$\$ \$596,851 \$37,110 \$20,250 \$11,967 \$2,268 \$112	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38 3	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%  100.0%  100.0%	\$21.3: \$15.5: \$4.4: \$13.1' \$17.8: \$21.5: \$65.5: \$68.0: \$113.0! \$\$Per Rx \$19.5: \$42.9' \$4.8: \$6.1! \$24.1!
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE EPINASTINE EPINASTINE EMEDASTINE TOtal	Y Y Y Y Y N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine Balamine Brand Patanol Zaditor Optivar Elestat Livostin	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454 Total \$\$ \$596,851 \$37,110 \$20,250 \$11,967 \$2,268 \$112	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38 3	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%  100.0%  100.0%	\$21.3: \$15.5: \$4.4: \$13.1: \$17.8: \$21.5: \$6.5: \$68.0: \$113.0!  \$\$ Per Rx  \$19.5: \$42.9 \$4.8: \$6.1! \$24.1!  \$\$ \$9.8: \$59.8: \$59.8: \$59.8: \$59.8: \$37.4:
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE EPINASTINE EMEDASTINE	Y Y Y Y Y N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine Balamine Brand Patanol Zaditor Optivar Elestat Livostin	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454 Total \$\$ \$596,851 \$37,110 \$20,250 \$11,967 \$2,268 \$112	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38 3	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%  100.0%  100.0%	\$21.3: \$15.5: \$4.4: \$13.1' \$17.8: \$21.5: \$65.5: \$68.0: \$113.0! \$\$Per Rx \$19.5: \$42.9' \$4.8: \$6.1! \$24.1!
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE EPINASTINE EPINASTINE EMEDASTINE TOtal	Y Y Y Y Y N N Y  MAC'd? N N N N N N N N N N N N N N N N N N N	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine Balamine Brand Patanol Zaditor Optivar Elestat Livostin	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454 Total \$\$ \$596,851 \$37,110 \$20,250 \$11,967 \$2,268 \$112	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38 3	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.4% 0.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0%  100.0%  100.0%	\$21.3: \$15.5: \$4.4: \$13.1' \$17.8: \$21.5: \$65.5: \$68.0: \$113.0! \$\$Per Rx \$19.5: \$42.9' \$4.8: \$6.1! \$24.1!
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE LEVOCABASTINE EMEDASTINE MEMEDASTINE TOTAL  ANTI-INFECTIVES DERMATOLOGIC Share of FFS Rx's: 0.29%	Y Y Y Y Y N N Y	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine  Brand Dalamine  Brand Patanol Zaditor Optivar Elestat Livostin Emadine	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba Alcon	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 <b>\$711,499</b> Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454 Total \$\$ \$99,454	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38 3 9,556	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%	\$21.3; \$15.5: \$4.4; \$13.1' \$17.8; \$21.5; \$65.4; \$68.0; \$15.4; \$13.05;  \$Per Rx \$19.5; \$42.9; \$4.8; \$6.1; \$24.15; \$\$9.86; \$59.86; \$37.46; \$69.96;
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE EPINASTINE EPINASTINE EPINASTINE EMEDASTINE TOTAL  ANTI-INFECTIVES DERMATOLOGIC Share of FFS Rx's: 0.29% Per Member SFY05 YTD: \$2.04	Y Y Y Y Y N N Y  MAC'd?  MAC'd?	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine  Brand Patanol Zaditor Optivar Elestat Livostin Emadine	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer Alcon Novartis Medpointe Allergan Ciba Alcon  Manufacturer	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 \$711,499 Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454 Total \$\$ \$596,851 \$37,110 \$20,250 \$11,967 \$2,268 \$112 \$668,558	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38 3 9,556	38.1% 15.3% 40.9% 4.4.4% 0.7% 0.2% 0.4% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0% 100.0% 100.0%  Market Share 88.1% 6.5% 3.1% 1.9% 0.4% 0.0% 100.0%	\$21.33 \$15.5-5 \$4.42 \$13.11 \$17.85 \$68.02 \$15.47 \$13.05 \$\$Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.15 \$59.85 \$68.44 \$66.85 \$59.66 \$37.46 \$69.96
HYDROXYZINE PROMETHAZINE DIPHENHYDRAMINE CYPROHEPTADINE CLEMASTINE CARBINOXAMINE CHLORPHENIRAMINE BROMPHENIRAMINE DEXCHLORPHENIRAMINE DEXCHLORPHENIRAMINE Total  ANTIHISTAMINES - SEDATING COME Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$0.30 PSEUDOPHEDRINE PHENYLEPHRINE PROMETHAZINE CARBINOXAMINE Total  ANTIHISTAMINES OPHTHALMIC Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$2.22 OLOPATADINE KETOTIFEN AZELASTINE EPINASTINE LEVOCABASTINE EMEDASTINE EMEDASTINE METOTIVES DERMATOLOGIC Share of FFS Rx's: 0.29%	Y Y Y Y Y N N Y	Atarax Phenergan Benadryl Periactin Tavist Balamine Chlor-Trimeton Various Various Various Various Phenergan Balamine  Brand Dalamine  Brand Patanol Zaditor Optivar Elestat Livostin Emadine	Pfizer Wyeth Pfizer Merck Novartis Ballay Schering-Plough  Manufacturer  Wyeth Ballay  Manufacturer  Alcon Novartis Medpointe Allergan Ciba Alcon	\$442,057 \$129,404 \$98,240 \$31,169 \$7,174 \$1,787 \$1,516 \$136 \$15 <b>\$711,499</b> Total \$\$ \$58,312 \$32,098 \$39 \$6 \$90,454 Total \$\$ \$99,454	20,724 8,329 22,206 2,377 402 83 232 2 1 54,356  Total Rx 2,982 748 8 1 3,739  Total Rx 8,420 620 296 179 38 3 9,556	38.1% 15.3% 40.9% 4.4% 0.7% 0.2% 0.0% 100.0% 100.0%  Market Share 79.8% 20.0% 0.2% 0.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%	\$21.33 \$15.54 \$4.42 \$13.11 \$17.85 \$68.02 \$15.47 \$13.05 \$Per Rx \$19.55 \$42.91 \$4.84 \$6.15 \$24.15 \$59.85 \$68.44 \$66.85 \$59.65 \$69.96

	- T		0. 0	4			
ACYCLOVIR	N	Zovirax	GlaxoSmithKline	\$114,536	1,353	4.5%	\$84.65
SILVER SULFADIAZINE	Y	Silvadene	Monarch	\$73,897	6,239	20.8%	\$11.84
SULFACETAMIDE	Y	Klaron	Dermik	\$37,932	745	2.5%	\$50.91
BACITRACIN	Y	Baciguent	Shire	\$36,617	5,475	18.2%	\$6.69
NEOMYCIN	Y	Myciguent	Shire	\$35,102	6,158	20.5%	\$5.70
HEXACHLOROPHENE	N	Phisohex	Winthrop	\$24,934	843	2.8%	\$29.58
PENCICLOVIR	N	Denavir	Novartis	\$17,478	631	2.1%	\$27.70
GENTAMICIN	Υ	Garamycin	Schering-Plough	\$10,503	1,781	5.9%	\$5.90
HYDROCORTISONE	Υ	Hytone	Aventis	\$4,433	85	0.3%	\$52.15
MAFENIDE	N	Sulfamylon	Bertek	\$2,292	41	0.1%	\$55.91
Total				\$615,058	30,037	100.0%	\$20.48
ANTUNEECTIVES OBJETUAL MIC							
ANTIINFECTIVES OPHTHALMIC							
Share of FFS Rx's: 0.30%							
Per Member SFY05 YTD: \$1.81	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MOXIFLOXACIN	N	Vigamox	Alcon	\$136,588	2,777	8.9%	\$49.19
GATIFLOXACIN	N	Zymar	Allergan	\$104,207	2,098	6.7%	\$49.67
CIPROFLOXACIN	N	Ciloxan	Alcon	\$71,025	2,572	8.2%	\$27.61
ERYTHROMYCIN BASE	Y	llotycin	Lilly	\$56,929	7,646	24.4%	\$7.45
SULFACETAMIDE	Y	Sod Sulamyd	Schering-Plough	\$38,690	3,532	11.3%	\$10.95
GENTAMICIN	V	Garamycin	Schering-Plough	\$34,335	4,183	13.4%	\$8.21
	Y				3,697	11.8%	\$8.01
POLYMYXIN B	V	Polytrim	Allergan Alcon	\$29,607			
TOBRAMYCIN	I NI	Tobrex		\$26,998	2,081	6.6%	\$12.97
TRIFLURIDINE	N	Viroptic	GlaxoSmithKline	\$13,987	163	0.5%	\$85.81
BACITRACIN	Y	AK-Tracin	Akorn	\$11,268	1,433	4.6%	\$7.86
OFLOXACIN	N	Floxin	Daiichi	\$10,167	601	1.9%	\$16.92
NEOMYCIN	N	NeoDecadron	Merck	\$6,102	382	1.2%	\$15.97
LEVOFLOXACIN	N	Quixin	Vistakon	\$6,006	144	0.5%	\$41.71
OXYTETRACYCLINE				\$29	2	0.0%	\$14.60
Total				\$545,940	31,311	100.0%	\$17.44
					•		
ANTI INFECTIVES OTIS							
ANTI-INFECTIVES OTIC							
Share of FFS Rx's: 0.09%							
Per Member SFY05 YTD: \$0.92	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
OFLOXACIN	N	Floxin	Ortho-McNeil	\$137,346	2,579	28.4%	\$53.26
NEOMYCIN	N	Cortisporin/Neospo		\$118,120	5,355	59.1%	\$22.06
ACETIC ACID	Y	Vosol	MedPoint	\$21,816	1,093	12.1%	\$19.96
HYDROCORTISONE	Y	Pediotic	Monarch	\$817	41	0.5%	\$19.92
	- '	1 Galotto	Worldron				
Total				\$278,098	9,068	100.0%	\$30.67
ANTIMALARIAL							
Share of FFS Rx's: 0.22%							
Per Member SFY05 YTD: \$1.70	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
QUININE	MAC'd?			\$359,928	16,138	69.9%	\$22.30
QUININE HYDROXYCHLOROQUINE	Y Y	Plaquenil	Sanofi-Synthelabo	\$359,928 \$139,499	16,138 6,670	69.9% 28.9%	\$22.30 \$20.91
QUININE HYDROXYCHLOROQUINE MEFLOQUINE	Y Y N	Plaquenil Lariam	Sanofi-Synthelabo Roche	\$359,928 \$139,499 \$7,475	16,138 6,670 138	69.9% 28.9% 0.6%	\$22.30 \$20.91 \$54.16
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE	Y Y N N	Plaquenil Lariam Malarone	Sanofi-Synthelabo Roche GlaxoSmithKline	\$359,928 \$139,499 \$7,475 \$3,432	16,138 6,670 138 29	69.9% 28.9% 0.6% 0.1%	\$22.30 \$20.91 \$54.16 \$118.36
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE	Y Y N	Plaquenil Lariam	Sanofi-Synthelabo Roche	\$359,928 \$139,499 \$7,475	16,138 6,670 138	69.9% 28.9% 0.6%	\$22.30 \$20.91 \$54.16 \$118.36
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE	Y Y N N	Plaquenil Lariam Malarone	Sanofi-Synthelabo Roche GlaxoSmithKline	\$359,928 \$139,499 \$7,475 \$3,432	16,138 6,670 138 29	69.9% 28.9% 0.6% 0.1%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE	Y Y N N	Plaquenil Lariam Malarone Daraprim	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117	16,138 6,670 138 29 66	69.9% 28.9% 0.6% 0.1% 0.3%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE	Y Y N N N	Plaquenil Lariam Malarone Daraprim Aralen	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253	16,138 6,670 138 29 66 35	69.9% 28.9% 0.6% 0.1% 0.3% 0.2%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE	Y Y N N N	Plaquenil Lariam Malarone Daraprim Aralen	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186	16,138 6,670 138 29 66 35 6	69.9% 28.9% 0.6% 0.11% 0.3% 0.2% 0.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total	Y Y N N N	Plaquenil Lariam Malarone Daraprim Aralen	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186	16,138 6,670 138 29 66 35 6	69.9% 28.9% 0.6% 0.11% 0.3% 0.2% 0.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS	Y Y N N N	Plaquenil Lariam Malarone Daraprim Aralen	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186	16,138 6,670 138 29 66 35 6	69.9% 28.9% 0.6% 0.11% 0.3% 0.2% 0.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total	Y Y N N N	Plaquenil Lariam Malarone Daraprim Aralen	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186	16,138 6,670 138 29 66 35 6	69.9% 28.9% 0.6% 0.11% 0.3% 0.2% 0.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS	Y Y N N N	Plaquenil Lariam Malarone Daraprim Aralen	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186	16,138 6,670 138 29 66 35 6	69.9% 28.9% 0.6% 0.11% 0.3% 0.2% 0.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30%	Y Y N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890	16,138 6,670 138 29 66 35 6 23,082	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47	Y Y N N N N N N M M AC'd?	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890	16,138 6,670 138 29 66 35 6 23,082	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE	Y Y N N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer Novartis AstraZeneca	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL	Y Y N N N N N N N N N N N Y	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56 \$94.87
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer Novartis AstraZeneca BMS Schering	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$ <b>Per Rx</b> \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.08 \$1,500.08
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE	Y	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,5920 \$196,399	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 0.8% 1.7%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$200,512 \$200,5920 \$196,399 \$195,662	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.08 \$378.42 \$220.59
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59 \$133.45 \$2,047.50
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 <b>\$22.26</b> \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59 \$133.45 \$2,047.50
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate AstraZeneca	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$138,230 \$118,722 \$100,305	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8% 30.1%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59 \$133.45 \$20.47.50 \$17.49
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 0.2% 21.8% 3.5% 0.2% 21.88	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59 \$133.45 \$2,047.50 \$17.749 \$10.70 \$25.77
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE EXEMESTANE EXEMESTANE EXEMESTANE EXEMESTANE ETOPOSIDE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  Pharm & Upjohn BMS Oncology	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.0.1% 0.2% 0.9% 0.1% 0.9%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$Per Rx \$2.458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59 \$13.34.45 \$2.20.59 \$13.34.55 \$1.74.9
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology BMS Oncology BMS Oncology	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 0.1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.9% 0.9% 0.9%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$378.42 \$220.59 \$133.45 \$240.47.50 \$1.77.49 \$10.77 \$225.77 \$501.58 \$220.88
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE EXEMESTANE EXEMESTANE EXEMESTANE EXEMESTANE ETOPOSIDE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology BMS Oncology Pharm&Upj/Roche	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.0.1% 0.2% 0.9% 0.1% 0.9%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59 \$133.45 \$2,047.50 \$17.749 \$10.70 \$25.77
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology BMS Oncology BMS Oncology	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 0.1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.9% 0.9% 0.9%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.06 \$378.42 \$220.59 \$133.45 \$20.47.50 \$17.49 \$10.77 \$501.58 \$90.91
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology BMS Oncology Pharm&Upj/Roche	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 0.9%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$\$ \$24.58.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$795.00 \$378.42 \$2,047.50 \$17.49 \$10.77 \$20.58 \$10
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  Pharm & Upjohn BMS Oncology BMS Oncology BMS Oncology Pharm&Upj/Roche BMS Oncology	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637 \$28,637	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 1.0% 0.5%	\$22.30 \$20.91 \$54.116 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$Per Rx \$2.458.66 \$211.56 \$94.87 \$1,026.90 \$1,500.06 \$795.00 \$378.42 \$2.20.55 \$133.45 \$2.047.50 \$10.77 \$20.81 \$
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCOVORIN CHLORAMBUCIL	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  Pharm & Upjohn BMS Oncology BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 <b>\$513,890</b> <b>Total \$\$</b> \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637 \$23,636 \$17,914 \$15,501	16,138 6,670 138 29 66 35 6 23,082 Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 315 1,596 315	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 1.0% 0.5% 0.5% 1.0%	\$22.36 \$20.97 \$54.16 \$118.36 \$32.07 \$35.87 \$30.93 \$22.26 \$\$ Per Rx \$2,458.66 \$211.56 \$94.87 \$1,026.96 \$1,500.06 \$378.42 \$220.55 \$133.44 \$20.47.56 \$17.46 \$10.77 \$225.77 \$501.56 \$90.91 \$140.65 \$40.36
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCOVORIN CYLOPAMBUCIL MESNA	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran Mesnex	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology Pharm&Upj/Roche BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane GlaxoSmithKline Baxter	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637 \$23,636 \$17,914 \$15,501 \$15,432	16,138 6,670 138 29 66 35 6 23,082  Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596 315 168 444 238	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 1.0% 0.5% 1.0% 0.5% 1.0% 0.5% 1.0% 0.5% 1.0% 0.9% 0.3% 5.1% 0.9% 0.3% 5.1% 0.9% 0.5% 1.0%	\$22.36 \$20.97 \$54.16 \$118.36 \$32.07 \$35.87 \$30.93 \$22.26 \$\$ Per Rx \$2,458.66 \$211.56 \$211.56 \$1,026.90 \$1,500.06 \$795.06 \$378.46 \$20.57 \$13.34 \$10.70 \$225.77 \$501.56 \$20.88 \$20.
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCOVORIN CHLORAMBUCIL MESNA MEROAPDIE MESNA MERCAPDIE MININE MESNA MERIMA MESNA MERCAPITICS  MEMICATION  METHORITICS  METHORIT	Y Y Y N N N N N N N N N N N N N N N N Y N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane GlaxoSmithKline	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637 \$23,636 \$17,914 \$15,501 \$15,432 \$14,332	16,138 6,670 138 29 66 35 6 23,082  Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596 315 168 444 238 21	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 1.0% 0.5% 1.4% 0.8% 0.1%	\$22.36 \$20.97 \$54.16 \$118.36 \$32.07 \$35.87 \$22.26 \$\$Per Rx \$2,458.66 \$211.56 \$94.87 \$1,500.06 \$795.00 \$795.00 \$1,500.06 \$378.42 \$2,047.56 \$1.74,56
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE LEUPROLIDE LCAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCONGIN CHLORAMBUCIL MESNA PROCARBAZINE TRETINOIN	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran Mesnex	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology Pharm&Upj/Roche BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane GlaxoSmithKline Baxter	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 <b>\$513,890</b> <b>Total \$\$</b> \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637 \$23,636 \$17,914 \$15,501 \$15,501 \$15,501 \$15,432 \$14,332 \$14,332	16,138 6,670 138 29 66 35 6 23,082  Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596 315 168 444 238 21 28	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 21.8% 30.1% 0.9% 0.3% 5.1% 1.0% 0.5% 0.3% 5.1% 1.0% 0.8% 0.1% 0.8% 0.1%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$Per Rx \$2,458.66 \$211.56 \$94.87 \$1,026.90 \$1,500.06 \$795.00 \$13.45 \$2,047.50 \$10.77 \$20.86 \$20.86 \$20.86 \$30.93 \$140.66 \$40.33 \$65.13
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ESTOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCOVORIN CHLORAMBUCIL MESNA PROCARBAZINE TRETINOIN RITUXIMAB	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran Mesnex DepoCyt Injection	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology BMS Oncology Pharm&Upj/Roche BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane GlaxoSmithKline Baxter Enzon	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 <b>\$513,890</b> <b>Total \$\$</b> \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637 \$21,636 \$17,914 \$15,501 \$15,432 \$14,632 \$14,631	16,138 6,670 138 29 66 35 6 23,082  Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 889 315,596 315 1644 238 444 238 21 28 7	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0%  100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 0.17% 2.8% 30.1% 0.9% 0.1% 0.5% 1.0% 0.5% 1.0% 0.5% 0.1% 0.1% 0.5% 0.1% 0.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.66 \$211.56 \$94.87 \$1,026.90 \$795.06 \$378.42 \$220.55 \$133.45 \$20.47.55 \$17.45 \$10.77 \$225.77 \$501.55 \$22.86 \$34.83 \$40.33 \$40.33 \$40.33 \$40.33 \$41.36 \$40.33 \$41.36 \$41
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCOVORIN CHLORAMBUCIL MESNA PROCARBAZINE TRETINOIN RITUXIMAB FLUTAMIDE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran Mesnex	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology Pharm&Upj/Roche BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane GlaxoSmithKline Baxter	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$118,722 \$100,305 \$65,473 \$418,631 \$33,322 \$28,637 \$23,636 \$17,914 \$15,501 \$15,432 \$14,332 \$14,332 \$14,369 \$11,460 \$11,480	16,138 6,670 138 29 66 35 6 23,082  Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596 315 1644 423 24 28 7 4	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 0.9% 0.5% 1.0% 0.5% 1.0% 0.5% 1.0% 0.9% 0.3% 5.1% 0.9% 0.3% 5.1% 0.0% 0.3%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.66 \$211.56 \$94.87 \$1,026.90 \$1,500.00 \$795.00 \$378.42 \$220.55 \$133.45 \$220.57 \$133.45 \$20.47.50 \$17.46 \$10.70 \$225.77 \$501.56 \$20.88 \$390.91 \$140.65 \$20.88 \$31.734.86 \$21.734.86
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCOVORIN CHLORAMBUCIL MESNA PROCARBAZINE TRETINOIN RITUXIMAB FLUTANIDE MITOTANE MITOTANE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran Mesnex DepoCyt Injection	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology Pharm&Upj/Roche BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane GlaxoSmithKline Baxter Enzon	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$139,230 \$118,722 \$100,305 \$65,473 \$41,631 \$33,322 \$28,637 \$23,636 \$17,914 \$15,501 \$15,432 \$14,332 \$12,169 \$11,460 \$10,882 \$10,233	16,138 6,670 138 29 66 35 6 23,082  Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596 315 168 444 238 7 4 90 90	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0% 100.0%  Market Share 0.9% 9.4% 16.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 1.0% 0.5% 1.4% 0.5% 1.4% 0.0% 0.1% 0.0% 0.0% 0.0%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$Per Rx \$2.458.66 \$211.56 \$94.87 \$1,026.90 \$1,500.06 \$795.00 \$1,500.06 \$795.00 \$1,744 \$20.47,55 \$378.46 \$20.88 \$90.91 \$140.65 \$40.33 \$40.33 \$65.13 \$73.48 \$40.33 \$1,738.46 \$1,738.46 \$2,965.12 \$1,738.46 \$2,965.12 \$1,720.91 \$339.357
QUININE HYDROXYCHLOROQUINE MEFLOQUINE ATOVAQUONE PYRIMETHAMINE CHLOROQUINE PRIMAQUINE Total  ANTINEOPLASTICS Share of FFS Rx's: 0.30% Per Member SFY05 YTD: \$12.47 IMATINIB ANASTROZOLE MEGESTROL TEMOZOLOMIDE LEUPROLIDE CAPECITABINE BICALUTAMIDE LETROZOLE MERCAPTOPURINE ERLOTINIB TAMOXIFEN METHOTREXATE EXEMESTANE ETOPOSIDE HYDROXYUREA FLUOROURACIL CYCLOPHOSPHAMIDE LEUCOVORIN CHLORAMBUCIL MESNA PROCARBAZINE TRETINOIN RITUXIMAB FLUTAMIDE	Y Y Y N N N N N N N N N N N N N N N N N	Plaquenil Lariam Malarone Daraprim Aralen Premaquine  Brand Gleevec Arimidex Megace Temodar Lupron Xeloda Casodex Femara Purinethol  Nolvadex Various Aromasin Vepesid Hydrea Adrucil/Fluoroplex Cytoxan Leucovorin Leukeran Mesnex DepoCyt Injection	Sanofi-Synthelabo Roche GlaxoSmithKline GlaxoSmithKline Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo  Manufacturer Novartis AstraZeneca BMS Schering TAP Roche AstraZeneca Novartis Gate  AstraZeneca Pharm & Upjohn BMS Oncology BMS Oncology Pharm&Upj/Roche BMS Oncology Pharm&Upj/Roche BMS Oncology Roxane GlaxoSmithKline Baxter Enzon	\$359,928 \$139,499 \$7,475 \$3,432 \$2,117 \$1,253 \$186 \$513,890 Total \$\$ \$703,183 \$617,536 \$473,592 \$306,016 \$220,512 \$205,920 \$196,399 \$195,662 \$146,131 \$118,722 \$100,305 \$65,473 \$418,631 \$33,322 \$28,637 \$23,636 \$17,914 \$15,501 \$15,432 \$14,332 \$14,332 \$14,369 \$11,460 \$11,480	16,138 6,670 138 29 66 35 6 23,082  Total Rx 286 2,919 4,992 298 147 259 519 887 1,095 68 6,788 9,372 290 83 1,596 315 1644 423 24 28 7 4	69.9% 28.9% 0.6% 0.1% 0.3% 0.2% 0.0% 100.0% 100.0%  Market Share 0.9% 9.4% 16.0% 1.0% 0.5% 0.8% 1.7% 2.8% 3.5% 0.2% 21.8% 30.1% 0.9% 0.3% 5.1% 0.9% 0.5% 1.0% 0.5% 1.0% 0.5% 1.0% 0.9% 0.3% 5.1% 0.9% 0.3% 5.1% 0.0% 0.3%	\$22.30 \$20.91 \$54.16 \$118.36 \$32.07 \$35.81 \$30.93 \$22.26 \$\$ Per Rx \$2,458.68 \$211.56 \$94.87 \$1,026.90 \$1,500.08 \$378.42 \$220.59 \$133.45 \$240.47.50 \$1.77.49 \$10.77 \$225.77 \$501.58 \$220.88

ALTRETAMINE	N	Emcyt	Pharm & Upjohn	\$5,845	6	0.0%	\$974.19
BEXAROTENE	N			\$4,015	3	0.0%	\$1,338.41
THIOGUANINE	N	Tabloid	GlaxoSmithKline	\$3,263	38	0.1%	\$85.86
ESTRAMUSTINE	N			\$2,506	4	0.0%	\$626.57
DICLOFENAC	N			\$2,279	21	0.1%	\$108.54
LOMUSTINE	N	Busulfex/Myleran	ESP/GlaxoSmithKIn	\$2,023	23	0.1%	\$87.96
NILUTAMIDE	N	Hexalen	MGI	\$1,809	5	0.0%	\$361.78
TOREMIFENE	N	Fareston	Shire	\$863	8	0.0%	\$107.86
CYTARABINE	N	Cytosar/Tarabine	Pharmacia	\$108	2	0.0%	\$54.2°
BUSULFAN	N			\$53	3	0.0%	\$17.8°
VINBLASTINE	N			\$45	13	0.0%	\$3.45
Total				\$3,763,721	31,168	100.0%	\$120.76
ANTIPLATELETS - AGGREGATION	INILIBITA	DC					
	INTIBITO	ro					
Share of FFS Rx's: 0.76%							
Per Member SFY05 YTD: \$29.09	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CLOPIDOGREL	N	Plavix	Bristol-Myers Squibb	\$7,923,644	68,803	87.1%	\$115.16
CILOSTAZOL	N	Pletal	Otsuka	\$432,782	4,901	6.2%	\$88.30
DIPYRIDAMOLE	Y	Persantine	Boehringer	\$408,439	4,471	5.7%	\$91.3
TICLOPIDINE	Υ	Ticlid	Roche	\$15,785	789	1.0%	\$20.0
Total				\$8,780,651	78,964	100.0%	\$111.20
				, , , , , , ,	-,		•
ANTIDOVOLICO ATVOLONIO							
ANTIPSYCHOTICS - ATYPICALS							
Share of FFS Rx's: 4.92%							
Per Member SFY05 YTD: \$385.03	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
OLANZAPINE	N	Zyprexa	Lilly	\$37,847,768	117,544	22.9%	\$321.99
RISPERIDONE	N	Risperdal	Janssen	\$29,002,357	141,099	27.5%	\$205.5
QUETIAPINE	N	Seroquel	AstraZeneca	\$24,831,960	124,155	24.2%	\$200.01
ARIPIPRAZOLE	N	Abilify	Bristol-Myers Squibb	\$13,371,714	42,049	8.2%	\$318.00
ZIPRASIDONE	N	Geodon	Pfizer	\$6,672,735	27,900	5.4%	\$239.17
CLOZAPINE	Y	Clozaril	Novartis	\$4,484,360	59,656	11.6%	\$75.17
Total				\$116,210,894	512,403	100.0%	\$226.80
10141				ψ110,210,004	012,100	100.070	<b>V</b> 220.00
ANTIPSYCHOTICS - NON-PHENOTH	HAZINE						
Share of FFS Rx's: 0.43%							
Per Member SFY05 YTD: \$5.39	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
HALOPERIDOL	Y	Haldol	McNeil	\$786,092	31,270	69.3%	\$25.14
LOXAPINE	Y	Loxitane	Watson	\$448,821	4,465	9.9%	\$100.52
MOLINDONE	N	Moban	Endo	\$201,158	1,070	2.4%	\$188.00
THIOTHIXENE	Y	Navane	Pfizer	\$146,922	7,716	17.1%	\$19.04
PIMOZIDE	N N	Orap	Gate	\$42,942	598	1.3%	\$71.81
DROPERIDOL	N	Inapsine	Akorn	\$273	10	0.0%	\$27.35
						01070	
		тарото		\$1.626.209	45 129	100.0%	\$36.03
Total		Парото		\$1,626,209	45,129	100.0%	\$36.03
Total		Парото		\$1,626,209	45,129	100.0%	\$36.03
		Маролго		\$1,626,209	45,129	100.0%	\$36.03
Total				\$1,626,209	45,129	100.0%	\$36.03
Total  ANTIPSYCHOTICS - PHENOTHIAZIN		Brand	Manufacturer	. , ,	45,129 Total Rx	100.0%  Market Share	\$36.03 \$\$ Per Rx
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32%	VES		Manufacturer	\$1,626,209  Total \$\$ \$243,411	Total Rx		\$\$ Per Rx
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50	VES	Brand	Manufacturer GlaxoSmithKline	Total \$\$ \$243,411	Total Rx 6,049	Market Share	\$\$ Per Rx \$40.24
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE	VES	Brand Thorazine Prolixin	Manufacturer GlaxoSmithKline Apothecon	Total \$\$ \$243,411 \$218,978	Total Rx 6,049 14,859	Market Share 18.0% 44.3%	\$\$ Per Rx \$40.24 \$14.74
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFV05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE	WES  MAC'd?  Y	Brand Thorazine	Manufacturer GlaxoSmithKline	Total \$\$ \$243,411	Total Rx 6,049	Market Share	\$\$ Per Rx \$40.24 \$14.74 \$18.89
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE THIORIDAZINE	MAC'd?	Brand Thorazine Prolixin Mellaril	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline	Total \$\$ \$243,411 \$218,978 \$147,475	Total Rx 6,049 14,859 7,807	Market Share 18.0% 44.3% 23.3%	\$\$ Per Rx \$40.24 \$14.74 \$18.89 \$34.75
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE TRIFLUOPERAZINE	WES MAC'd? Y Y Y Y	Brand Thorazine Prolixin Mellaril Stelazine	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961	Total Rx 6,049 14,859 7,807 2,876	Market Share 18.0% 44.3% 23.3% 8.6%	\$\$ Per Rx \$40.24 \$14.77 \$18.88 \$34.75 \$22.32
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE MESORIDAZINE	MAC'd? Y Y Y Y Y Y	Brand Thorazine Prolixin Mellaril Stelazine Trilafon	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961 \$3,737	Total Rx 6,049 14,859 7,807 2,876 1,880 51	Market Share 18.0% 44.3% 23.3% 8.6% 5.6% 0.2%	\$\$ Per Rx \$40.24 \$14.77 \$18.83 \$34.75 \$22.32 \$73.28
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE PERPHENAZINE	MAC'd? Y Y Y Y Y Y	Brand Thorazine Prolixin Mellaril Stelazine Trilafon	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961	Total Rx 6,049 14,859 7,807 2,876 1,880	Market Share 18.0% 44.3% 23.3% 8.6% 5.6%	\$\$ Per Rx \$40.24 \$14.77 \$18.83 \$34.75 \$22.32 \$73.28
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE MESORIDAZINE Total	MAC'd? Y Y Y Y Y Y	Brand Thorazine Prolixin Mellaril Stelazine Trilafon	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961 \$3,737	Total Rx 6,049 14,859 7,807 2,876 1,880 51	Market Share 18.0% 44.3% 23.3% 8.6% 5.6% 0.2%	\$\$ Per Rx \$40.24 \$14.77 \$18.83 \$34.75 \$22.32 \$73.28
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE MESORIDAZINE Total  ANTIRETROVIRAL	MAC'd? Y Y Y Y Y Y	Brand Thorazine Prolixin Mellaril Stelazine Trilafon	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961 \$3,737	Total Rx 6,049 14,859 7,807 2,876 1,880 51	Market Share 18.0% 44.3% 23.3% 8.6% 5.6% 0.2%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.32 \$73.26
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE MESORIDAZINE Total	MAC'd? Y Y Y Y Y Y	Brand Thorazine Prolixin Mellaril Stelazine Trilafon	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961 \$3,737	Total Rx 6,049 14,859 7,807 2,876 1,880 51	Market Share 18.0% 44.3% 23.3% 8.6% 5.6% 0.2%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.32 \$73.26
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE MESORIDAZINE Total  ANTIRETROVIRAL	MAC'd? Y Y Y Y Y Y	Brand Thorazine Prolixin Mellaril Stelazine Trilafon	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961 \$3,737	Total Rx 6,049 14,859 7,807 2,876 1,880 51	Market Share 18.0% 44.3% 23.3% 8.6% 5.6% 0.2%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.32 \$73.26
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17%	MAC'd? Y Y Y Y Y N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522	Market Share 18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.33 \$73.28 \$22.54
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53	MAC'd? Y Y Y Y N MAC'd?	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%	\$\$ Per Rx \$40,24 \$14,74 \$18.88 \$34.75 \$22.32 \$73.26 \$22.54 \$Per Rx \$506.66
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR	MAC'd? Y Y Y Y N MAC'd?	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961 \$3,737 \$755,493	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.32 \$73.25 \$22.54 \$Per Rx \$506.66 \$427.76
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE	MAC'd? Y Y Y Y Y N N MAC'd?	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 100.0%  Market Share 15.7% 17.2%	\$\$ Per Rx \$40.24 \$14.77 \$18.88 \$34.75 \$22.32 \$73.26 \$22.54 \$Per Rx \$506.66 \$427.76 \$664.75
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR	MAC'd?  Y  Y  Y  Y  N  MAC'd?	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share  15.7% 17.2% 9.5% 7.4%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.33 \$73.25 \$22.54 \$\$ Per Rx \$506.66 \$427.78 \$664.75 \$731.72
Total  ANTIPSYCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR	MAC'd? Y Y Y Y N N MAC'd? N N N N N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.33 \$73.25 \$22.54  \$\$ Per Rx \$506.66 \$427.76 \$664.75 \$731.72 \$403.70
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ	MAC'd? Y Y Y Y Y N N MAC'd? N N N N N N N N N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 100.0%  100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.34 \$73.25 \$22.54 \$Per Rx \$506.66 \$427.76 \$664.75 \$731.72 \$403.70 \$415.50
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE TOtal  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIYUDINE ABACAVIR ATAZANAVIR TEANING EFAVIRENZ EMTRICITABINE	MAC'd?  Y  Y  Y  Y  Y  N  MAC'd?  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$7755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3%	\$\$ Per Rx \$40.24 \$14.77 \$18.88 \$34.75 \$22.32 \$73.26 \$22.54 \$\$ Per Rx \$506.66 \$427.76 \$664.75 \$731.72 \$403.77 \$415.56
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICTABINE NEVIRAPINE	MAC'd?   Y	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.8%	\$\$ Per Rx \$40.2 \$14.74 \$18.8 \$34.75 \$22.33 \$73.20 \$22.54 \$\$Per Rx \$506.66 \$427.78 \$664.75 \$415.50 \$415.50 \$415.50 \$435.82 \$358.25
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE STAVUDINE STAVUDINE	MAC'd?  Y  Y  Y  Y  N  N  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.3% 6.3%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.33 \$73.21 \$22.54  \$\$ Per Rx \$506.66 \$427.76 \$664.75 \$731.77 \$403.70 \$415.50 \$523.66 \$358.25
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NEVIRAPINE NEVIRAPINE STAVUDINE NELFINAVIR	MAC'd? Y Y Y Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline GilaxoSmithKline Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Flizer	Total \$\$ \$243,411 \$218,978 \$147,475 \$99,931 \$41,961 \$3,737 \$755,493  Total \$\$ \$1,428,791 \$1,322,681 \$1,132,738 \$965,870 \$796,502 \$646,519 \$493,834 \$371,486 \$347,239 \$334,236	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.8% 6.3% 6.3% 2.7%	\$\$ Per Rx \$40.24 \$14.77 \$18.86 \$34.77 \$22.35 \$73.21 \$22.54 \$\$ Per Rx \$506.66 \$427.77 \$664.75 \$731.72 \$4415.56 \$523.66 \$358.22 \$307.25
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE SYAVUDINE NELFINAVIR NELFINAVIR RESORIDAZINE TOTAL	MAC'd? Y Y Y Y Y Y N  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Flizer Roche	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.8% 6.3% 2.7% 0.7%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.35 \$73.26 \$\$ Per Rx \$506.66 \$427.76 \$664.77 \$403.77 \$415.56 \$523.66 \$358.22 \$\$80.72 \$\$880.77
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NEVIRAPINE STAVUDINE NELIFINAVIR ENEVIRAPINE STAVUDINE NELIFINAVIR ENFUVIRTIDE DIDANOSINE	MAC'd?  Y Y Y Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Flizer Roche Bristol-Myers Squibt	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221     \$176,819	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.8% 6.3% 2.7% 0.7% 4.6%	\$\$ Per Rx \$40.2 \$14.74 \$18.8 \$34.75 \$22.3 \$73.20 \$22.54 \$\$ Per Rx \$506.66 \$427.76 \$403.77 \$403.77 \$415.50 \$523.66 \$358.23 \$307.27 \$1,812.26 \$214.88
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE THIORIDAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE STAVUDINE STAVUDINE STAVUDINE STAVUDINE NELIFINAVIR ENFUVIRTIDE DIDANOSINE FOSAMPRENAVIR	MAC'd?  Y  Y  Y  Y  Y  N  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx Lexiva	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Pfizer Roche Bristol-Myers Squibt Pfizer Roche Bristol-Myers Squibt GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share  15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 6.3% 6.3% 6.3% 4.6% 1.0%	\$\$ Per Rx \$40.2: \$14.7: \$18.8: \$34.7: \$22.3: \$73.2: \$22.5- \$\$ \$\$Per Rx \$506.6: \$427.7: \$664.7: \$731.7: \$403.7: \$403.7: \$415.5: \$523.6: \$358.2: \$3680.7: \$1,812.2: \$214.8: \$564.3:
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE TOtal  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELFINAVIR ENEVURTIDE DIDANOSINE FOSSAMPRENAVIR SAQUINAVIR SAQUINAVIR SAQUINAVIR	WES  MAC'd?  Y  Y  Y  Y  Y  N  MAC'd?  N  N  N  N  N  N  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx Lexiva Fortovase, Invirase	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline GiaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Pfizer Roche Bristol-Myers Squibt Flizer Roche GlaxoSmithKline Roche	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$  \$1,428,791 \$1,322,681 \$1,132,738 \$965,870 \$796,502 \$646,519 \$493,834 \$371,486 \$347,239 \$334,236 \$239,221 \$176,819 \$99,328 \$99,402	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 1766 219	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.8% 6.3% 2.7% 0.7% 4.6% 1.0% 1.0%	\$\$ Per Rx \$40.2 \$14.7 \$18.8 \$34.7 \$22.3 \$73.2 \$22.5 \$\$22.5 \$\$24.7 \$\$506.60 \$427.70 \$664.70 \$403.70 \$415.5 \$523.60 \$358.2 \$307.2 \$1,812.20 \$214.8 \$564.30 \$421.9
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE SYAVUDINE NELFINAVIR ENELFINAVIR ENELFINAVIR ENFUVIRTIDE DIDANOSINE FOAGMAVIR SAQUINAVIR INDINAVIR INDINAVIR	MAC'd? Y Y Y Y Y Y N  MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viranune Zerit Viracept Fuzeon Videx Lexiva Fortovase, Invirase Crixivan	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Gilead Bristol-Myers Squibt Roche Bristol-Myers Squibt GlaxoSmithKline Roche	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$92,402     \$86,703	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share  15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 6.3% 5.8% 6.3% 2.7% 0.7% 4.6% 1.0% 1.2% 1.2% 1.3%	\$\$ Per Rx \$40.2: \$14.7- \$18.8: \$34.7: \$22.3: \$73.2: \$22.5-  \$\$ Per Rx \$506.6: \$427.7: \$664.7: \$731.7: \$403.7: \$415.5: \$523.6: \$358.2: \$307.2: \$214.8: \$564.3: \$364.2: \$214.8: \$564.3: \$373.7:
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EFMIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELFINAVIR RELFIVIRTIDE DIDANOSINE FOSAMPRENAVIR SAQUINAVIR INDINAVIR ZIDOVUDINE	MAC'd?  Y Y Y Y Y Y N N MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx Lexiva Fortovase, Invirase Crixivan Retrovir	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlatoHyers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Gilead Bristol-Myers Squibt Roche Bristol-Myers Squibt GlaxoSmithKline Roche Merck GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$99,402     \$86,703     \$49,426	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219 232 206	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.8% 6.3% 2.7% 0.7% 4.6% 1.0% 1.2% 1.3% 1.3%	\$\$ Per Rx \$40.2 \$14.7 \$18.8 \$34.7 \$22.3 \$73.2 \$22.5 \$22.5 \$\$ \$\$ Per Rx \$506.60 \$427.7 \$403.70 \$415.60 \$358.2 \$307.2 \$18.12.2 \$214.80 \$564.3 \$421.9 \$214.80 \$564.3 \$358.2 \$309.3 \$358.2 \$358.2 \$309.3
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFV05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE THIORIDAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELIFINAVIR ENEVIVIRTIDE DIDANOSINE FOSAMPRENAVIR SAQUINAVIR INDINAVIR SAQUINAVIR SAQUINAVIR SAQUINAVIR SAQUINAVIR SAQUINAVIR INDINAVIR ZIDOVUDINE AMPRENAVIR	MAC'd?  Y Y Y Y Y Y N N N N N N N N N N N N N	Brand Thorazine Prolixin Mellarii Stelazine Trilazine Tr	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Pfizer Roche Bristol-Myers Squibt GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$99,328     \$92,402     \$86,703     \$49,426     \$16,559	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219 232 206 37	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share  15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.8% 6.3% 2.7% 0.7% 4.6% 1.0% 1.2% 1.3% 1.1% 0.2%	\$\$ Per Rx \$40.2: \$14.7: \$18.8: \$34.7: \$22.3: \$73.2: \$22.5- \$\$ \$Per Rx \$506.6: \$427.7: \$664.7: \$731.7: \$403.7: \$403.7: \$415.5: \$3307.2: \$214.8: \$564.3: \$341.9: \$373.7: \$233.7:
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE FLUPHENAZINE TRIFLUOPERAZINE MESORIDAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELFINAVIR ENFUVIRTIDE DIDANOSINE FOSAMPRENAVIR SAQUINAVIR SIDOVUDINE AMPRENAVIR DELAVIRDINE	WES  MAC'd?  Y  Y  Y  Y  Y  Y  N  MAC'd?  N  N  N  N  N  N  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx Lexiva Fortovase, Invirase Crixivan Retrovir Agenerase Rescriptor	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Frizer Roche Bristol-Myers Squibt Plizer Roche GlaxoSmithKline Roche Merck GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493   Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$99,322     \$86,703     \$49,426     \$16,559     \$7,165	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219 232 206 37 29	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.8% 6.33% 2.7% 4.6% 1.0% 1.2% 1.3% 1.1% 0.2% 0.2%	\$\$ Per Rx \$40.24 \$14.7- \$118.86 \$34.7- \$22.35 \$22.56  \$\$ Per Rx \$506.66 \$427.7- \$664.7- \$731.7- \$403.7- \$415.5- \$523.66 \$358.2- \$307.22 \$214.81 \$564.36 \$373.7- \$373.7
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE TOtal  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELFINAVIR ENFUVIRTIDE DIDANOSINE FOSAMPRENAVIR SAQUINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR SAQUINAVIR SAQUINAVIR INDINAVIR ZIDOVUDINE AMPRENAVIR DELAVIRDINE ZALCITABINE	MAC'd?  Y Y Y Y Y Y N N N N N N N N N N N N N	Brand Thorazine Prolixin Mellarii Stelazine Trilazine Tr	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Pfizer Roche Bristol-Myers Squibt GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$331,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$92,402     \$86,703     \$49,426     \$16,559     \$7,165     \$2,715	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219 232 206 37 29	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share  15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 6.3% 5.8% 6.3% 2.7% 0.7% 4.6% 1.0% 1.2% 0.2% 0.2% 0.2% 0.1%	\$\$ Per Rx \$40.24 \$14.7- \$118.84 \$34.74 \$22.33 \$73.22 \$\$22.54  \$\$ Per Rx \$506.66 \$427.74 \$664.73 \$731.72 \$403.70 \$415.56 \$523.66 \$358.22 \$11,812.28 \$8680.72 \$1,812.28 \$214.84 \$564.36 \$357.37 \$239.93 \$447.55 \$224.00
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE FLUPHENAZINE TRIFLUOPERAZINE MESORIDAZINE MESORIDAZINE Total  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELFINAVIR ENFUVIRTIDE DIDANOSINE FOSAMPRENAVIR SAQUINAVIR SIDOVUDINE AMPRENAVIR DELAVIRDINE	WES  MAC'd?  Y  Y  Y  Y  Y  Y  N  MAC'd?  N  N  N  N  N  N  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx Lexiva Fortovase, Invirase Crixivan Retrovir Agenerase Rescriptor	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Frizer Roche Bristol-Myers Squibt Plizer Roche GlaxoSmithKline Roche Merck GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493   Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$371,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$99,322     \$86,703     \$49,426     \$16,559     \$7,165	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219 232 206 37 29	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share 15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 5.3% 5.8% 6.33% 2.7% 4.6% 1.0% 1.2% 1.3% 1.1% 0.2% 0.2%	\$\$ Per Rx \$40.24 \$14.77 \$18.88 \$34.75 \$22.35 \$\$22.55 \$\$Per Rx \$506.66 \$427.76 \$664.75 \$731.72 \$403.70 \$415.50 \$523.66 \$358.22 \$11,812.28 \$214.86 \$564.36 \$3573.72 \$239.93 \$447.55 \$224.90
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE TOtal  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELFINAVIR ENFUVIRTIDE DIDANOSINE FOSAMPRENAVIR SAQUINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR SAQUINAVIR SAQUINAVIR INDINAVIR ZIDOVUDINE AMPRENAVIR DELAVIRDINE ZALCITABINE	WES  MAC'd?  Y  Y  Y  Y  Y  Y  N  MAC'd?  N  N  N  N  N  N  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx Lexiva Fortovase, Invirase Crixivan Retrovir Agenerase Rescriptor	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Frizer Roche Bristol-Myers Squibt Plizer Roche GlaxoSmithKline Roche Merck GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$331,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$92,402     \$86,703     \$49,426     \$16,559     \$7,165     \$2,715	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219 232 206 37 29	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share  15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 6.3% 5.8% 6.3% 2.7% 0.7% 4.6% 1.0% 1.2% 0.2% 0.2% 0.2% 0.1%	\$\$ Per Rx \$40.24 \$14.74 \$118.85 \$34.75 \$22.35 \$22.54 \$\$ Per Rx \$506.66 \$427.76 \$664.75 \$731.72 \$403.70 \$415.50 \$523.68 \$358.23 \$307.25 \$214.85 \$564.36 \$357.37 \$247.07 \$226.26
Total  ANTIPS YCHOTICS - PHENOTHIAZIN Share of FFS Rx's: 0.32% Per Member SFY05 YTD: \$2.50 CHLORPROMAZINE FLUPHENAZINE TRIFLUOPERAZINE PERPHENAZINE MESORIDAZINE TOtal  ANTIRETROVIRAL Share of FFS Rx's: 0.17% Per Member SFY05 YTD: \$28.53 RITONAVIR LAMIVUDINE ABACAVIR ATAZANAVIR TENOFOVIR EFAVIRENZ EMTRICITABINE NEVIRAPINE STAVUDINE NELFINAVIR ENFUVIRTIDE DIDANOSINE FOSAMPRENAVIR SAQUINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR INDINAVIR SAQUINAVIR SAQUINAVIR INDINAVIR ZIDOVUDINE AMPRENAVIR DELAVIRDINE ZALCITABINE	WES  MAC'd?  Y  Y  Y  Y  Y  Y  N  MAC'd?  N  N  N  N  N  N  N  N  N  N  N  N  N	Brand Thorazine Prolixin Mellaril Stelazine Trilafon Serentil  Brand Norvir Epivir Ziagen Reyataz Viread Sustiva Emtriva Viramune Zerit Viracept Fuzeon Videx Lexiva Fortovase, Invirase Crixivan Retrovir Agenerase Rescriptor	Manufacturer GlaxoSmithKline Apothecon Novartis GlaxoSmithKline Schering-Plough Boehringer-Ingelheit  Manufacturer Abbott GlaxoSmithKline GlaxoSmithKline Bristol-Myers Squibt Gilead Bristol-Myers Squibt Gilead Boehringer-Ingelheit Bristol-Myers Squibt Frizer Roche Bristol-Myers Squibt Plizer Roche GlaxoSmithKline Roche Merck GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline	Total \$\$     \$243,411     \$218,978     \$147,475     \$99,931     \$41,961     \$3,737     \$755,493  Total \$\$     \$1,428,791     \$1,322,681     \$1,132,738     \$965,870     \$796,502     \$646,519     \$493,834     \$331,486     \$347,239     \$334,236     \$239,221     \$176,819     \$99,328     \$92,402     \$86,703     \$49,426     \$16,559     \$7,165     \$2,715	Total Rx 6,049 14,859 7,807 2,876 1,880 51 33,522  Total Rx 2,820 3,092 1,704 1,320 1,973 1,556 943 1,037 1,130 491 132 823 176 219 232 206 37 29	Market Share  18.0% 44.3% 23.3% 8.6% 5.6% 0.2% 100.0%  Market Share  15.7% 17.2% 9.5% 7.4% 11.0% 8.7% 6.3% 5.8% 6.3% 2.7% 0.7% 4.6% 1.0% 1.2% 0.2% 0.2% 0.2% 0.1%	\$\$ Per Rx \$40.24 \$14.74 \$18.85 \$34.75 \$22.32 \$73.26 \$22.54

Share of FFS Rx's: 0.06%							
Per Member SFY05 YTD: \$0.34	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SODIUM CL IRRIG SOLN	Y			\$42,708	2,476	40.1%	\$17.25
ACETIC ACID	Y			\$31,562	1,675	27.2%	\$18.84
WATER FOR IRRIGATION, STERILE	Y			\$28,632	1,996	32.4%	\$14.34
FORMALDEHYDE	N	Formalyde	Pedinol	\$755	19	0.3%	\$39.74
NEOMYCIN		,		\$29	1		***
RINGERS SOLUTION	N			\$15	1	0.0%	\$15.00
MANNITOL				\$1	1	0.0,0	******
Total				\$103,702	6,169	100.0%	\$16.81
Total				ψ103,702	0,103	100.070	φ10.01
ANTISPASMODICS/ANTICHOLINERO	GICS						
Share of FFS Rx's: 0.14%							
Per Member SFY05 YTD: \$0.99	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
GLYCOPYRROLATE	N	Robinul	First Horizon	\$233,228	2,598	17.7%	\$89.77
HYOSCYAMINE	N	Cystospaz	PolyMedica	\$218,643	7,889	53.8%	\$27.71
DICYCLOMINE	Y	Bentyl	Axcan	\$46,719	5,903	40.2%	\$7.91
PROPANTHELINE	Υ	Pro-Banthine	Shire	\$11,363	317	2.2%	\$35.84
SCOPOLAMINE	N	Transderm	Novartis	\$9,235	109	0.7%	\$84.72
ATROPINE	N	Urised	PolyMedica	\$8,882	388	2.6%	\$22.89
CHLORDIAZEPOXIDE	N	Olisea	1 Olymedica		23	2.070	Ψ22.03
		0.1		\$3,542		0.00/	***
ERGOTAMINE	N	Cafergot/Ergodryl	Novartis	\$781	33	0.2%	\$23.66
MEPENZOLATE	N	Cantil	Aventis	\$214	2	0.0%	\$107.10
BELLADONNA ALKALOIDS				\$81	2		
Total				\$299,460	14,666	100.0%	\$20.42
ANTITUBERCULAR							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$0.48	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
RIFAMPIN	V V	Rifadin	Aventis	\$70,470	1,271	47.3%	\$55.44
RIFABUTIN	N				1,271	4.7%	\$259.92
		Mycobutin	Pharm & Upjohn	\$32,490			
ETHAMBUTOL	N	Myambutol	Dura	\$31,351	295	11.0%	\$106.28
ISONIAZID	Y	Various		\$6,269	930	34.6%	\$6.74
PYRAZINAMIDE	N	Various		\$4,148	64	2.4%	\$64.81
CAPREOMYCIN				\$448	1		
ETHIONAMIDE				\$270	1		
CYCLOSERINE				\$220	1		
Total				\$145,666	2,688	100.0%	\$54.19
ANTIVIRAL							
Share of FFS Rx's: 0.20%							
Per Member SFY05 YTD: \$8.41	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
VALGANCICLOVIR	N	Valcyte	Roche	\$1,011,981	962	4.5%	\$1,051.96
VALACYCLOVIR	N	Valtrex	GlaxoSmithKline	\$974,893	7,173	33.9%	\$135.91
OSELTAMIVIR	N	Tamiflu	Roche	\$254,526	3,349	15.8%	\$76.00
FAMCICLOVIR	N	Famvir	Novartis	\$118,519	766	3.6%	\$154.72
RIMANTADINE	N		Forest				Ψ10-1.72
ACYCLOVIR	14				1718	22.3%	\$17.01
	l v	Flumadine		\$70,330	4,718	22.3%	\$14.91
	Y	Zovirax	GlaxoSmithKline	\$56,313	4,073	19.2%	\$13.83
GANCICLOVIR	N	Zovirax Cytovene	GlaxoSmithKline Roche	\$56,313 \$34,043	4,073 100	19.2% 0.5%	\$13.83 \$340.43
CIDOFOVIR	N N	Zovirax Cytovene Vistide	GlaxoSmithKline Roche Gilead	\$56,313 \$34,043 \$16,183	4,073 100 13	19.2% 0.5% 0.1%	\$13.83 \$340.43 \$1,244.82
CIDOFOVIR FOSCARNET	N N N	Zovirax Cytovene Vistide Foscavir	GlaxoSmithKline Roche Gilead AstraZeneca	\$56,313 \$34,043 \$16,183 \$1,217	4,073 100 13 6	19.2% 0.5% 0.1% 0.0%	\$13.83 \$340.43 \$1,244.82 \$202.85
CIDOFOVIR FOSCARNET ZANAMIVIR	N N	Zovirax Cytovene Vistide	GlaxoSmithKline Roche Gilead	\$56,313 \$34,043 \$16,183 \$1,217 \$523	4,073 100 13 6	19.2% 0.5% 0.1% 0.0% 0.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69
CIDOFOVIR FOSCARNET	N N N	Zovirax Cytovene Vistide Foscavir	GlaxoSmithKline Roche Gilead AstraZeneca	\$56,313 \$34,043 \$16,183 \$1,217	4,073 100 13 6	19.2% 0.5% 0.1% 0.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69
CIDOFOVIR FOSCARNET ZANAMIVIR Total	N N N	Zovirax Cytovene Vistide Foscavir	GlaxoSmithKline Roche Gilead AstraZeneca	\$56,313 \$34,043 \$16,183 \$1,217 \$523	4,073 100 13 6	19.2% 0.5% 0.1% 0.0% 0.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS	N N N	Zovirax Cytovene Vistide Foscavir	GlaxoSmithKline Roche Gilead AstraZeneca	\$56,313 \$34,043 \$16,183 \$1,217 \$523	4,073 100 13 6	19.2% 0.5% 0.1% 0.0% 0.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93%	N N N	Zovirax Cytovene Vistide Foscavir	GlaxoSmithKline Roche Gilead AstraZeneca	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528	4,073 100 13 6	19.2% 0.5% 0.1% 0.0% 0.0%	\$13.83
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS	N N N	Zovirax Cytovene Vistide Foscavir	GlaxoSmithKline Roche Gilead AstraZeneca	\$56,313 \$34,043 \$16,183 \$1,217 \$523	4,073 100 13 6	19.2% 0.5% 0.1% 0.0% 0.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93%	N N N N	Zovirax Cytovene Vistide Foscavir Relenza	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528	4,073 100 13 6 4 21,164	19.2% 0.5% 0.1% 0.0% 100.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05	N N N N	Zovirax Cytovene Visitide Foscavir Relenza	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528	4,073 100 13 6 4 21,164	19.2% 0.5% 0.1% 0.0% 100.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL	N N N N N	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347	4,073 100 13 6 4 21,164 Total Rx	19.2% 0.5% 0.1% 0.0% 0.0% 100.0% Market Share 48.3%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL	N N N N N N	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835	19.2% 0.5% 0.1% 0.0% 0.0% 100.0% Market Share 48.3% 37.6%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 <b>\$119.95</b> \$\$ Per Rx \$20.28 \$6.30
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL	N N N N N N MAC'd? Y Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth	\$56,313 \$34,043 \$16,183 \$1,217 \$523 <b>\$2,538,528</b> Total \$\$ \$2,995,347 \$723,191 \$665,362 \$59,545	4,073 100 13 6 4 <b>21,164</b> <b>Total Rx</b> 147,664 114,835 30,564 4,793	19.2% 0.5% 0.1% 0.0% 0.0% 100.0% Market Share 48.3% 37.6% 10.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 <b>\$119.95</b> \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL	N N N N N N N N N N N N N N N N N N N	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 <b>\$119.95</b> \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05  METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL	N N N N N N N N N N N N N N N N N N N	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827	19.2% 0.5% 0.1% 0.0% 100.0% 100.0% Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 1.3%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 <b>\$119.95</b> \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL ACEBUTOLOL	MAC'd? Y Y Y Y Y Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626	19.2% 0.5% 0.1% 0.0% 0.0% 100.0% 100.0% Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 1.3% 0.2%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL BETAXOLOL BETAXOLOL	MAC'd? Y Y Y Y Y Y Y Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$9,061	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 10.0% 1.6% 0.8% 1.3% 0.2% 0.1%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 <b>\$119.95</b> <b>\$\$ Per Rx</b> \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL PINDOLOL	MAC'd? Y Y Y Y Y Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$9,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.3% 0.2% 0.1%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 <b>\$119.95</b> \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05  METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL JIMOLOL TIMOLOL	MAC'd?  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$665,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 0.2% 0.1% 0.1%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 <b>\$119.95</b> \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL TIMOLOL PINDOLOL TIMOLOL PENBUTOLOL	MAC'd? Y Y Y Y Y Y Y Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 1.3% 0.2% 0.1% 0.1% 0.1% 0.0%	\$13.83 \$340.43 \$1,244.85 \$10.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL TIMOLOL PINDOLOL TIMOLOL PENBUTOLOL PENBUTOLOL TOtal	MAC'd?  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$665,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162	19.2% 0.5% 0.1% 0.0% 100.0% 100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 0.2% 0.1% 0.1%	\$13.83 \$340.43 \$1,244.85 \$10.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL TIMOLOL PINDOLOL TIMOLOL PENBUTOLOL BETAXOLOL PENBUTOLOL BETAXOLOL PINDOLOL TOTAL	MAC'd?  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 1.3% 0.2% 0.1% 0.1% 0.1% 0.0%	\$13.83 \$340.43 \$1,244.85 \$10.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL TIMOLOL PENBUTOLOL TOtal  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08%	MAC'd? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren Levatol	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck Schwarz	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 1.3% 0.2% 0.1% 0.1% 0.1% 0.0% 100.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$114.47 \$24.57 \$10.12 \$20.22 \$58.60 \$14.86
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL TIMOLOL PENBUTOLOL TOtal  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$0.10	MAC'd?  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$4,9,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875 \$4,540,986	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 0.1% 0.1% 0.1% 0.0% 100.0%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60 \$14.86
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05  METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL BETAXOLOL PINDOLOL TIMOLOL PENBUTOLOL BETAXOLOL PINDOLOL Total  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$0.10 BACTERIOSTATIC SODIUM CHLORIDE	MAC'd?  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren Levatol	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck Schwarz	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$665,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875 \$4,540,986	4,073 100 13 6 4 21,164  Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 0.2% 0.1% 0.1% 0.1% 0.0% 100.0%  Market Share 37.8%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$\$Per Rx \$20.22 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60 \$14.86
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05  METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL TIMOLOL PENBUTOLOL DETAXOLOL PENBUTOLOL TOTAL  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$0.10 BACTERIOSTATIC SODIUM CHLORIDE BULK CHEMICAL	MAC'd?  Y Y Y Y Y Y Y Y Y N  MAC'd?	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren Levatol	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck Schwarz	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875 \$4,540,986	4,073 100 13 6 4 21,164  Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580  Total Rx  Total Rx	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 0.2% 0.1% 0.1% 0.1% 0.0% 100.0%  Market Share 37.8% 33.8%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60 \$14.86
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05  METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL BETAXOLOL PINDOLOL TIMOLOL PENBUTOLOL BETAXOLOL PINDOLOL Total  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$0.10 BACTERIOSTATIC SODIUM CHLORIDE	MAC'd? Y Y Y Y Y Y Y Y Y Y N N  MAC'd?	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren Levatol	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck Schwarz	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875 \$4,540,986 Total \$\$	4,073 100 13 6 4 21,164  Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580  Total Rx 3,219 2,875 1,180	19.2% 0.5% 0.1% 0.0% 0.0% 100.0% 100.0%  Market Share 48.3% 37.6% 10.0% 1.3% 0.2% 0.1% 0.1% 0.1% 0.0% 100.0% 100.0%  Market Share 37.8% 33.8% 13.9%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$119.95 \$12.42 \$20.22 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$20.22 \$58.60 \$14.486 \$14.486
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL BETAXOLOL PINDOLOL TIMOLOL TOTAL  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$0.10 BACTERIOSTATIC SODIUM CHLORIDE BULK CHEMICAL	MAC'd?  Y Y Y Y Y Y Y Y Y N  MAC'd?	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren Levatol	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck Schwarz	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875 \$4,540,986	4,073 100 13 6 4 21,164  Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580  Total Rx  Total Rx	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 0.2% 0.1% 0.1% 0.1% 0.0% 100.0%  Market Share 37.8% 33.8%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$119.95 \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60 \$14.86
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL BETAXOLOL PINDOLOL TIMOLOL PENBUTOLOL Total  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$0.10 BACTERIOSTATIC SODIUM CHLORIDE BULK CHEMICAL CHERRY FLAVOR	MAC'd? Y Y Y Y Y Y Y Y Y Y N N  MAC'd?	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren Levatol	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck Schwarz	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$49,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875 \$4,540,986 Total \$\$	4,073 100 13 6 4 21,164  Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580  Total Rx 3,219 2,875 1,180	19.2% 0.5% 0.1% 0.0% 0.0% 100.0% 100.0%  Market Share 48.3% 37.6% 10.0% 1.3% 0.2% 0.1% 0.1% 0.1% 0.0% 100.0% 100.0%  Market Share 37.8% 33.8% 13.9%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$14.47 \$24.57 \$10.12 \$20.22 \$58.60 \$14.86
CIDOFOVIR FOSCARNET ZANAMIVIR Total  BETA BLOCKERS Share of FFS Rx's: 2.93% Per Member SFY05 YTD: \$15.05 METOPROLOL ATENOLOL PROPRANOLOL BISOPROLOL SOTALOL NADOLOL ACEBUTOLOL PINDOLOL PINDOLOL TIMOLOL PENBUTOLOL TOTAL  BULK CHEMICAL/ADJUVANTS Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$0.10 BACTERIOSTATIC SODIUM CHLORIDE BULK CHEMICAL CHERRY FLAVOR SORBITOL SOLUTION	MAC'd? Y Y Y Y Y Y Y Y Y Y N N N N N N N N N	Zovirax Cytovene Vistide Foscavir Relenza  Brand Lopressor Tenormin Inderal Zebeta Betapace Corgard Sectral Kerlone Visken Blocadren Levatol	GlaxoSmithKline Roche Gilead AstraZeneca GlaxoSmithKline  Manufacturer Novartis AstraZeneca Wyeth Duramed Berlex Monarch ESP Sanofi Novartis Merck Schwarz	\$56,313 \$34,043 \$16,183 \$1,217 \$523 \$2,538,528 Total \$\$ \$2,995,347 \$723,191 \$655,362 \$59,545 \$4,9,944 \$34,216 \$9,061 \$5,455 \$3,713 \$3,276 \$1,875 \$4,540,986	4,073 100 13 6 4 21,164 Total Rx 147,664 114,835 30,564 4,793 2,488 3,827 626 222 367 162 32 305,580 Total Rx 3,219 2,875 1,180 96	19.2% 0.5% 0.1% 0.0% 0.0% 100.0%  100.0%  Market Share 48.3% 37.6% 10.0% 1.6% 0.8% 0.1% 0.1% 0.1% 0.0% 100.0%  Market Share 37.8% 33.8% 13.9% 13.9% 1.1%	\$13.83 \$340.43 \$1,244.82 \$202.85 \$130.69 \$119.95 \$\$ Per Rx \$20.28 \$6.30 \$21.44 \$12.42 \$20.07 \$8.94 \$114.47 \$24.57 \$10.12 \$20.22 \$58.60 \$14.86

COLISITN				\$744	10	0.1%	\$74.43
AMPHOTERICIN B	N			\$208	16	0.2%	\$12.98
NEOMYCIN	N			\$132	30	0.4%	\$4.39
COCAINE				\$107	3	0.0%	\$35.51
MORPHINE				\$94	1	0.0%	\$93.79
KETOPROFEN	N			\$93	20	0.1%	\$6.01
QUINACRINE				\$89	3		
POLOXAMER	N			\$69	28	0.1%	\$4.46
GLYCOPYRROLATE	N			\$65	1	0.0%	\$64.90
TESTOSTERONE	N			\$45	10	0.4%	\$4.39
TRIAMCINOLONE	N			\$42	7	0.1%	\$6.01
DILTIAZEM				\$42	10	0.1%	\$4.20
CAFFEINE	N			\$31	73	0.9%	\$0.42
EMOLLIENT				\$22	1		
GABAPENTIN				\$13	1		
DEXAMETHASONE				\$10	1		
COAL TAR	N			\$8	3	0.0%	\$2.50
LIDOCAINE	14			\$4	14	0.070	Ψ2.50
DIPHENHYDRAMINE	NI.					0.40/	ድር ጋር
	N			\$2	6	0.1%	\$0.32
PROPYLENE GLYCOL				\$0	2		
Total				\$31,521	8,517	100.0%	\$3.70
CALCIUM							
Share of FFS Rx's: 0.06%		1					
Per Member SFY05 YTD: \$0.17	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CALCIUM				\$50,155	6,763	100.0%	\$7.42
CALCIUM CHANNEL BLOCKERS							
Share of FFS Rx's: 1.96%		1					
Per Member SFY05 YTD: \$29.34	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMLODIPINE	N	Norvasc	Pfizer	\$5,493,476	101,451	49.6%	\$54.15
DILTIAZEM	Υ	Cardizem/Dilacor	Biovail/Watson	\$1,661,415	52,504	25.7%	\$31.64
NIFEDIPINE	Υ	Adalat/Procardia	Schering/Pfizer	\$940,606	22,248	10.9%	\$42.28
VERAPAMIL	Υ	Verelan	Schwarz	\$371,829	21,448	10.5%	\$17.34
FELODIPINE	Υ	Plendil	AstraZeneca	\$177,611	3,649	1.8%	\$48.67
ISRADIPINE	N	DynaCirc	Reliant	\$108,282	1,266	0.6%	\$85.53
NISOLDIPINE	N	Sular	First Horizon	\$71,084	1,499	0.7%	\$47.42
NICARDIPINE	Y	Cardene	Roche	\$21,345	480	0.2%	\$44.47
NIMODIPINE	N	Nimotop	Bayer	\$10,736	20	0.0%	\$536.81
Total				\$8,856,385	204,565	100.0%	\$43.29
				, -,,	, , , , , , ,		,
CARROUVERATES							
CARBOHYDRATES							
CARBOHYDRATES Share of FFS Rx's: 0.03%							
	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.03%	MAC'd?	Brand	Manufacturer	Total \$\$ \$42,056	<b>Total Rx</b> 1,242	Market Share 39.2%	
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35		Brand	Manufacturer				
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER		Brand	Manufacturer	\$42,056	1,242	39.2%	\$33.86 \$23.53
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER DEXTROSE 70%-WATER	Y Y	Brand	Manufacturer	\$42,056 \$21,224	1,242 902	39.2% 28.4%	\$33.86 \$23.53 \$108.13
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE	Y Y Y	Brand	Manufacturer	\$42,056 \$21,224 \$20,978	1,242 902 194	39.2% 28.4% 6.1%	\$33.86 \$23.53 \$108.13 \$23.42
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE	Y Y Y	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794	1,242 902 194 589	39.2% 28.4% 6.1% 18.6%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER DEXTROSE 70%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.25 NORMAL SALINE	Y Y Y Y	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099	1,242 902 194 589 171	39.2% 28.4% 6.1% 18.6% 5.4%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER	Y Y Y Y Y	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206	1,242 902 194 589 171 22	39.2% 28.4% 6.1% 18.6% 5.4% 0.7%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS	Y Y Y Y Y N N	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933	1,242 902 194 589 171 22 25	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-UNATER	Y Y Y Y Y N N N	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102	1,242 902 194 589 171 22 25 23	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-WATER  DEXTROSE 5%-USNORMAL SALINE  DEXTROSE 5%-USNORMAL SALINE  DEXTROSE 5%-USNORMAL SALINE	Y Y Y Y Y N N N	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17	1,242 902 194 589 171 22 25 23 3	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-UNATER	Y Y Y Y Y N N N	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102	1,242 902 194 589 171 22 25 23	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5.5%-0.5NORMAL SALINE  DEXTROSE 5.5%-0.5NORMAL SALINE  DEXTROSE 5% IN RINGERS  Total	Y Y Y Y Y N N N	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17	1,242 902 194 589 171 22 25 23 3	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-WATER  DEXTROSE 5%-USNORMAL SALINE  DEXTROSE 5%-USNORMAL SALINE  DEXTROSE 5%-USNORMAL SALINE	Y Y Y Y Y N N N	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17	1,242 902 194 589 171 22 25 23 3	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 70%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5.5%-0.5NORMAL SALINE  DEXTROSE 5.5%-0.5NORMAL SALINE  DEXTROSE 5% IN RINGERS  Total	Y Y Y Y Y N N N	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17	1,242 902 194 589 171 22 25 23 3	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5.5%-0.5NORMAL SALINE  DEXTROSE 5.5%-0.5NORM	Y Y Y Y Y N N N N Y			\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 \$104,677	1,242 902 194 589 171 22 25 23 3 1 1 3,172	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 101.0%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.5 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5.5%-0.5NORMAL SALINE DEXTROSE 5%-IN RINGERS TOTAL  CEPHALOSPORINS Share of FFS Rx's: 0.53% Per Member SFY05 YTD: \$7.34	Y Y Y Y Y N N N Y Y MAC'd?	Brand	Manufacturer	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 \$104,677	1,242 902 194 589 171 22 25 23 3 1 3,172	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 100.0%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5% IN RINGERS  Total  CEPHALOSPORINS  Share of FFS Rx's: 0.53%  Per Member SFY05 YTD: \$7.34  CEFTRIAXONE	Y Y Y Y Y N N N N Y  MAC'd?	Brand Rocephin Injectable	Manufacturer Roche	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b>	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.1% 100.0%  Market Share 7.2%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5% IN RINGERS  Total  CEPHALOSPORINS  Share of FFS Rx's: 0.53%  Per Member SFY05 YTD: \$7.34  CEFTRIAXONE  CEFDINIR	Y Y Y Y Y N N N N N N N N N N N N N N N	Brand Rocephin Injectable Omnicerf	Manufacturer Roche Abbott	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$\$Per Rx \$180.51 \$73.70
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NATER  DEXTROSE 5%-NATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-NATER  DEXTROSE 5%-	Y Y Y Y Y N N N N Y  MAC'd?	Brand Rocephin Injectable Comnicerf Keflex	Manufacturer Roche Abbott Dista Labs	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.1% 100.0%  Market Share 7.2% 10.8% 56.9%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$\$Per Rx \$180.51 \$73.70 \$9.64
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  TOTAL  CEPHALOSPORINS  Share of FFS Rx's: 0.53%  Per Member SFY05 YTD: \$7.34  CEFTRIAXONE  CEPHALEXIN  CEFUROXIME	Y Y Y Y Y N N N N N Y   MAC'd? N N N Y Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin	Manufacturer Rochet Abbott Labs GlaxoSmithKline	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 \$104,677 Total \$\$ \$720,976 \$430,087 \$303,087 \$176,403	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.1% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$180.51 \$73.70 \$9.64
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-NORMAL SALINE  DE	Y Y Y Y Y N N N N N N N N N N N N N N N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$180.51 \$73.70 \$9.64 \$32.51 \$84.61
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-NORMAL SALINE	Y Y Y Y Y N N N N N N Y   MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$\$Per Rx \$180.51 \$73.70 \$9.64 \$32.51 \$84.61 \$298.75
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NATER  DEXTROSE 5%-NATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-1.5 NORMAL SALINE  DEXTROSE 5%-NATER  D	Y Y Y Y Y N N N N N N Y   MAC'd? N N N N Y Y Y Y Y Y Y Y Y Y N N N Y Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 1,934 339 3,217	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$180.51 \$73.70 \$9.64 \$32.51 \$84.61 \$298.75
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.5 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5%-LACTATED RINGERS TOTAL  CEPHALOSPORINS Share of FFS Rx's: 0.53% Per Member SFY05 YTD: \$7.34 CEFTRIAXONE CEFDINIR CEPHALEXIN CEFUROXIME CEFPROZIL CEFEPIME CEFADROXIL CEFPODOXIME	Y Y Y Y Y N N N N N Y Y Y N N N N N N N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.1% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$180.51 \$73.70 \$9.64 \$32.51 \$84.61 \$298.75 \$30.88
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-NORMAL SALINE  DE	Y Y Y Y Y N N N N N Y   MAC'd? N N N N Y  N N N N N N N N N N N N N N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibl Elan WC Prof Pharmacia GlaxoSmithKline	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217 928 339	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.1% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.6%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$\$ Per Rx \$180.51 \$73.70 \$9.64 \$22.51 \$84.61 \$298.75 \$30.89 \$80.71
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 10%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  TOTAL  CEPHALOSPORINS  Share of FFS Rx's: 0.53%  Per Member SFY05 YTD: \$7.34  CEFTAIAXONE  CEFPIALEXIN  CEFUROXIME  CEFPROZIL  CEFPODOXIME  CEFADOXIME  CEFADOXIME  CEFAZOLIN	Y Y Y Y Y N N N N N Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline GlaxoSmithKline Watson	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217 928 339 431	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 5.5.9% 9.8% 0.6% 5.8% 0.6% 5.8% 0.6% 0.8%	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$\$180.51 \$73.70 \$9.64 \$225.75 \$84.61 \$298.75 \$30.88 \$80.71 \$185.16 \$84.13
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NATER  DEXTR	Y Y Y Y Y Y N N N N Y Y Y N N N N N N Y Y N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipme Injection Duricer Vantin Fortaz Injection Cedazoline Injection Ceclor	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$113,305	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217 928 339 431 939	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.6% 0.6% 0.6% 0.6%	\$33.86 \$23.52 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$33.00 \$33.00 \$33.00 \$33.00 \$33.51 \$73.70 \$9.64 \$32.51 \$4.61 \$29.75 \$30.85 \$4.61 \$185.16 \$185.11 \$185.11 \$185.11 \$185.11
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.5 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5%-LACTATED RINGERS TOTAL  CEPHALOSPORINS Share of FFS Rx's: 0.53% Per Member SFY05 YTD: \$7.34 CEFTRIAXONE CEFDINIR CEPHALEXIN CEFPROZIL CEFEPIME CEFADROXIME CEFADROXIL CEFPODOXIME CEFAZOLIN CEFAZOLIN CEFALOR CEFAZOLIN CEFACLOR CEFACLOR CEFACLOR CEFACLOR CEFOTAXIME	Y Y Y Y Y N N N N N N N N N N N N N N N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Ceclor Spectracef	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217 928 339 431 939 442	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.1% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.55% 0.6% 5.8% 1.7% 0.8% 1.7% 0.8%	\$33.86 \$23.52 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$33.00 \$33.00 \$4.80 \$180.51 \$298.75 \$30.86 \$80.71 \$185.16 \$84.17 \$185.16
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  TOTAL  CEPHALOSPORINS  Share of FFS Rx's: 0.53%  Per Member SFY05 YTD: \$7.34  CEFTRIAXONE  CEFDINIR  CEPHALEXIN  CEFPROZIL  CEFPIME  CEFADROXIL  CEFFONOXIME  CEFTAZIDIME  CEFTAZIDIME  CEFAZOLIN  CEFAZOLIN  CEFACLOR  CEFOTOREN	Y Y Y Y Y Y N N N N Y    MAC'd? N N N N Y  N N N N N Y N N N N N N N N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Cefazoline Injection Cefazoline Cefazoline Injection Cefazoline Injection Cefazoline Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibl Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 342 1,934 339 3,217 928 339 431 939 42	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.1% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.6% 0.8% 0.8% 0.7%	\$33.86 \$23.55 \$108.15 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$\$180.51 \$73.77 \$9.64 \$32.57 \$84.61 \$298.75 \$30.77 \$185.16 \$84.13 \$14.17 \$17.9.26 \$42.25
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-OWATER  DEXTROSE 5%-O.25 NORMAL SALINE  DEXTROSE 5%-O.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-IN RINGERS  TOTAL  CEPHALOSPORINS  Share of FFS Rx's: 0.53% Per Member SFY05 YTD: \$7.34  CEFTIAXONE  CEFDINIR  CEPHALEXIN  CEFUROXIME  CEFPROZIL  CEFEDIME  CEFADOXIME  CEFADOXIME  CEFACLOR  CEFACLOR  CEFACLOR  CEFACLOR  CEFOLNIME  CEFACLOR  CEFOLNIME  CEFACLOR  CEFOLNIME	Y Y Y Y Y N N N N Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Cefazoline Injection Cefazoline Spectracef Cefotan Suprax	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000 \$4,497	1,242 902 194 589 171 22 25 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217 928 339 431 939 431 939 421 142	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.0.8% 0.1% 0.1%	\$33.86 \$23.55 \$108.13 \$23.44 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.92 \$33.00 \$33.00 \$43.25 \$4.61 \$298.75 \$30.88 \$80.71 \$14.11 \$179.25 \$42.25 \$42.25 \$42.25
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-VATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-IN RINGERS  TOTAL  CEPHALOSPORINS  Share of FFS Rx's: 0.53%  Per Member SFY05 YTD: \$7.34  CEFTRIAXONE  CEFDINIR  CEFPACIL  CEFPACIL  CEFPACIL  CEFPACIL  CEFPACIL  CEFPADOXIME  CEFPADOXIME  CEFPADOXIME  CEFADROXIL  CEFALOR  CEFALOR  CEFALOR  CEFALOR  CEFALOR  CEFALOR  CEFALOR  CEFALOR  CEFOTANIME  CEFOTOXIME  CEFOTOXIME  CEFOTOXIME  CEFALOR  CEFOTOXIME  CEFALOR  CEFALOR  CEFOTOXIME	Y Y Y Y Y Y N N N N N N N N N N N N N N	Brand Rocephin Injectable Omnicer Keflex Ceftin Cefzil Maxipme Injection Duricef Vantin Fortaz Injection Ceclor Spectracef Cefotan Suprax Lorabid	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth Lilly	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 \$104,677 Total \$\$ \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$330,887 \$7530 \$6,000 \$4,497 \$4,441	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 431 938 431 939 421 142 57 55	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 100.0%  Market Share 7.2% 10.8% 55.9% 9.8% 3.5% 0.6% 0.6% 0.8% 0.17% 0.18% 0.18% 0.19% 0.1% 0.1%	\$33.86 \$23.55 \$108.15 \$23.42 \$23.97 \$54.82 \$37.33 \$11.66 \$33.92 \$33.00 \$\$ Per Rx \$180.57 \$73.77 \$9.64 \$32.51 \$84.61 \$39.82 \$185.11 \$14.17 \$179.22 \$78.88 \$80.74
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.5 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5%-0.5NORMAL SALINE DEXTROSE 5%-0.5NORMAL SALINE DEXTROSE 5%-10.5NORMAL SALINE DEXTROSE 5% IN RINGERS TOTAI  CEPHALOSPORINS Share of FFS Rx's: 0.53% Per Member SFY05 YTD: \$7.34 CEFTRIAXONE CEFDINIR CEFPACIL CEFPACIL CEFEPIME CEFADROXIL CEFPODOXIME CEFTAZIDIME CEFAZOLIN CEFAZOLIN CEFOTOXIME CEFOTAXIME CEFOTOXIME	Y Y Y Y Y Y N N N N N N N N N N N N N N	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Cefactor Spectracef Cefotan Suprax Lorabid Claforan Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth Lilly Aventis	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000 \$4,441 \$1,088	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 431 939 421 142 557 561 10	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.6% 0.8% 1.7% 0.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.0%	\$33.86 \$23.52 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$33.00 \$180.51 \$180.51 \$298.75 \$30.85 \$80.71 \$185.16 \$84.13 \$179.28 \$42.25 \$78.85 \$80.74
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35 DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.5 NORMAL SALINE DEXTROSE 5%-0.5 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-LACTATED RINGERS DEXTROSE 5%-LACTATED RINGERS TOTAL  CEPHALOSPORINS Share of FFS Rx's: 0.53% Per Member SFY05 YTD: \$7.34 CEFTRIAXONE CEFDINIR CEPHALEXIN CEFPALEXIN CEFPALEXIN CEFPAROXIME CEFADOXIME CEFADOXIME CEFAZOLIN CEFAZOLIN CEFACLOR CEFOTAXIME CEFOTAXIME CEFDITOREN CEFDITOREN CEFDITOREN CEFDITOREN CEFOTAXIME	Y Y Y Y Y N N N N N Y	Brand Rocephin Injectable Omnicer Keflex Ceftin Cefzil Maxipme Injection Duricef Vantin Fortaz Injection Ceclor Spectracef Cefotan Suprax Lorabid	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth Lilly	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000 \$4,497 \$4,441 \$1,088 \$592	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 343 342 1,934 339 421 422 57 55 10	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.6% 0.8% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	\$33.86 \$23.55 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00 \$\$ Per Rx \$180.51 \$73.77 \$9.64 \$32.51 \$84.61 \$298.75 \$30.85 \$80.71 \$185.16 \$84.13 \$14.17 \$179.26 \$42.25 \$78.86 \$80.77 \$179.26
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NATER DEXTROSE 5%-NATE	Y Y Y Y Y Y N N N N Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Cefactor Spectracef Cefotan Suprax Lorabid Claforan Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth Lilly Aventis	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000 \$4,497 \$4,441 \$1,088 \$592 \$497	1,242 902 194 589 171 22 25 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217 928 339 431 939 421 142 57 55 10 8	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 0.1%  100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.0% 0.0	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92 \$33.00  \$\$Per Rx \$180.51 \$73.70 \$9.64 \$32.51 \$84.61 \$298.75 \$30.89 \$80.74 \$108.77 \$74.05 \$62.07
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NATER DEXTROSE 5%-NATE	Y Y Y Y Y N N N N N Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Cefactor Spectracef Cefotan Suprax Lorabid Claforan Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth Lilly Aventis	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 \$104,677 Total \$\$ \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000 \$4,497 \$4,441 \$1,088 \$592 \$497 \$12	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 431 939 431 142 57 55 10 8	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.1% 100.0%  Market Share 7.2% 10.8% 55.9% 9.8% 3.5% 0.6% 0.6% 0.8% 0.17% 0.11% 0.1% 0.1% 0.0% 0.1% 0.0% 0.0% 0.	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92  \$33.00  \$\$ Per Rx \$180.51 \$73.70 \$9.64 \$32.51 \$84.61 \$298.75 \$30.89 \$80.71 \$1179.28 \$42.25 \$78.89 \$80.74 \$108.77 \$74.05 \$62.07
Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER DEXTROSE 5%-WATER DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-0.25 NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NORMAL SALINE DEXTROSE 5%-NATER DEXTROSE 5%-NATE	Y Y Y Y Y Y N N N N Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Cefactor Spectracef Cefotan Suprax Lorabid Claforan Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth Lilly Aventis	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 <b>\$104,677</b> <b>Total \$\$</b> \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000 \$4,497 \$4,441 \$1,088 \$592 \$497	1,242 902 194 589 171 22 25 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 3,217 928 339 431 939 421 142 57 55 10 8	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.8% 0.7% 0.1%  100.0%  Market Share 7.2% 10.8% 56.9% 9.8% 3.5% 0.6% 5.8% 1.7% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.0% 0.0	\$33.86 \$23.53 \$108.13 \$23.42 \$23.97 \$54.82 \$37.31 \$11.66 \$33.92
Share of FFS Rx's: 0.03%  Per Member SFY05 YTD: \$0.35  DEXTROSE 5%-WATER  DEXTROSE 5%-WATER  DEXTROSE 5%-0.25 NORMAL SALINE  DEXTROSE 5%-0.5 NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-NORMAL SALINE  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-LACTATED RINGERS  DEXTROSE 5%-IN RINGERS  TOTAL  CEPHALOSPORINS  Share of FFS Rx's: 0.53%  Per Member SFY05 YTD: \$7.34  CEFTRIAXONE  CEFDINIR  CEFPHALEXIN  CEFPROZIL  CEFPADOXIME  CEFPADOXIME  CEFPADOXIME  CEFAALOIME  CEFAALOR  CEFOLIN  CEFACLOR  CEFOLIN  CEFACLOR  CEFOLINE  C	Y Y Y Y Y Y N N N N Y	Brand Rocephin Injectable Omnicerf Keflex Ceftin Cefzil Maxipime Injection Duricef Vantin Fortaz Injection Cefazoline Injection Cefactor Spectracef Cefotan Suprax Lorabid Claforan Injection	Manufacturer Roche Abbott Dista Labs GlaxoSmithKline Bristol-Myers Squibt Elan WC Prof Pharmacia GlaxoSmithKline Watson Lilly Purdue/TAP AstraZeneca Wyeth Lilly Aventis	\$42,056 \$21,224 \$20,978 \$13,794 \$4,099 \$1,206 \$933 \$268 \$102 \$17 \$104,677 Total \$\$ \$720,976 \$439,967 \$303,087 \$176,403 \$163,629 \$101,275 \$99,360 \$74,895 \$62,769 \$36,262 \$13,305 \$7,530 \$6,000 \$4,497 \$4,441 \$1,088 \$592 \$497 \$12	1,242 902 194 589 171 22 25 23 3 1 3,172 Total Rx 3,994 5,970 31,433 5,426 1,934 339 431 939 431 142 57 55 10 8	39.2% 28.4% 6.1% 18.6% 5.4% 0.7% 0.1% 100.0%  Market Share 7.2% 10.8% 55.9% 9.8% 3.5% 0.6% 0.6% 0.8% 0.17% 0.11% 0.1% 0.1% 0.0% 0.1% 0.0% 0.0% 0.	\$33.80 \$23.5: \$108.1: \$23.4: \$23.9: \$54.8: \$37.3: \$11.6: \$33.9: \$33.00 \$33.00 \$33.00 \$33.00 \$33.00 \$33.00 \$10.5: \$73.7: \$9.6: \$29.7: \$30.8: \$80.7: \$185.1: \$14.1: \$179.2: \$42.2: \$78.8: \$80.7: \$10.8: \$74.0: \$10.8: \$10.

CHOLINERGICS							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$1.26	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
BETHANECHOL	N	Urecholine	Merck	\$216,381	1,673	47.7%	\$129.34
PILOCARPINE	N	Salagen	MGI	\$77,334	594	16.9%	\$130.19
PYRIDOSTIGMINE	N	Mestinon	ICN	\$55,115	932	26.6%	\$59.14
CEVIMELINE	N	Evoxac	Daiichi	\$27,874	266	7.6%	\$104.79
NEOSTIGMINE	N	Prostigmin	ICN	\$1,254	33	0.9%	\$38.00
AMBENONIUM	N	Mytelase	Sanofi Winthrop	\$1,000	10	0.3%	\$99.97
PHYSOSTIGMINE				\$21	1	0.0%	\$21.30
Total				\$378,979	3,509	100.0%	\$108.00
CONTRACEPTIVES ORAL							
Share of FFS Rx's: 0.53%							
Per Member SFY05 YTD: \$7.01	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NORGESTIMATE-ETHINYL ESTRADIOL	N	Ortho Tri-Cyclen	Ortho-McNeil	\$715,108	17,457	31.7%	\$40.96
LEVONORGESTREL-ETH ESTRA	N	Nordette	Wyeth	\$344,504	7,884	14.3%	\$43.70
NORETHINDRONE-ETHINYL ESTRAD	Y	Ortho-Novum	Ortho-McNeil	\$297,498	8,387	15.2%	\$35.47
DESOGESTREL-ETHINYL ESTRADIOL	N	Desogen/Mircette	Organon	\$188,204	5,451	9.9%	\$34.53
NORGESTREL-ETHINYL ESTRADIOL	N	Lo/Ovral	Wyeth	\$151,816	4,069	7.4%	\$37.31
ETHINYL ESTRADIOL	N	Estinyl	Schering	\$114,083	2,559	4.6%	\$44.58
NORETHINDRONE	N	Micronor	Ortho-McNeil	\$113,205	2,836	5.2%	\$39.92
NORETHINDRONE A-E ESTRADIOL	N	Lo-estrin	Duramed	\$95,306	2,699	4.9%	\$35.31
LEVONORGESTREL	N	Norplant	Wyeth	\$45,668	2,135	3.9%	\$21.39
ETHYNODIOL D-ETHINYL ESTRADIOL	N	Demulen	Pharmacia	\$31,641	989	1.8%	\$31.99
NORETHINDRONE-MESTRANOL	Υ	Norinyl 1/50	Watson	\$17,893	565	1.0%	\$31.67
NORGESTREL	N	Ovrette	Wyeth	\$1,165	26	0.0%	\$44.82
Total				\$2,116,090	55,057	100.0%	\$38.43
CONTRACEPTIVES OTHER			1				
Share of FFS Rx's: 0.22%							
Per Member SFY05 YTD: \$3.32	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CONTRACEPTIVES,TRANSDERMAL CLASSIFIER	N	Ortho-Evra	Ortho	\$817,283	19,191	83.0%	\$42.59
CONTRACEPTIVES,INJECTABLE CLASSIFIER	N	Depo-Provera	Pharmacia	\$94,374	1,709	7.4%	\$55.22
ETONOGESTREL	N	NuvaRing	Organon	\$90,151	2,210	9.6%	\$40.79
NONOXYNOL 9	N			\$46	4	0.0%	\$11.58
Total				\$1,001,854	23,114	100.0%	\$43.34
COUGH AND COLD							
Share of FFS Rx's: 0.44%							
Per Member SFY05 YTD: \$2.64	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
GUAIFENESIN	Υ	Fenesin	Biovail	\$318,014	25,283	55.0%	\$12.58
DEXTROMETHORPHAN	Υ	Various		\$251,315	9,868	21.5%	\$25.47
BENZONATATE	Υ	Tessalon Perles	Forest	\$202,644	7,940	17.3%	\$25.52
PSEUDOEPHEDRINE	Υ	Sudafed	Pfizer	\$13,633	2,465	5.4%	\$5.53
CARBETAPENTANE	N	Tussizone	Mallinckrodt	\$6,468	150	0.3%	\$43.12
PHENYLEPHRINE	Υ			\$4,387	284	0.6%	\$15.45
POTASSIUM GUAIACOLSULFON				\$13	1	0.0%	\$13.45
Total				\$796,475	45,991	100.0%	\$17.32
COUGH SUPPRESSANTS - NARCOT	TC.						
	70						
Share of FFS Rx's: 0.32%							
Per Member SFY05 YTD: \$1.95	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
HYDROCODONE	Y	Hycodan	Endo	\$426,981	13,388	39.6%	\$31.89
CODEINE	Υ			\$160,117	20,312	60.0%	\$7.88
DIHYDROCODEINE	N			\$2,621	132	0.4%	\$19.86
Total				\$589,719	33,832	100.0%	\$17.43
DECONGESTANTS OPHTHALMIC							
Share of FFS Rx's: 0.00%		-					
Per Member SFY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
			1	\$1,277	53	70.7%	\$24.09
PHENYLEPHRINE	N	Various			-		\$8.63
PHENYLEPHRINE NAPHAZOLINE	N Y	Various Naphcon	Alcon	\$190	22	29.3%	
PHENYLEPHRINE	N Y		Alcon		22 <b>75</b>	29.3% <b>100.0%</b>	
PHENYLEPHRINE NAPHAZOLINE	N Y		Alcon	\$190			\$19.55
PHENYLEPHRINE NAPHAZOLINE	N Y		Alcon	\$190			
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS	N Y		Alcon	\$190			
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15%	Y	Naphcon		\$190 <b>\$1,467</b>	75	100.0%	\$19.55
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52	Y MAC'd?	Naphcon  Brand	Alcon	\$190 <b>\$1,467</b> Total <b>\$\$</b>	75 Total Rx	100.0% Market Share	\$19.55 \$\$ Per Rx
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION	Y	Naphcon  Brand Various	Manufacturer	\$190 \$1,467 Total \$\$ \$69,059	75 Total Rx 8,286	100.0% Market Share 52.2%	\$19.55 \$\$ Per Rx \$8.33
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE	MAC'd?	Naphcon  Brand Various Peridex		\$190 \$1,467 Total \$\$ \$69,059 \$52,757	75 Total Rx 8,286 6,439	100.0% Market Share 52.2% 40.6%	\$19.55 \$\$ Per Rx \$8.33 \$8.19
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE	MAC'd?	Naphcon  Brand  Various Peridex Various	Manufacturer  Zila Pharmaceutical	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850	75 Total Rx 8,286 6,439 488	100.0% Market Share 52.2% 40.6% 3.1%	\$19.55 \$\$ Per Rx \$8.33 \$8.19 \$55.02
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE TRIAMCINOLONE	MAC'd?	Naphcon  Brand Various Peridex	Manufacturer  Zila Pharmaceutical	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850 \$9,304	75  Total Rx 8,286 6,439 488 659	100.0%  Market Share 52.2% 40.6% 3.1% 4.2%	\$19.55 \$\$ Per Rx \$8.33 \$8.19 \$55.02 \$14.12
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE	MAC'd?	Naphcon  Brand  Various Peridex Various	Manufacturer  Zila Pharmaceutical	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850	75 Total Rx 8,286 6,439 488	100.0% Market Share 52.2% 40.6% 3.1%	\$19.55 \$\$ Per Rx \$8.33 \$8.19 \$55.02 \$14.12
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE TRIAMCINOLONE	MAC'd?	Naphcon  Brand  Various Peridex Various	Manufacturer  Zila Pharmaceutical	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850 \$9,304	75  Total Rx 8,286 6,439 488 659	100.0%  Market Share 52.2% 40.6% 3.1% 4.2%	\$19.55 \$\$ Per Rx \$8.33 \$8.19 \$55.02 \$14.12
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE TRIAMCINOLONE	MAC'd? N Y N	Naphcon  Brand  Various Peridex Various	Manufacturer  Zila Pharmaceutical	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850 \$9,304	75  Total Rx 8,286 6,439 488 659	100.0%  Market Share 52.2% 40.6% 3.1% 4.2%	\$19.55 \$\$ Per Rx \$8.33 \$8.19 \$55.02 \$14.12
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE TRIAMCINOLONE Total  DERMATOLOGIC IMMUNOSUPPRES	MAC'd? N Y N	Naphcon  Brand  Various Peridex Various	Manufacturer  Zila Pharmaceutical	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850 \$9,304	75  Total Rx 8,286 6,439 488 659	100.0%  Market Share 52.2% 40.6% 3.1% 4.2%	\$19.55 \$\$ Per Rx \$8.33 \$8.19 \$55.02 \$14.12
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE TRIAMCINOLONE Total  DERMATOLOGIC IMMUNOSUPPRES Share of FFS Rx's: 0.07%	MAC'd? N Y N Y SSANTS	Brand Various Peridex Various Kenalog in Orabase	Manufacturer  Zila Pharmaceutical  Apothecon	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850 \$9,304 \$157,971	Total Rx 8,286 6,439 488 659 15,872	100.0%  Market Share 52.2% 40.6% 3.1% 4.2% 100.0%	\$19.55 \$\$ Per Rx \$8.33 \$8.15 \$55.00 \$14.12 \$9.95
PHENYLEPHRINE NAPHAZOLINE Total  DENTAL AGENTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$0.52 FLUORIDE ION CHLORHEXIDINE DOXYCYCLINE TRIAMCINOLONE Total  DERMATOLOGIC IMMUNOSUPPRES	MAC'd? N Y N	Naphcon  Brand  Various Peridex Various	Manufacturer  Zila Pharmaceutical	\$190 \$1,467 Total \$\$ \$69,059 \$52,757 \$26,850 \$9,304	75  Total Rx 8,286 6,439 488 659	100.0%  Market Share 52.2% 40.6% 3.1% 4.2%	\$19.55

TACROLIMUS	N	Prograf	Fujisawa	\$205,780	1,821	24.3%	\$113.00
Total				\$706,807	7,492	100.0%	\$94.34
DIAGNOSTICS							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
THYROTROPINE	mirto u .	Diana	manadatarer	\$1,438	1	7.7%	\$1,437.88
ARGININE	N	Various		\$1,438 \$269	12	92.3%	\$1,437.86
Total	IN	various		\$1,707	13	100.0%	\$131.30
Total				\$1,707	13	100.0%	\$131.30
DIGESTIVE ENZYMES							
Share of FFS Rx's: 0.04%							
Per Member SFY05 YTD: \$3.22	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMYLASE	N	Various		\$972,892	4,617	100.0%	\$210.72
7.111.12.102		Vanous		<b>40.2,002</b>	.,	1001070	<b>V</b> =.V
DICITAL IS CLACOSIDES							
DIGITALIS GLYCOSIDES							
Share of FFS Rx's: 0.76%							
Per Member SFY05 YTD: \$2.11	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DIGOXIN	Υ	Lanoxin	GlaxoSmithKline	\$635,648	79,223	100.0%	\$8.02
Total							•
DISTIL EIDAM		+			-		
DISULFIRAM							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.13	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
DISULFIRAM	N	Antabuse	Odyssey	\$38,757	1,346	100.0%	\$28.79
			. ,				
DIURETICS COMBINATION							
Share of FFS Rx's: 0.51%							
Per Member SFY05 YTD: \$1.19	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
TRIAMTERENE	Υ	Dyazide	GlaxoSmithKline	\$316,599	49,549	92.5%	\$6.39
SPIRONOLACTONE	Υ	Aldactazide	Pharmacia	\$36,592	2,911	5.4%	\$12.57
AMILORIDE	Υ	Midamor	Merck	\$5,857	1,116	2.1%	\$5.25
Total				\$359,048	53,576	100.0%	\$6.70
DIURETICS LOOP							
Share of FFS Rx's: 2.78%							
Per Member SFY05 YTD: \$6.40	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
FUROSEMIDE	Υ	Lasix	Aventis	\$1,579,233	272,463	94.0%	\$5.80
TORSEMIDE	Υ	Demadex	Roche	\$209,474	5,079	1.8%	\$41.24
BUMETANIDE	Υ	Bumex	Roche	\$142,154	12,202	4.2%	\$11.65
ETHACRYNIC ACID	N	Edecrin	Merck	\$955	30	0.0%	\$31.82
Total				\$1,931,815	289,774	100.0%	\$6.67
DIURETICS OTHER							
Share of FFS Rx's: 0.03%	*** * ** **			T			***
Per Member SFY05 YTD: \$0.23	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ACETAZOLAMIDE	Y	Diamox	Duramed	\$61,455	2,978	90.8%	\$20.64
METHAZOLAMIDE	Υ	Neptazane	Lederle	\$6,666	293	8.9%	\$22.75
MANNITOL				\$48	10		
Total				\$68,169	3,281	100.0%	\$20.78
DIURETICS POTASSIUM SPARING				П	Т	Т	
Share of FFS Rx's: 0.38%							
	MAC'd?	Brand	Manufacturer	Total co	Total Pro	Market Chara	¢¢ Bor Bu
Per Member SFY05 YTD: \$2.23 SPIRONOLACTONE	WAC 0 ?	Aldactone	Pharmacia Pharmacia	Total \$\$ \$624,429	Total Rx 38,817	Market Share 97.0%	\$\$ Per Rx \$16.09
EPLERENONE EPLERENONE	N N	Inspra	Pfizer	\$624,429 \$31,051	38,817	97.0%	\$16.09
AMILORIDE	Y	Midamor	Merck	\$31,051 \$18,557	315 865	2.2%	\$98.58 \$21.45
	1	IVIIUdIIIUI	IVICICA				
Total				\$674,037	39,997	100.0%	\$16.85
DIURETICS THIAZIDE							
Share of FFS Rx's: 1.13%							
Per Member SFY05 YTD: \$3.43	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
HYDROCHLOROTHIAZIDE	Y	Hydrodiuril	Merck	\$588,591	95,064	80.6%	\$6.19
METOLAZONE	Y	Zaroxolyn	Celltech	\$412,074	17,426	14.8%	\$23.65
INDAPAMIDE	Y	Lozol	Aventis	\$18,604	3,171	2.7%	\$5.87
CHLORTHALIDONE	Y	Hygroton	Aventis	\$8,589	1,541	1.3%	\$5.57
CHLOROTHIAZIDE	Y	Diuril	Merck	\$4,355	532	0.5%	\$8.19
METHYCLOTHIAZIDE	Ý	Enduron	Abbott	\$1,638	151	0.1%	\$10.85
BENDROFLUMETHIAZIDE	N	Corzide	Monarch	\$372	11	0.0%	\$33.85
Total		00.2100		\$1,034,223	117,896	100.0%	\$8.77
10(4)				ψ1,034,223	111,090	100.0%	<b>ФО.</b> / /
DMS/DME							
Share of FFS Rx's: 0.00%							
	1	1					
Per Member SEY05 YTD: \$0.00	MACINO	Brand	Manufacturer	Total \$\$	Total Pv	Market Share	\$\$ Per Pv
Per Member SFY05 YTD: \$0.00 DIAPHRAGMS, ARC-SPRING	MAC'd?	Brand	Manufacturer	Total \$\$ \$72	Total Rx	Market Share 100.0%	\$\$ Per Rx \$23.91

ESTROGENS							
Share of FFS Rx's: 0.44%							
Per Member SFY05 YTD: \$4.54	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ESTROGENS,CONJUGATED	N	Premarin	Wyeth	\$1,133,131	33,300	73.4%	\$34.03
ESTRADIOL	Y	Estrace	WC Prof	\$184,331	9,916	21.9%	\$18.59
ETHINYL ESTRADIOL	N	Various		\$29,997	802	1.8%	\$37.40
ESTROGENS, ESTERIFIED	N	Estratest	Solvay	\$15,416	542	1.2%	\$28.44
ESTROPIPATE	Υ	Ogen	Pharmacia	\$6,537	808	1.8%	\$8.09
Total		- 3		\$1,369,412	45,368	100.0%	\$30.18
ETUANO							
ETHANOL Share of FFS Rx's: 0.00%							
	*** ***			T			***
Per Member SFY05 YTD: \$0.01 ETHYL ALCOHOL	MAC'd? N	Brand	Manufacturer	Total \$\$ \$2,749	Total Rx 50	Market Share 100.0%	\$\$ Per Rx \$54.98
FOLATE ANTAGONISTS							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.06	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
TRIMETHOPRIM	Υ	Proloprim	Monarch	\$17,945	1,307	100.0%	\$13.73
GENERAL ANESTHETICS							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
KETAMINE	N N	Ketalar	Monarch	\$1,081	1 <b>0tai KX</b>	44.1%	\$72.07
MIDAZOLAM	N	Midazolam	Roxane	\$294	19	55.9%	\$15.47
Total	1.3	iviiudzUlaIII	Novalle	\$1,375	34	100.0%	\$15.47 <b>\$40.44</b>
Total				\$1,375	34	100.0%	\$40.44
GLUCOCORTICOIDS							
Share of FFS Rx's: 0.92%							
				T			** ** **
Per Member SFY05 YTD: \$3.97	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
TRIAMCINOLONE	N	Kenacort	BMS	\$515,049	6,134	6.4%	\$83.97
PREDNISONE	Y	Orasone	Solvay	\$381,863	70,622	73.3%	\$5.41
PREDNISOLONE	Y	Prelone	Aero	\$119,486	7,102	7.4% 4.2%	\$16.82
HYDROCORTISONE DEXAMETHASONE	N	Cortef Decadron	Pharmacia Merck	\$64,541 \$55,693	4,018 3,157	3.3%	\$16.06 \$17.64
METHYLPREDNISOLONE	Y	Medrol	Pharmacia		4,975	5.2%	\$17.64
CORTISONE	N	Cortisone	Filalillacia	\$53,590 \$7,287	319	0.3%	\$22.84
BETAMETHASONE	IN	Cortisorie		\$30	319	0.3%	\$22.04
Total				\$1,197,539	96,328	100.0%	\$12.43
GROWTH HORMONE							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$5.84	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SOMATROPIN	N	Various	Serono	\$1,761,655	1,053	100.0%	\$1,672.99
HEMORRHEOLOGIC AGENTS							
Share of FFS Rx's: 0.05%							
Per Member SFY05 YTD: \$0.22	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PENTOXIFYLLINE	Υ	Trental	Aventis	\$67,825	5,159	100.0%	\$13.15
HEMOSTATICS - ANTIFIBRINOLYTIC							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.09	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMINOCAPROIC ACID	N	Amicar	Xanodyne	\$28,101	92	100.0%	\$305.45
HYPOTENSIVES - CENTRALLY ACTIN	VG						
Share of FFS Rx's: 0.56%							
Per Member SFY05 YTD: \$5.34	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CLONIDINE	Υ	Catapres	Boehringer	\$1,507,268	48,969	84.6%	\$30.78
GUANFACINE	Υ	Tenex	ESP	\$70,200	6,688	11.6%	\$10.50
METHYLDOPA	Υ	Aldomet	Merck	\$22,119	1,619	2.8%	\$13.66
RESERPINE	N	Various	-	\$11,241	585	1.0%	\$19.21
GUANABENZ	Y	Wytensin	Wyeth	\$562	15	0.0%	\$37.50
DESERPIDINE Total	N			\$354 <b>\$1,611,744</b>	57,880	0.0% <b>100.0%</b>	\$88.40 <b>\$27.85</b>
					,		
HYPOTENSIVES - VASODILATORS							
Share of FFS Rx's: 0.02%	MA C: 10	D	Manuel	T-1-1-00	T-1-17	Mandad C	66 D
Per Member SFY05 YTD: \$0.19	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
HYDRALAZINE	Y	Apresoline	Novartis	\$64,664	5,733	247.9%	\$11.28
MINOXIDIL	Υ	Loniten	Pharmacia	\$57,071	2,313	100.0%	\$24.67
Total		+		\$57,071	2,313	100.0%	\$24.67
HYDOTENSIVES OTHER		+					
HYPOTENSIVES OTHER	1	1	I	1			

Per Member SFY05 YTD: \$0.02  METYROSINE  IMMUNE GLOBULINS  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$3.03  IMMU GLOBULIN,GAMMA (IGG)  IMMUNOMODULATORS  Share of FFS Rx's: 0.01%  Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON ALFA-2A,RECOMB.  INTERFERON ALFA-2A,RECOMB.  INTERFERON GAMMA  ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS	MAC'd? N MAC'd? N MAC'd? N N N N N	Brand Demser  Brand Gamimune/Gammag  Brand Aldara Intron/Rebetron Roferon A  Proleukin	Manufacturer Merck  Manufacturer Bayer  Manufacturer 3M Schering Roche	Total \$\$ \$4,825  Total \$\$ \$915,168  Total \$\$ \$211,659 \$121,212 \$10,191	Total Rx  11  Total Rx  436  Total Rx  1,283	Market Share 100.0%  Market Share 100.0%  Market Share 92.0%	\$\$ Per Rx \$438.64 \$\$ Per Rx \$2,099.01
IMMUNE GLOBULINS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$3.03 IMMU GLOBULIN,GAMMA (IGG)  IMMUNOMODULATORS Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$1.18 IMIQUIMOD INTERFERON ALFA-2B,RECOMB. INTERFERON ALFA-2A,RECOMB. INTERFERON GAMMA ALDESLEUKIN Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS	MAC'd? N MAC'd? N N N	Brand Gamimune/Gammag Brand Aldara Intron/Rebetron Roferon A	Manufacturer Bayer  Manufacturer 3M Schering	Total \$\$ \$915,168  Total \$\$ \$211,659 \$121,212	Total Rx 436 Total Rx 1,283	Market Share 100.0%  Market Share	\$\$ Per Rx \$2,099.01 \$\$ Per Rx
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$3.03  IMMU GLOBULIN,GAMMA (IGG)  IMMUNOMODULATORS  Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON ALFA-2A,RECOMB.  INTERFERON GAMMA ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID TACROLIMUS	MAC'd? N N	Brand Aldara Intron/Rebetron Roferon A	Manufacturer 3M Schering	\$915,168  Total \$\$     \$211,659     \$121,212	436 Total Rx 1,283	100.0% Market Share	\$2,099.01 \$\$ Per Rx
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$3.03  IMMU GLOBULIN,GAMMA (IGG)  IIMMUNOMODULATORS  Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON ALFA-2A,RECOMB.  INTERFERON GAMMA ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID TACROLIMUS	MAC'd? N N	Brand Aldara Intron/Rebetron Roferon A	Manufacturer 3M Schering	\$915,168  Total \$\$     \$211,659     \$121,212	436 Total Rx 1,283	100.0% Market Share	\$2,099.0° \$\$ Per Rx
Per Member SFY05 YTD: \$3.03  IMMU GLOBULIN,GAMMA (IGG)  IIMMUNOMODULATORS  Share of FFS Rx's: 0.01%  Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON ALFA-2A,RECOMB.  INTERFERON GAMMA  ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS	MAC'd? N N	Brand Aldara Intron/Rebetron Roferon A	Manufacturer 3M Schering	\$915,168  Total \$\$     \$211,659     \$121,212	436 Total Rx 1,283	100.0% Market Share	\$2,099.01 \$\$ Per Rx
IMMU GLOBULIN,GAMMA (IGG)  IMMUNOMODULATORS  Share of FFS Rx's: 0.01%  Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON GAMMA  ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS	MAC'd? N N	Brand Aldara Intron/Rebetron Roferon A	Manufacturer 3M Schering	\$915,168  Total \$\$     \$211,659     \$121,212	436 Total Rx 1,283	100.0% Market Share	\$2,099.01 \$\$ Per Rx
IMMUNOMODULATORS Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$1.18 IMIQUIMOD INTERFERON ALFA-2B,RECOMB. INTERFERON ALFA-2A,RECOMB. INTERFERON GAMMA ALDESLEUKIN Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS	MAC'd? N N	Brand Aldara Intron/Rebetron Roferon A	Manufacturer 3M Schering	Total \$\$ \$211,659 \$121,212	Total Rx 1,283	Market Share	\$\$ Per Rx
IMMUNOMODULATORS Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$1.18 IMIQUIMOD INTERFERON ALFA-2B,RECOMB. INTERFERON ALFA-2A,RECOMB. INTERFERON GAMMA ALDESLEUKIN Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS	N N N	Brand Aldara Intron/Rebetron Roferon A	Manufacturer 3M Schering	Total \$\$ \$211,659 \$121,212	Total Rx 1,283	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.01%  Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON GAMMA  ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS	N N N	Aldara Intron/Rebetron Roferon A	3M Schering	\$211,659 \$121,212	1,283		
Share of FFS Rx's: 0.01%  Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON GAMMA  ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS	N N N	Aldara Intron/Rebetron Roferon A	3M Schering	\$211,659 \$121,212	1,283		
Per Member SFY05 YTD: \$1.18  IMIQUIMOD  INTERFERON ALFA-2B,RECOMB.  INTERFERON GAMMA  ALDESLEUKIN  Total  IMMUNOSUPPRESSANTS  Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS	N N N	Aldara Intron/Rebetron Roferon A	3M Schering	\$211,659 \$121,212	1,283		
IMIQUIMOD INTERFERON ALFA-2B,RECOMB. INTERFERON ALFA-2A,RECOMB. INTERFERON GAMMA ALDESLEUKIN Total  IMMUNOSUPPRESANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS	N N N	Aldara Intron/Rebetron Roferon A	3M Schering	\$211,659 \$121,212	1,283		
INTERFERON ALFA-2B,RECOMB. INTERFERON ALFA-2A,RECOMB. INTERFERON GAMMA ALDESLEUKIN Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS	N N	Intron/Rebetron Roferon A	Schering	\$121,212		92.0%	
INTERFERON ALFA-2A,RECOMB. INTERFERON GAMMA ALDESLEUKIN Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS	N	Roferon A				C F0/	\$164.97 \$1,346.80
INTERFERON GAMMA ALDESLEUKIN Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS			Rocite		18	6.5% 1.3%	\$1,346.80
ALDESLEUKIN Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS	N	Proleukin		\$8,780	2	1.370	φ500.10
Total  IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS		Toloutin	Chiron	\$2,828	2	0.1%	\$1,414.06
IMMUNOSUPPRESSANTS Share of FFS Rx's: 0.15% Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS			Official	\$354,670	1,395	100.0%	\$254.24
Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS		+		ψ554,010	1,000	100.070	Ψ204.2-
Share of FFS Rx's: 0.15%  Per Member SFY05 YTD: \$14.79  MYCOPHENOLIC ACID  TACROLIMUS			-				
Per Member SFY05 YTD: \$14.79 MYCOPHENOLIC ACID TACROLIMUS							
MYCOPHENOLIC ACID TACROLIMUS							
TACROLIMUS	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
	N	CellCept	Roche	\$1,745,017	4,198	26.8%	\$415.68
	N	Prograf	Fujisawa	\$1,624,932	3,695	23.6%	\$439.77
CYCLOSPORINE	Y	Neoral	Novartis	\$636,667	3,435	21.9%	\$185.35
SIROLIMUS	N	Rapamune	Wyeth	\$351,864	578	3.7%	\$608.76
AZATHIOPRINE	Υ	Imuran	Prometheus	\$104,130	3,759	24.0%	\$27.70
Total				\$4,462,609	15,665	100.0%	\$284.88
INTESTINAL MOTILITY STIMULANTS							
Share of FFS Rx's: 0.30%							
Per Member SFY05 YTD: \$0.99	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
METOCLOPRAMIDE	Υ	Reglan	Schwarz	\$297,958	31,269	100.0%	\$9.53
		rogian	Comman	<b>\$20.,000</b>	0.,200		<b>,</b>
LAXATIVES							
Share of FFS Rx's: 0.83%							
Per Member SFY05 YTD: \$6.17	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
POLYETHYLENE GLYCOL 3350	N	Various		\$1,316,610	53,579	62.1%	\$24.57
LACTULOSE	Y	Enulose	Alpharma	\$423,187	22,763	26.4%	\$18.59
SODIUM SULFATE	N	Colyte	Schwartz	\$42,862	2,192	2.5%	\$19.55
SODIUM MAGNESIUM SALT	Υ			\$29,519 \$17,691	1,185 4,519	1.4% 5.2%	\$24.9° \$3.9°
SODIUM PHOSPHATE	N	Various	+	\$10,485	208	0.2%	\$50.4°
BISACODYL	Y	Correctol	S-P Healthcare	\$7,824	291	0.2%	\$26.89
SENNA	Y	Senokot	Purdue	\$6,835	550	0.6%	\$12.43
DOCUSATE	Y	Colace	Purdue	\$6,730	929	1.1%	\$7.24
PSYLLIUM	Y	Konsyl	Konsyl	\$41	7	0.0%	\$5.90
CASANTHRANOL	N	Various	-	\$12	2	0.0%	\$5.99
Total				\$1,861,795	86,225	100.0%	\$21.59
				, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			•
LINCOSAMIDES							
Share of FFS Rx's: 0.11%							
Per Member SFY05 YTD: \$0.95	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CLINDAMYCIN	Y	Cleocin	Pharm & Upjohn	\$286,527	11,180	99.7%	\$25.63
LINCOMYCIN	N	Lincocin	Pharm & Upjohn	\$790	31	0.3%	\$25.49
Total	1			\$287,317	11,211	100.0%	\$25.63
			1				
LIPIDS PARENTERAL	1						
		1					
	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.01%				\$81,682	1,067	100.0%	\$76.55
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27	Υ		+	Ψ01,002	.,501	. 50.0 /0	ψ1 0.00
Share of FFS Rx's: 0.01%	Υ			1		+	
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS	Y		+				
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS	Y						
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03%							
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67	Y MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03%		Brand Vytorin	Manufacturer Merck	Total \$\$ \$200,716	Total Rx 2,682	Market Share 55.4%	<b>\$\$ Per Rx</b> \$74.84
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67	MAC'd?						
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67 EZETIMIBE	MAC'd?			\$200,716	2,682	55.4%	\$74.84 \$80.99
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67 EZETIMIBE NIACIN	MAC'd?			\$200,716 \$174,855	2,682 2,159	55.4% 44.6%	\$74.84 \$80.99
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67 EZETIMIBE NIACIN Total	MAC'd?			\$200,716 \$174,855	2,682 2,159	55.4% 44.6%	\$74.8 \$80.9
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67 EZETIMIBE NIACIN Total  LIPOTROPES - NON STATINS	MAC'd?			\$200,716 \$174,855	2,682 2,159	55.4% 44.6%	\$74.8 \$80.9
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67 EZETIMIBE NIACIN Total  LIPOTROPES - NON STATINS Share of FFS Rx's: 0.72%	MAC'd?	Vytorin	Merck	\$200,716 \$174,855 <b>\$375,571</b>	2,682 2,159 <b>4,841</b>	55.4% 44.6% 100.0%	\$74.8 \$80.9 <b>\$77.5</b>
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES- COMBOS Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67 EZETIMIBE NIACIN Total  LIPOTROPES - NON STATINS Share of FFS Rx's: 0.72% Per Member SFY05 YTD: \$13.11	MAC'd?	Vytorin	Merck  Manufacturer	\$200,716 \$174,855 <b>\$375,571</b> Total \$\$	2,682 2,159 <b>4,841</b> Total Rx	55.4% 44.6% 100.0% Market Share	\$74.8 \$80.9 \$77.56 \$Per Rx
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27  FAT EMULSIONS  LIPOTROPES- COMBOS  Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67  EZETIMIBE  NIACIN Total  LIPOTROPES - NON STATINS  Share of FFS Rx's: 0.72% Per Member SFY05 YTD: \$13.11  EZETIMIBE	MAC'd? N MAC'd?	Vytorin  Brand Zetia	Manufacturer Schering	\$200,716 \$174,855 <b>\$375,571</b> Total <b>\$\$</b> \$1,352,523	2,682 2,159 <b>4,841</b> Total Rx 18,498	55.4% 44.6% 100.0% Market Share 24.6%	\$74.84 \$80.99 <b>\$77.58</b> \$ <b>Per Rx</b> \$73.12
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27 FAT EMULSIONS  LIPOTROPES - COMBOS  Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67 EZETIMIBE NIACIN Total  LIPOTROPES - NON STATINS Share of FFS Rx's: 0.72% Per Member SFY05 YTD: \$13.11 EZETIMIBE FENOFIBRATE	MAC'd? N MAC'd? N Y	Vytorin  Brand Zetia Tricor	Manufacturer Schering Abbott	\$200,716 \$174,855 \$375,571 Total \$\$ \$1,352,523 \$1,011,912	2,682 2,159 <b>4,841</b> Total Rx 18,498 12,904	55.4% 44.6% 100.0% Market Share 24.6% 17.2%	\$74.8 \$80.9 \$77.5 \$78.42 \$78.42
Share of FFS Rx's: 0.01% Per Member SFY05 YTD: \$0.27  FAT EMULSIONS  LIPOTROPES- COMBOS  Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.67  EZETIMIBE  NIACIN Total  LIPOTROPES - NON STATINS  Share of FFS Rx's: 0.72% Per Member SFY05 YTD: \$13.11  EZETIMIBE	MAC'd? N MAC'd?	Vytorin  Brand Zetia	Manufacturer Schering	\$200,716 \$174,855 <b>\$375,571</b> Total <b>\$\$</b> \$1,352,523	2,682 2,159 <b>4,841</b> Total Rx 18,498	55.4% 44.6% 100.0% Market Share 24.6%	\$74.84 \$80.99 <b>\$77.5</b> 8

CHOLESTYRAMINE	lv.	Ougatran	Day Dharma	£440.004	2 200	4.20/	<b>#</b> 07.07
COLESEVELAM	N N	Questran WelChol	Par Pharma Sankyo	\$119,821 \$119,727	3,206 945	4.3% 1.3%	\$37.37 \$126.70
COLESTIPOL	N	Colestid	Pharm & Upjohn	\$43,855	758	1.0%	\$57.86
Total		Colcolid	т папт а орјопт	\$3,956,574	75,164	100.0%	\$52.64
10141				ψο,σοσ,σ. 4	70,104	100.070	Ψ02.0
LIPOTROPES - STATINS							
Share of FFS Rx's: 2.63%				T			** -
Per Member SFY05 YTD: \$75.85	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ATORVASTATIN	N N	Lipitor	Parke-Davis	\$12,238,134	148,324	54.2%	\$82.51
SIMVASTATIN	N N	Zocor	Merck BristolMyerSqb	\$6,714,501 \$1,859,249	57,966	21.2%	\$115.84 \$111.90
PRAVASTATIN LOVASTATIN	Y	Pravachol Mevacor	Merck	\$1,859,249 \$874,282	16,616 33,513	6.1% 12.3%	\$111.90
ROSUVASTATIN	N	Crestor	AstraZeneca	\$874,282 \$697.010	9,211	3.4%	\$75.67
FLUVASTATIN	N	Lescol	Novartis	\$510,381	7,819	2.9%	\$65.27
Total		200001	140401110	\$22,893,557	273,449	100.0%	\$83.72
Total				<b>\$22,033,337</b>	213,443	100.076	ψ03.7 Z
LITHIUM							
Share of FFS Rx's: 0.33%							
Per Member SFY05 YTD: \$2.64	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LITHIUM	Υ	Eskalith	GlaxoSmithKline	\$797,128	33,922	100.0%	\$23.50
LOCAL ANESTHETICS							
		+	+				
Share of FFS Rx's: 0.06%		<del>_</del>					** -
Per Member SFY05 YTD: \$0.32	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LIDOCAINE	Y	Xylocaine	AstraZeneca	\$95,843	5,898	99.2%	\$16.25
BUPIVACAINE	N	Sensorcaine	AstraZeneca	\$691	47 5 0 4 5	0.8%	\$14.70
Total		1		\$96,534	5,945	100.0%	\$16.24
		1					
LUBRICANTS OPHTHALMIC							
Share of FFS Rx's: 0.26%							
Per Member SFY05 YTD: \$0.89	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
POLYVINYL ALCOHOL	N N	Refresh	Allergan	\$107,724	14,022	52.4%	\$7.68
CARBOXYMETHYLCELLULOSE SODIUM	N	Celluvisc	Allergan	\$79,792	6,241	23.3%	\$12.79
HYPROMELLOSE	N	Ocucoat	Bausch & Lomb	\$37,322	2,984	11.2%	\$12.51
PETROLATUM,WHITE	N	Puralube	E Fougera	\$20,059	1,707	6.4%	\$11.75
DEXTRAN 70	N	Tears Naturale	Alcon	\$17,706	1,431	5.4%	\$12.37
PROPYLENE GLYCOL	N			\$3,727	333	1.2%	\$11.19
HYDROXYPROPYL CELLULOSE	N	Lacrisert	Merck	\$1,343	24	0.1%	\$55.96
Total				\$267,674	26,742	100.0%	\$10.01
MACROLIDES							
Share of FFS Rx's: 0.73%							
Per Member SFY05 YTD: \$11.82	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AZITHROMYCIN	N	Zithromax	Pfizer	\$3,140,219	65,991	87.1%	\$47.59
CLARITHROMYCIN	N	Biaxin	Abbott	\$358,070	4,042	5.3%	\$88.59
ERYTHROMYCIN BASE	Y	Ery-tab	Abbott	\$69,837	5,774	7.6%	\$12.10
Total				\$3,568,126	75,807	100.0%	\$47.07
MAGNESIUM							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.03	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MAGNESIUM SALT	V	Diana	Manadatarer	\$7,619	1,436	100.0%	\$5.31
WACINEDIOW GAET				Ψ1,013	1,400	100.070	ψ0.01
MACT OF LOTABILIZEDO OBJETO	A I ACIO	+					
MAST CELL STABILIZERS OPHTHA	ALIVIC	1					
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.10	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NEDOCROMIL	N	Alocril	Allergen	\$13,481	195	30.7%	\$69.13
LODOXAMIDE	N	Alomide	Alcon	\$7,377	106	16.7%	\$69.59
PEMIROLAST	N	Alamast	Santen	\$5,089	88	13.9%	\$57.82
CROMOLYN	Y	Crolom	Bausch and Lomb	\$3,850	246	38.7%	\$15.65
IT-4-1		1		\$29,796	635	100.0%	\$46.92
Total							
METRONIDAZOLE							
METRONIDAZOLE Share of FFS Rx's: 0.12%	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27	MAC'd?	Brand Flagyl	Manufacturer Pharmacia	Total \$\$ \$80.574	Total Rx		\$\$ Per Rx
METRONIDAZOLE Share of FFS Rx's: 0.12%	MAC'd?	Brand Flagyl	Manufacturer Pharmacia	Total \$\$ \$80,574	Total Rx 12,414	Market Share	
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE	MAC'd?						
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE MINERALS	MAC'd?						
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE  MINERALS Share of FFS Rx's: 0.16%	Y	Flagyl	Pharmacia	\$80,574	12,414	100.0%	\$6.49
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE MINERALS	MAC'd?						
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE  MINERALS Share of FFS Rx's: 0.16% Per Member SFY05 YTD: \$0.62 IRON	Y MAC'd?	Flagyl	Pharmacia	\$80,574  Total \$\$ \$141,407	12,414  Total Rx 12,204	100.0% Market Share 73.1%	\$6.49 \$\$ Per Rx \$11.59
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE  MINERALS Share of FFS Rx's: 0.16% Per Member SFY05 YTD: \$0.62 IRON ZINC	MAC'd?	Flagyl	Pharmacia	\$80,574  Total \$\$ \$141,407 \$37,688	12,414 Total Rx 12,204 3,404	100.0% Market Share 73.1% 20.4%	\$6.49 \$\$ Per Rx \$11.59 \$11.07
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE  MINERALS Share of FFS Rx's: 0.16% Per Member SFY05 YTD: \$0.62 IRON ZINC SELENIUM	MAC'd? Y N N	Flagyl	Pharmacia	\$80,574  Total \$\$ \$141,407 \$37,688 \$5,440	12,414 Total Rx 12,204 3,404 777	100.0% Market Share 73.1% 20.4% 4.7%	\$6.49 \$\$ Per Rx \$11.59 \$11.07 \$7.00
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE  MINERALS Share of FFS Rx's: 0.16% Per Member SFY05 YTD: \$0.62 IRON ZINC SELENIUM SOD FERRIC GLUC COMPLX	MAC'd? Y N N	Flagyl	Pharmacia	\$80,574  Total \$\$ \$141,407 \$37,688 \$5,440 \$2,089	12,414  Total Rx 12,204 3,404 777 14	100.0% Market Share 73.1% 20.4% 4.7% 0.1%	\$6.49 \$\$ Per Rx \$11.59 \$11.07 \$7.00 \$149.22
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE  MINERALS Share of FFS Rx's: 0.16% Per Member SFY05 YTD: \$0.62 IRON ZINC SELENIUM SOD FERRIC GLUC COMPLX POTASSIUM IODIDE	MAC'd? Y N N N	Flagyl	Pharmacia	\$80,574  Total \$\$   \$141,407   \$37,688   \$5,440   \$2,089   \$1,428	12,414  Total Rx 12,204 3,404 777 14 112	100.0%  Market Share 73.1% 20.4% 4.7% 0.1% 0.7%	\$6.49 \$\$ Per Rx \$11.59 \$11.07 \$7.00 \$149.22 \$12.75
METRONIDAZOLE Share of FFS Rx's: 0.12% Per Member SFY05 YTD: \$0.27 METRONIDAZOLE  MINERALS Share of FFS Rx's: 0.16% Per Member SFY05 YTD: \$0.62 IRON ZINC SELENIUM SOD FERRIC GLUC COMPLX	MAC'd? Y N N	Flagyl	Pharmacia	\$80,574  Total \$\$ \$141,407 \$37,688 \$5,440 \$2,089	12,414  Total Rx 12,204 3,404 777 14	100.0% Market Share 73.1% 20.4% 4.7% 0.1%	\$6.49 \$\$ Per Rx \$11.59 \$11.07 \$7.00 \$149.22

COPPER				\$14	7		
Total				\$188,494	16,690	100.0%	\$11.29
MYDRIATICS							
Share of FFS Rx's: 0.02%							
Per Member SFY05 YTD: \$0.07	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SCOPOLAMINE	N N	Isopto Hyoscine	Alcon	\$6,655	296	18.1%	\$22.48
HOMATROPINE ATROPINE	Y	Isopto Homatropine Isopto Atropine	Alcon Alcon	\$5,035 \$4,635	212 657	13.0% 40.2%	\$23.75 \$7.05
CYCLOPENTOLATE	Y	Cyclogyl	Alcon	\$2,249	218	13.3%	\$10.32
DIPIVEFRIN	Y	Propine	Allergan	\$1,577	164	10.0%	\$9.62
PHENYLEPHRINE	N	Various	, morgan	\$677	30	1.8%	\$22.58
TROPICAMIDE	Υ	Mydriacyl	Alcon	\$515	58	3.5%	\$8.87
Total				\$21,343	1,635	100.0%	\$13.05
NARCOTIC ANTAGONISTS							
Share of FFS Rx's: 0.02%							
Per Member SFY05 YTD: \$0.44	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NALTREXONE	V	Revia	Barr	\$132,729	1,842	98.3%	\$72.06
NALOXONE	N	Narcan	Endo	\$144	29	1.5%	\$4.96
TWILDWOITE	- 1	rarouri	Endo	\$12	2	1.070	ψ4.00
Total				\$132,885	1,873	100.0%	\$70.95
				<b>V</b> 102,000	1,010	1001010	******
NASAL - AGENTS FOR RHINORRHE	Δ						
	-						
Share of FFS Rx's: 0.04%	M & OL 10	Browd	Manufacture	Tc+-1 66	Te/-15	Mark-1 Ob	¢¢ D D
Per Member SFY05 YTD: \$0.58 AZELASTINE	MAC'd?	Brand Actolin	Manufacturer Modpointo	Total \$\$	Total Rx 2,012	Market Share 52.6%	\$\$ Per Rx
IPRATROPIUM	N Y	Astelin Atrovent	Medpointe Boehringer	\$119,058 \$56,880	2,012 1,813	52.6% 47.4%	\$59.17 \$31.37
Total	+'	, alovoin	230mingal	\$175,938	3,825	100.0%	\$46.00
1 Otal	+	+	+	\$113,330	3,023	100.0%	φ40.00
NACAL DECONOCCTANTO	1						
NASAL DECONGESTANTS	1						
Share of FFS Rx's: 0.00%	1						
Per Member SFY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
TETRAHYDROZOLINE	N	Murine	Ross Consumer	\$21	1	100.0%	\$21.03
NASAL MUPIROCIN							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.02	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MUPIROCIN	N	Bactroban	GlaxoSmithKline	\$6,427	108	100.0%	\$59.51
				, ,			• • • • • • • • • • • • • • • • • • • •
NASAL STEROIDS							
Share of FFS Rx's: 0.55%	*** ***						** -
Per Member SFY05 YTD: \$12.56	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
FLUTICASONE MOMETASONE FUROATE	N N	Flovent Nasonex	GlaxoSmithKline Schering	\$2,060,889 \$1,033,588	31,648 15,034	55.2% 26.2%	\$65.12 \$68.75
TRIAMCINOLONE	N	Nasacort	Aventis	\$1,033,588	4,869	8.5%	\$66.45
BUDESONIDE	N	Rhinocort	AstraZeneca	\$276,371	4,064	7.1%	\$68.00
BECLOMETHASONE	N	Qvar	IVAX	\$68,677	985	1.7%	\$69.72
FLUNISOLIDE	Y	Nasalide	IVAX	\$29,172	723	1.3%	\$40.35
Total				\$3,792,220	57,323	100.0%	\$66.16
				, - ,,	,	7,55,570	¥******
NEUROMUSCULAR BLOCKING AGE	NTS						
	,,,,						
Share of FFS Rx's: 0.00%	MAC'd?	Brand	Manufactura	Total co	Total Pr	Market Chara	\$\$ Per Rx
Per Member SFY05 YTD: \$0.02		Brand	Manufacturer	Total \$\$	Total Rx	Market Share	
BOTULINUM TOXIN TYPE A	N	Botox		\$4,552	9	100.0%	\$505.78
AUT A TOWAND -	1						
NITAZOXANIDE							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.06	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NITAZOXANIDE	N	Alinia	Romark	\$18,891	65	100.0%	\$290.63
NITRATES							
Share of FFS Rx's: 0.91%	1						
Per Member SFY05 YTD: \$5.03	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NITROGLYCERIN	Y	Various	manunacturer	\$1,130,970	45,444	47.8%	\$24.89
ISOSORBIDE	Y	Various		\$387,382	49,542	52.2%	\$7.82
AMYL NITRITE	1			\$12	1	OZ.Z /0	ψ1.02
Total				\$1,518,364	94,987	100.0%	\$15.98
				, . ,	,1	1 2010 70	÷.5.50
NITROFURANS							
	1						
Share of FFS Rx's: 0.25%	MA CL-IC	Prond	Manufacture	Total on	Total De	Market Ch	¢¢ Dau D
Per Member SFY05 YTD: \$2.51	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NITROFURANTOIN	Y	Macrodantin	P & G Pharma	\$758,788	26,139	100.0%	\$29.03
NOV. / 10775 - 1 - 1 - 1 - 1 - 1							
NON-LISTED PA DRUGS							

Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.40	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
		brano	wanuracturer				
NON-LISTED PA DRUGS	N/A			\$122,046	165	100.0%	\$739.67
NON-NDC COMPOUND DRUGS							
Share of FFS Rx's: 0.22%							
	MACIAO	Duend	Manufacturer	Tatal 66	Total Dv	Market Chara	ff Day Dy
Per Member SFY05 YTD: \$1.11	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
NON-NDC COMPOUND DRUGS	N/A			\$336,087	23,341	100.0%	\$14.40
Total							
NO AIDO ODUTUAL MIO							
NSAIDS OPHTHALMIC							
Share of FFS Rx's: 0.02%							
Per Member SFY05 YTD: \$0.39	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
KETOROLAC	N	Acular	Allergan	\$93,172	1,343	74.2%	\$69.38
DICLOFENAC	N	Voltaren Ophthalmic		\$24,219	434	24.0%	\$55.80
FLURBIPROFEN	N	Ocufen	Allergan	\$494	32	1.8%	\$15.44
Total				\$117,885	1,809	100.0%	\$65.17
OPHTHALMIC STEROIDS							
Share of FFS Rx's: 0.07%							
Per Member SFY05 YTD: \$0.52	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PREDNISOLONE	Υ	Pred Forte	Allergan	\$61,424	4,433	60.9%	\$13.86
LOTEPREDNOL	N	Alrex/Lotemax	Bausch & Lomb	\$59,698	1,514	20.8%	\$39.43
FLUOROMETHOLONE	Y	FML Forte	Allergan	\$16,643	783	10.8%	\$21.26
DEXAMETHASONE	Y	Decadron	Merck	\$10,421	258	3.5%	\$40.39
RIMEXOLONE	N	Vexol	Alcon	\$8,650	263	3.6%	\$32.89
MEDRYSONE	Υ	HMS Liquiflim	Allergan	\$866	24	0.3%	\$36.09
Total				\$157,702	7,275	100.0%	\$21.68
OTHER ANTI-INFECTIVES							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$4.47	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LINEZOLID	N	Zyvox	Pharm & Upjohn	\$780,918	645	22.5%	\$1,210.73
COLISTIMETHATE SODIUM	N	Coly-Mycin	Monarch	\$200,053	154	5.4%	\$1,299.05
IMIPENEM	N	Primaxin	Merck	\$85,885	236	8.2%	\$363.92
ERTAPENEM	N	Invanz	Merck	\$76,642	253	8.8%	\$302.93
MEROPENEM	N	Merrem	AstraZeneca	\$57,986	79	2.8%	\$734.00
DAPTOMYCIN	N	Cubicin	Cubist	\$54,051	158	5.5%	\$342.09
AZTREONAM	N	Azactam	Dura/Elan	\$30,983	98	3.4%	\$316.16
POLYMYXIN B	Y			\$29,920	672	23.5%	\$44.52
TELITHROMYCIN	N	Ketek	Aventis	\$21,092	366	12.8%	\$57.63
RIFAXIMIN	N	Xifaxan	Salix	\$8,107	64	2.2%	\$126.67
BACITRACIN	Y			\$2,635	94	3.3%	\$28.04
PAROMOMYCIN	Υ	Humatin	Monarch	\$1,343	20	0.7%	\$67.13
TINIDAZOLE				\$294	10	0.3%	\$29.44
CHLORAMPHENICOL	N	Chloromycetin	Monarch	\$189	13	0.5%	\$14.54
Total				\$1,350,099	2,862	100.0%	\$471.73
OTHER CARDIOVASCULAR							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$1.39	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MIDODRINE	N	ProAmantine	Shire	\$415,170	2,567	91.5%	\$161.73
PAPAVERINE	N	Pavabid	Aventis	\$1,765	132	4.7%	\$13.37
ERGOLOID	Y	Hydergine	Novartis	\$848	12	0.4%	\$70.68
EPINEPHRINE	N		-	\$505	94	3.4%	\$5.38
Total				\$418,289	2,805	100.0%	\$149.12
OTHER DERMATOLOGIC			<u> </u>				
Share of FFS Rx's: 0.33%							
Per Member SFY05 YTD: \$10.34	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LIDOCAINE	Υ			\$2,422,305	17,544	50.5%	\$138.07
METRONIDAZOLE	N	Metrocream	Galderma	\$204,728	2,967	8.5%	\$69.00
LACTIC ACID	Υ	Amlactin	Upsher Smith	\$141,615	3,620	10.4%	\$39.12
BENZOYL PEROXIDE	N	Benzac	Galderma	\$112,902	3,080	8.9%	\$36.66
UREA	N			\$93,078	1,555	4.5%	\$59.86
SELENIUM SULFIDE	Y	Selsun	Ross	\$28,889	2,856	8.2%	\$10.12
	Υ	1		\$21,890	391	1.1%	\$55.98
HYDROCORTISONE				\$21,342	372	1.1%	\$57.37
DOXEPIN	V	Candulas	Mataan				\$128.24
DOXEPIN PODOFILOX	Y	Condylox	Watson	\$14,491	113	0.3%	<b>#00.15</b>
DOXEPIN PODOFILOX TRETINOIN	Υ	Retin-A	Ortho Derm	\$11,725	141	0.4%	
DOXEPIN PODOFILOX TRETINOIN HYDROQUINONE	Y N			\$11,725 \$11,054	141 273	0.4% 0.8%	\$40.49
DOXEPIN PODOFILOX TRETINOIN HYDROQUINONE MENTHOL	Y N N	Retin-A	Ortho Derm	\$11,725 \$11,054 \$6,039	141 273 576	0.4% 0.8% 1.7%	\$40.49 \$10.48
DOXEPIN PODOFILOX TRETINOIN HYDROQUINONE MENTHOL ALUMINUM	Y N N Y	Retin-A	Ortho Derm	\$11,725 \$11,054 \$6,039 \$4,691	141 273 576 430	0.4% 0.8% 1.7% 1.2%	\$40.48 \$10.48 \$10.9
DOXEPIN PODOFILOX TRETINOIN HYDROQUINONE MENTHOL ALUMINUM SALICYLIC ACID	Y N N	Retin-A	Ortho Derm	\$11,725 \$11,054 \$6,039 \$4,691 \$4,335	141 273 576 430 56	0.4% 0.8% 1.7% 1.2% 0.2%	\$40.49 \$10.48 \$10.9 \$77.42
DOXEPIN PODDFILOX TRETINOIN HYDROQUINONE MENTHOL ALUMINUM SALICYLIC ACID CAPSAICIN	Y N N Y	Retin-A Solaquin Forte	Ortho Derm Valeant	\$11,725 \$11,054 \$6,039 \$4,691 \$4,335 \$4,142	141 273 576 430 56 381	0.4% 0.8% 1.7% 1.2% 0.2% 1.1%	\$40.48 \$10.48 \$10.9° \$77.42 \$10.87
DOXEPIN PODOFILOX TRETINOIN HYDROQUINONE MENTHOL ALUMINUM SALICYLIC ACID CAPSAICIN SULFACETAMIDE	Y N N Y N	Retin-A	Ortho Derm	\$11,725 \$11,054 \$6,039 \$4,691 \$4,335 \$4,142 \$4,062	141 273 576 430 56 381	0.4% 0.8% 1.7% 1.2% 0.2% 1.1% 0.2%	\$40.49 \$10.49 \$10.9° \$77.42 \$10.87 \$52.76
DOXEPIN PODDFILOX TRETINOIN HYDROQUINONE MENTHOL ALUMINUM SALICYLIC ACID CAPSAICIN	Y N N Y	Retin-A Solaquin Forte	Ortho Derm Valeant	\$11,725 \$11,054 \$6,039 \$4,691 \$4,335 \$4,142	141 273 576 430 56 381	0.4% 0.8% 1.7% 1.2% 0.2% 1.1%	\$83.15 \$40.45 \$10.45 \$10.91 \$77.42 \$10.87 \$52.76 \$47.90

OCTINOXATE	N			\$2,173	19	0.1%	\$114.37
CHLOROXINE	N	Capitrol	Westwood	\$1,449	66	0.2%	\$21.95
MONOBENZONE	N			\$434	10	0.0%	\$43.36
ETHYL CHLORIDE	N			\$417	7	0.0%	\$59.55
VITAMIN E	Y			\$279	5	0.0%	\$55.74
TETRACAINE	Y			\$170	10	0.0%	\$16.98
AVOBENZONE				\$88	1	0.0%	\$87.80
VITAMINS A AND D	N			\$63	13	0.0%	\$4.83
PODOPHYLLUM				\$60	1	0.0%	\$59.71
BENZOCAINE				\$44	2	0.0%	\$21.78
CALAMINE	Υ			\$27	5	0.0%	\$5.38
TOTAL				\$3,120,951	34,719	100.0%	\$89.89
OTHER ELECTROLYTES							
Share of FFS Rx's: 0.07%							
Per Member SFY05 YTD: \$0.47	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CALCIUM				\$109,062	3,268	46.6%	\$33.37
SODIUM BICARBONATE				\$25,485	2,926	41.7%	\$8.71
SODIUM ACETATE				\$8,415	820	11.7%	\$10.26
Total				\$142,961	7,014	100.0%	\$20.38
Total				\$142,901	7,014	100.0%	\$20.30
OTHER ENDOODING							
OTHER ENDOCRINE Share of FFS Rx's: 0.06%							
Per Member SFY05 YTD: \$2.11	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
CINACALCET	N	Sensipar	Amgen	\$526,417	1,369	22.0%	\$384.53
FLUDROCORTISONE	Y	Florinef	Monarch	\$107,350	4,628	74.4%	\$23.20
METHYLERGONOVINE	N	Methergine	Novartis	\$2,652	226	3.6%	\$11.74
Total				\$636,419	6,223	100.0%	\$102.27
OTHER GASTROINTESTINAL							
Share of FFS Rx's: 0.05%							
Per Member SFY05 YTD: \$2.94	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
	N N	Zelnorm	Novartis			90.5%	\$141.54
TEGASEROD				\$706,591	4,992		
PHENYLBUTYRATE	N	Buphenyl	Medicis	\$150,350	47	0.9%	\$3,198.94
ALOSETRON	N	Lotronex	GlaxoSmithKline	\$20,701	60	1.1%	\$345.01
SACROSIDASE	N	Sucraid	QOL Medical	\$5,704	7	0.1%	\$814.86
SIMETHICONE	N	1.91		\$1,982	301	5.5%	\$6.59
ACETOHYDROXAMIC ACID	N	Lithostat	Mission	\$1,954	39	0.7%	\$50.11
LACTASE	N			\$708	44	0.8%	\$16.10
AMLEXANOX	N	Aphthasol	Access	\$179	7	0.1%	\$25.59
LACTOBACILLUS	Y	Lactinex	BD Micro	\$115	17	0.3%	\$6.74
Total				\$888,285	5,514	100.0%	\$161.10
OTHER NUTRITION							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$0.97	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LEVOCARNITINE	N	Carnitor	Sigma-Tau	\$240,269	3,421	97.7%	\$70.23
GLYCINE	N		3	\$32,040	45	1.3%	\$711.99
BETAINE	N			\$20,158	34	1.0%	\$592.89
OMEGA-3 FATTY ACIDS	N			\$58	1	0.0%	\$57.50
Total				\$292,525	3,501	100.0%	\$83.55
				, , ,	-,		***************************************
OTHER OPHTHALMIC Share of FFS Rx's: 0.06%							
	MACIAO	Brand	Manufacturer	Total \$\$	Total Dv	Market Share	tt Dor Du
Per Member SFY05 YTD:\$0.91	MAC'd?	Brand			Total Rx	Market Share	\$\$ Per Rx
CYCLOSPORINE	N	Restasis	Allergan	\$233,068	2,356	36.6%	\$98.93 \$10.61
LANOLIN	N			\$32,789	3,089	48.0%	
PETROLATUM,WHITE	N	1		\$5,127	766	11.9%	\$6.69
MINERAL OIL	N	C a d C	Caharing Discort	\$3,899	212	3.3%	\$18.39
SULFACETAMIDE	Y	Sod Sulamyd	Schering Plough	\$215	8	0.1%	\$26.91
TETRACAINE	N	Pontocaine	Abbott	\$23	3	0.0%	\$7.67
PROPARACAINE Total	Y	Alcaine	Alcon	\$22 <b>\$275,143</b>	6,436	0.0% <b>100.0%</b>	\$10.87 <b>\$42.75</b>
OTUED OTIO							
OTHER OTIC Share of FFS Rx's: 0.02%							
Per Member SFY05 YTD: \$0.05	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ANTIPYRINE	Y	Aurodex	aiuotalti	\$13,285	2,116	98.5%	\$6.28
	1.			\$283	10	0.5%	\$28.31
I I RIE I HANOLAMINE	N	_		\$249	17	0.8%	\$14.67
TRIETHANOLAMINE BENZOCAINE	N Y			ψ <u>2</u> +3		0.3%	\$14.00
BENZOCAINE	N Y			\$24	61		Ψ17.00
				\$84 <b>\$13,901</b>	6 <b>2,149</b>	100.0%	\$6.47
BENZOCAINE PHENYLEPHRINE Total							\$6.47
BENZOCAINE PHENYLEPHRINE Total OTHER RENAL							\$6.47
BENZOCAINE PHENYLEPHRINE Total  OTHER RENAL Share of FFS Rx's: 0.05%	Y			\$13,901	2,149	100.0%	
BENZOCAINE PHENYLEPHRINE Total  OTHER RENAL Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.60	MAC'd?	Brand	Manufacturer	\$13,901 Total \$\$	2,149 Total Rx	100.0% Market Share	\$\$ Per Rx
BENZOCAINE PHENYLEPHRINE Total  OTHER RENAL Share of FFS Rx's: 0.05%	Y	Brand	Manufacturer	\$13,901	2,149	100.0%	

	To a	To an					
METHENAMINE	N	Hiprex	Aventis	\$30,939	924	19.7%	\$33.48
CITRIC ACID				\$20,386	654	14.0%	\$31.17
SODIUM	N	Cuataman	Mulan	\$14,542	178	3.8%	\$81.69
CYSTEAMINE	N	Cystagon	Mylan	\$9,590	44	0.9%	\$217.95
PHOSPHORUS POTASSIUM PHOSPHATE	N Y			\$6,303 \$1,820	511 140	10.9% 3.0%	\$12.34 \$13.00
SODIUM PHOSPHATE	N			\$258	16	0.3%	\$16.15
Total	IN			\$182,074	4,688	100.0%	\$38.84
Total				ψ102,074	4,000	100.076	ψ30.04
OTHER RESPIRATORY							
Share of FFS Rx's: 0.01%				T			**
Per Member SFY05 YTD: \$0.04	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SODIUM CL FOR INHALATION	Y			\$12,498	616	100.0%	\$20.29
OVULATION STIMULANTS							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD:	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
FOLLITROPIN				\$556	1		
GONADOTROPIN,CHORIONIC,HUMAN	N	Profasi	Serono	\$363	2	20.0%	\$181.42
PROGESTERONE				\$310	7	70.0%	\$44.22
Total				\$1,229	10	100.0%	\$122.89
PEDICULOCIDES							
Share of FFS Rx's: 0.06%							
Per Member SFY05 YTD: \$0.83	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PERMETHRIN	Y	Elimite	Herbert	\$129,563	5,196	79.5%	\$24.94
LINDANE	Y	Kwell	Schwarz	\$77,786	670	10.3%	\$116.10
MALATHION	N	Ovide	Taro	\$40,808	401	6.1%	\$101.77
CROTAMITON	N	Eurax	Westwood	\$2,859	176	2.7%	\$16.24
PIPERONYL BUTOXIDE	Y	p : 1		\$985	88	1.3%	\$11.19
PYRETHRINS	Y	Pyrinyl	Alpharma	\$16	3	0.0%	\$5.48
Total				\$252,017	6,534	100.0%	\$38.57
PENICILLINS							
Share of FFS Rx's: 1.17%							
Per Member SFY05 YTD: \$9.09	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMOXICILLIN	Υ	Amoxil	GlaxoSmithKline	\$2,214,066	103,153	84.9%	\$21.46
PIPERACILLIN	N	Pipracil	Wyeth	\$163,463	616	0.5%	\$265.36
PENICILLIN V	Y	Pen Vee K	Wyeth	\$123,837	13,210	10.9%	\$9.37
NAFCILLIN	N	Nafcil	Sandoz	\$86,757	198	0.2%	\$438.17
DICLOXACILLIN	Υ	Pathocil	Wyeth	\$60,664	3,199	2.6%	\$18.96
AMPICILLIN	N	Principen	Sandoz	\$47,834	894	0.7%	\$53.51
PENICILLIN G	N	Wycillin	Wyeth	\$27,873	99	0.1%	\$281.55
TICARCILLIN	Y	Timentin	GlaxoSmithKline	\$11,901	63	0.1%	\$188.91
OXACILLIN	Y	Prostaphlin	BMS	\$4,678	17	0.0%	\$275.20
CARBENICILLIN	N	Geocillin	Pfizer	\$3,338	22	0.0%	\$151.74
Total				\$2,744,413	121,471	100.0%	\$22.59
PHARMACEUTICAL CARE							
Share of FFS Rx's: 0.06%							
Per Member SFY05 YTD: \$0.52	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PHARMACEUTICAL CARE	N			\$156,640	6,690	100.0%	\$23.41
PHOSPHATE							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.02							
	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SODIUM PHOSPHATE	MAC'd?	Brand	Manufacturer	\$3,492	566	59.4%	\$6.17
SODIUM PHOSPHATE POTASSIUM PHOSPHATE		Brand	Manufacturer			59.4% 40.6%	\$6.17
	N	Brand	Manufacturer	\$3,492	566	59.4%	\$\$ Per Rx \$6.17 \$7.59 \$6.75
POTASSIUM PHOSPHATE	N	Brand	Manufacturer	\$3,492 \$2,937	566 387	59.4% 40.6%	\$6.17 \$7.59
POTASSIUM PHOSPHATE Total	N	Brand	Manufacturer	\$3,492 \$2,937	566 387	59.4% 40.6%	\$6.17 \$7.59
POTASSIUM PHOSPHATE  Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%	N Y			\$3,492 \$2,937 <b>\$6,429</b>	566 387 <b>953</b>	59.4% 40.6% <b>100.0%</b>	\$6.17 \$7.59 <b>\$6.7</b> 5
POTASSIUM PHOSPHATE  Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$6.01	N Y	Brand	Manufacturer	\$3,492 \$2,937 <b>\$6,429</b> Total \$\$	566 387 <b>953</b> Total Rx	59.4% 40.6% <b>100.0%</b> Market Share	\$6.17 \$7.59 \$6.75 \$ Per Rx
POTASSIUM PHOSPHATE Total  PHOSPHATE BINDER Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$6.01 SEVELAMER	N Y	Brand Renagel	Manufacturer Genzyme	\$3,492 \$2,937 <b>\$6,429</b>	566 387 <b>953</b> Total Rx 6,162	59.4% 40.6% 100.0% Market Share 69.6%	\$6.17 \$7.59 <b>\$6.75</b> \$ <b>9.75</b> \$ <b>9.75</b>
POTASSIUM PHOSPHATE Total  PHOSPHATE BINDER Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$6.01 SEVELAMER POLYSTYRENE SULFONATE	MAC'd?	Brand Renagel Kayexalate	Manufacturer Genzyme Sanofi	\$3,492 \$2,937 <b>\$6,429</b> Total \$\$ \$1,637,759 \$120,081	566 387 <b>953</b> Total Rx 6,162 2,486	59.4% 40.6% <b>100.0%</b> Market Share	\$6.17 \$7.59 <b>\$6.75</b> \$ <b>9.75</b> \$ <b>9.75</b>
POTASSIUM PHOSPHATE  Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFV05 YTD: \$6.01  SEVELAMER  POLYSTYRENE SULFONATE  LANTHANUM	N Y MAC'd?	Brand Renagel	Manufacturer Genzyme	\$3,492 \$2,937 <b>\$6,429</b> Total <b>\$\$</b> \$1,637,759	566 387 <b>953</b> Total Rx 6,162	59.4% 40.6% 100.0% Market Share 69.6%	\$6.17 \$7.55 \$6.75 \$8.75 \$9.75 \$9.75 \$1.55
POTASSIUM PHOSPHATE  Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$6.01  SEVELAMER  POLYSTYRENE SULFONATE  LANTHANUM  Total	MAC'd?	Brand Renagel Kayexalate	Manufacturer Genzyme Sanofi	\$3,492 \$2,937 <b>\$6,429</b> Total \$\$ \$1,637,759 \$120,081 \$55,392	566 387 <b>953</b> Total Rx 6.162 2,486 210	59.4% 40.6% 100.0% Market Share 69.6% 28.1%	\$6.17 \$7.55 \$6.75 \$8.75 \$9.75 \$9.75 \$1.55
POTASSIUM PHOSPHATE  Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$6.01  SEVELAMER POLYSTYRENE SULFONATE  LANTHANUM  Total  PITUITARY HORMONES	MAC'd?	Brand Renagel Kayexalate	Manufacturer Genzyme Sanofi	\$3,492 \$2,937 <b>\$6,429</b> Total \$\$ \$1,637,759 \$120,081 \$55,392	566 387 <b>953</b> Total Rx 6.162 2,486 210	59.4% 40.6% 100.0% Market Share 69.6% 28.1%	\$6.17 \$7.59 <b>\$6.75</b> <b>\$1.75</b> <b>\$2.65.78</b> \$48.30
POTASSIUM PHOSPHATE  Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$6.01  SEVELAMER POLYSTYRENE SULFONATE  LANTHANUM  Total	MAC'd?	Brand Renagel Kayexalate	Manufacturer Genzyme Sanofi	\$3,492 \$2,937 <b>\$6,429</b> Total \$\$ \$1,637,759 \$120,081 \$55,392	566 387 <b>953</b> Total Rx 6.162 2,486 210	59.4% 40.6% 100.0% Market Share 69.6% 28.1%	\$6.17 \$7.55 \$6.75 \$8.75 \$9.75 \$9.75 \$1.55
POTASSIUM PHOSPHATE  Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$6.01  SEVELAMER  POLYSTYRENE SULFONATE  LANTHANUM  Total  PITUITARY HORMONES  Share of FFS Rx's: 0.02%	MAC'd? N N N	Brand Renagel Kayexalate Fosrenol	Manufacturer Genzyme Sanofi Shire	\$3,492 \$2,937 \$6,429 Total \$\$ \$1,637,759 \$120,081 \$55,392 \$1,813,232	566 387 953 953 Total Rx 6,162 2,486 210 8,858	59.4% 40.6% 100.0% Market Share 69.6% 28.1% 100.0%	\$6.17 \$7.55 \$6.75 \$\$ Per Rx \$265.76 \$48.30 \$204.70
POTASSIUM PHOSPHATE Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$6.01  SEVELAMER POLYSTYRENE SULFONATE LANTHANUM Total  PITUITARY HORMONES  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$2.80  OCTREOTIDE	MAC'd?  MAC'd?	Brand Renagel Kayexalate Fosrenol  Brand	Manufacturer Genzyme Sanofi Shire  Manufacturer	\$3,492 \$2,937 \$6,429 Total \$\$ \$1,637,759 \$120,081 \$55,392 \$1,813,232	566 387 953 Total Rx 6,162 2,486 210 8,858	59.4% 40.6% 100.0% Market Share 69.6% 28.1% 100.0% Market Share	\$6.17 \$7.55 \$6.75 \$\$ Per Rx \$265.76 \$48.30 \$204.70 \$\$ Per Rx \$1,224.92
POTASSIUM PHOSPHATE Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$6.01  SEVELAMER POLYSTYRENE SULFONATE LANTHANUM Total  PITUITARY HORMONES  Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.80	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Renagel Kayexalate Fosrenol  Brand Sandostatin	Manufacturer Genzyme Sanofi Shire  Manufacturer Novartis	\$3,492 \$2,937 \$6,429 Total \$\$ \$1,637,759 \$120,081 \$55,392 \$1,813,232	566 387 953 Total Rx 6,162 2,486 210 8,858	59.4% 40.6% 100.0% Market Share 69.6% 28.1% 100.0% Market Share 10.0%	\$6.17 \$7.55 \$6.75 \$\$ Per Rx \$265.76 \$48.30 \$204.70 \$\$ Per Rx \$1,224.92 \$162.94
POTASSIUM PHOSPHATE Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09%  Per Member SFY05 YTD: \$6.01  SEVELAMER POLYSTYRENE SULFONATE LANTHANUM Total  PITUITARY HORMONES  Share of FFS Rx's: 0.02%  Per Member SFY05 YTD: \$2.80  OCTREOTIDE BROMOCRIPTINE	MAC'd? N N N N N Y	Brand Renagel Kayexalate Fosrenol  Brand Sandostatin Parlodel Lupron Dostinex	Manufacturer Genzyme Sanofi Shire  Manufacturer Novartis Tap Pharmacia	\$3,492 \$2,937 \$6,429 Total \$\$ \$1,637,759 \$120,081 \$55,392 \$1,813,232 Total \$\$ \$260,908 \$191,449 \$187,174 \$81,000	566 387 953 Total Rx 6,162 2,486 210 8,858 Total Rx 213 1,175	59.4% 40.6% 100.0% Market Share 69.6% 28.1% 100.0% Market Share 10.0% 55.1% 12.8%	\$6.17 \$7.55 \$6.75 \$\$.75 \$\$.75 \$265.76 \$48.30 \$204.70 \$\$.724.92 \$162.94 \$688.14 \$302.24
POTASSIUM PHOSPHATE Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$6.01 SEVELAMER POLYSTYRENE SULFONATE LANTHANUM Total  PITUITARY HORMONES Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.80 OCTREOTIDE BROMOCRIPTINE LEUPROLIDE CABERGOLINE CORTICOTROPIN	MAC'd? N N N N N N N N N N N N N N N N N N N	Brand Renagel Kayexalate Fosrenol  Brand Sandostatin Parlodel Lupron Dostinex Acthar	Manufacturer Genzyme Sanofi Shire  Manufacturer Novartis Novartis Tap Pharmacia Questcor	\$3,492 \$2,937 \$6,429 Total \$\$ \$1,637,759 \$120,081 \$55,392 \$1,813,232 Total \$\$ \$260,908 \$191,449 \$187,174 \$81,000 \$74,222	566 387 953 Total Rx 6,162 2,486 210 8,858 Total Rx 213 1,175 272 268 61	59.4% 40.6% 100.0% Market Share 69.6% 28.1% 100.0% Market Share 10.0% 55.1% 12.8% 12.8% 2.9%	\$6.17 \$7.55 \$6.75 \$\$.75 \$\$.75 \$265.78 \$48.30 \$204.70 \$\$.70 \$\$.70 \$162.94 \$688.14 \$302.24 \$1,216.75
POTASSIUM PHOSPHATE Total  PHOSPHATE BINDER  Share of FFS Rx's: 0.09% Per Member SFY05 YTD: \$6.01  SEVELAMER POLYSTYRENE SULFONATE LANTHANUM Total  PITUITARY HORMONES  Share of FFS Rx's: 0.02% Per Member SFY05 YTD: \$2.80  OCTREOTIDE BROMOCRIPTINE LEUPROLIDE CABERGOLINE	MAC'd? N N N MAC'd? N N N N N N N N N N N N N N N	Brand Renagel Kayexalate Fosrenol  Brand Sandostatin Parlodel Lupron Dostinex	Manufacturer Genzyme Sanofi Shire  Manufacturer Novartis Tap Pharmacia	\$3,492 \$2,937 \$6,429 Total \$\$ \$1,637,759 \$120,081 \$55,392 \$1,813,232 Total \$\$ \$260,908 \$191,449 \$187,174 \$81,000	566 387 953 70tal Rx 6,162 2,486 210 8,858 Total Rx 213 1,175 272 268	59.4% 40.6% 100.0% Market Share 69.6% 28.1% 100.0% Market Share 10.0% 55.1% 12.8%	\$6.17 \$7.59 \$6.75 \$\$ Per Rx \$265.78 \$48.30 \$204.70

		1		0500			
NAFARELIN GANIRELIX				\$590 \$339	1		
COSYNTROPIN				\$160	2	0.1%	\$80.16
Total				\$844,998	2,131	100.0%	\$396.53
				4011,000	_,		***************************************
PLASMA PROTEINS / EXPANDERS							
Share of FFS Rx's: 0.00%	MA 01:10	D	M	T-1-1-00	Tetal Dec	Mantat Obana	AA D D
Per Member SFY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ALBUMIN HUMAN	N			\$4,696	13	100.0%	\$361.26
DI ATELET DOOLIEEDATION CTIMU	ANTO						
PLATELET PROLIFERATION STIMUL	ANIS						
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
OSPRELVEKIN	N			\$5,431	3	100.0%	\$1,810.33
PLATELET REDUCING AGENTS							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.60	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ANAGRELIDE	N	Agrylin	Shire US	\$179,796	274	100.0%	\$656.19
POSITIVE INOTROPES							
Share of FFS Rx's: 0.00%		+					
Per Member SFY05 YTD: \$0.87	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MILRINONE	N N	Primacor	Sanofi	\$253,873	238	64.9%	\$1,066.69
DOBUTAMINE	N	Dobutrex	Lilly	\$7,750	129	35.1%	\$60.08
Total				\$261,623	367	100.0%	\$712.87
				<del>+</del>	007	. 30.0 /0	Ţ. 1 <b>2.01</b>
POTASSIUM		+					
		+					
Share of FFS Rx's: 1.68%		_					
Per Member SFY05 YTD: \$7.89	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
POTASSIUM POTASSIUM SALTS CLASSIFIER	Υ			\$2,359,426	174,280	99.3%	\$13.54
				\$20,919	1,223	0.7%	\$17.10
Total				\$2,380,345	175,503	100.0%	\$13.56
DD00507440							
PROGESTINS							
Share of FFS Rx's: 0.07%							
Per Member SFY05 YTD: \$0.34	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PROGESTERONE	N	Various		\$44,457	1,122	14.8%	\$39.62
MEDROXYPROGESTERONE	Υ	Provera	Pharmacia	\$33,461	5,927	78.0%	\$5.65
NORETHINDRONE	N	Various		\$25,186	548	7.2%	\$45.96
Total				\$103,104	7,597	100.0%	\$13.57
PROTEIN REPLACEMENT							
Share of FFS Rx's: 0.01%							
Per Member SFY05 YTD: \$0.34	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMINO ACIDS 10%	Υ			\$51,118	757	69.1%	\$67.53
AMINO ACIDS 15%	N			\$46,707	318	29.0%	\$146.88
AMINO ACIDS 6%	N			\$3,939	14	1.3%	\$281.38
AMINO ACIDS 8.5%	N			\$574	4	0.4%	\$143.38
CYSTEINE	N			\$77	2	0.2%	\$38.28
Total				\$102,414	1,095	100.0%	\$93.53
QUINOLONES							
Share of FFS Rx's: 0.69%							
Per Member SFY05 YTD: \$13.82	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
LEVOFLOXACIN	N	Levaquin	Ortho-McNeil	\$2,942,013	37,393	52.0%	\$78.68
CIPROFLOXACIN	Y	Cipro	Bayer	\$731,433	28,517	39.7%	\$25.65
MOXIFLOXACIN	N	Avelox	Bayer	\$349,052	4,084	5.7%	\$85.47
GATIFLOXACIN	N	Tequin	Bristol-Myers Squibl	\$121,896	1,550	2.2%	\$78.64
NORFLOXACIN	N	Noroxin	Merck	\$17,744	260	0.4%	\$68.24
OFLOXACIN	Υ	Floxin	Ortho-McNeil	\$9,685	115	0.2%	\$84.21
GEMIFLOXACIN				\$86	1	0.0%	\$86.00
Total				\$4,171,909	71,920	100.0%	\$58.01
RBC STIMULANTS		1					
Share of FFS Rx's: 0.08%							
Per Member SFY05 YTD: \$13.41	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
EPOETIN ALFA	N	Epogen/Procrit	Amgen/Ortho	\$2,911,203	5,919	73.5%	\$491.84
DARBEPOETIN ALFA	N	Aranesp	Amgen	\$1,137,342	2,138	26.5%	\$531.97
Total				\$4,048,545	8,057	100.0%	\$502.49
RETINOIDS							<del></del>
Share of FFS Rx's: 0.05%							
Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$1.55	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$1.55  ADAPALENE	MAC'd?	Brand Differin	Manufacturer Galderma	Total \$\$ \$198,904	Total Rx 2,226	Market Share 41.0%	\$\$ Per Rx \$89.36
Per Member SFY05 YTD: \$1.55							

IOOTDETINON.		Ta .	5 .			0.00/	A070.05
ISOTRETINOIN Total	Υ	Accutane	Roche	\$101,863	369 E 426	6.8%	\$276.05
Total				\$466,850	5,426	100.0%	\$86.04
CEDATIVE UVDNOTICS							
SEDATIVE HYPNOTICS							
Share of FFS Rx's: 0.43%	*** ***			T			
Per Member SFY05 YTD: \$1.39 TEMAZEPAM	MAC'd?	Brand Restoril	Manufacturer Mallinkrodt	Total \$\$ \$182,924	Total Rx	Market Share 36.0%	\$\$ Per Rx \$11.45
PHENOBARBITAL	Y	Tuinal	Lilly	\$140,411	15,972 21,581	48.7%	\$6.51
LORAZEPAM	Y	Ativan	Biovail	\$27,110	879	2.0%	\$30.84
TRIAZOLAM	Y	Halcion	Pharmacia	\$24,989	2,360	5.3%	\$10.59
CHLORAL HYDRATE	N	Aquachoral Supprett	Polymedica	\$12,932	1,210	2.7%	\$10.69
QUAZEPAM	N	Doral	MedPoint	\$8,774	76	0.2%	\$115.45
ESTAZOLAM	Υ	Prosom	Abbott	\$8,734	591	1.3%	\$14.78
FLURAZEPAM	Y	Dalmane	Valeant	\$8,697	1,533	3.5%	\$5.67
BUTABARBITAL SECOBARBITAL	Y	Butisol Seconal	MedPoint Ranbaxy	\$3,331 \$1,479	52 38	0.1% 0.1%	\$64.05 \$38.91
MIDAZOLAM	N	Versed	Roche	\$568	14	0.0%	\$40.54
Total		Verseu	roone	\$419,948	44,306	100.0%	\$9.48
				<b>4</b> 110,0 10	1 1,000		******
SEDATIVE HYPNOTICS - OTHER							
Share of FFS Rx's: 0.68%							
Per Member SFY05 YTD: \$19.11	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ZALEPLON	N	Sonata	Monarch	\$315,710	3,458	5.2%	\$91.30
ZOLPIDEM	N	Ambien	Sanofi-Synthelabo	\$5,397,488	62,859	93.9%	\$85.87
ESZOPICLONE	N	Lunesta	Sepracor	\$54,864	613	0.9%	\$89.50
Total			· ·	\$5,768,062	66,930	100.0%	\$86.18
SKELETAL MUSCLE RELAXANTS							
Share of FFS Rx's: 1.02%							
Per Member SFY05 YTD: \$9.93	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
BACLOFEN	Y	Lioresal	Novartis	\$873,861	29,434	27.8%	\$29.69
METAXALONE	N	Skelaxin	Monarch	\$766,524	6,426	6.1%	\$119.28
TIZANIDINE	Υ	Zanaflex	Acorda	\$464,935	14,401	13.6%	\$32.28
CYCLOBENZAPRINE	Υ	Flexeril	McNeil	\$416,158	35,855	33.9%	\$11.61
DANTROLENE	N	Dantrium	Proctor & Gamble	\$221,367	1,936	1.8%	\$114.34
CARISOPRODOL	Υ	Soma	MedPoint	\$121,225	11,601	11.0%	\$10.45
ORPHENADRINE	Υ	Norflex	3M	\$90,778	2,623	2.5%	\$34.61
METHOCARBAMOL	Y	Robaxin	Schwarz	\$33,186	2,591	2.4%	\$12.81
CHLORZOXAZONE  Total	Y	Parafon Forte	McNeil	\$9,564 <b>\$2,997,598</b>	967 <b>105,834</b>	0.9% <b>100.0%</b>	\$9.89 <b>\$28.32</b>
Total				\$2,991,590	105,654	100.076	\$20.32
CODUM							
SODIUM							
Share of FFS Rx's: 0.13%							
Per Member SFY05 YTD: \$1.50	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SODIUM REPLACEMENT 0.9%				\$430,995	12,157	87.8%	\$35.45
SODIUM				\$14,221	1,357	9.8%	\$10.48 \$22.77
SODIUM REPLACEMENT 0.45% SODIUM REPLACEMENT 3%				\$7,082 \$308	311	2.2%	\$22.11
SODIUM REPLACEMENT 5%				\$129	14	0.1%	\$9.25
Total				\$452,735	13,841	100.0%	\$32.71
10141				ψ-10 <b>2</b> ,1 00	10,041	100.070	<b>402.7</b> 1
SOLUTIONS							
Share of FFS Rx's: 0.02%							
Per Member SFY05 YTD: \$0.31	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ELECTROLYTE,ORAL	N	Brand	Manufacturer	\$90,326	1,718	96.6%	\$52.58
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED		Brand	Manufacturer	\$90,326 \$3,585	1,718 60	96.6% 3.4%	\$52.58 \$59.75
ELECTROLYTE, ORAL	N	Brand	Manufacturer	\$90,326	1,718	96.6%	\$52.58 \$59.75
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total	N N		Manufacturer	\$90,326 \$3,585	1,718 60	96.6% 3.4%	\$52.58 \$59.75
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total STEROID ANTIBIOTIC COMBO OPHT	N N		Manufacturer	\$90,326 \$3,585	1,718 60	96.6% 3.4%	\$52.58
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05%	N N THALMIC			\$90,326 \$3,585 <b>\$93,911</b>	1,718 60 <b>1,778</b>	96.6% 3.4% 100.0%	\$52.58 \$59.75 <b>\$52.82</b>
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79	N N	Brand	Manufacturer	\$90,326 \$3,585 <b>\$93,911</b> Total <b>\$\$</b>	1,718 60 1,778 Total Rx	96.6% 3.4% 100.0% Market Share	\$52.58 \$59.75 <b>\$52.82</b> \$\$ Per Rx
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN	N N N N N N N N N N N N N N N N N N N	Brand Tobradex	Manufacturer Alcon	\$90,326 \$3,585 <b>\$93,911</b> Total <b>\$</b> \$224,710	1,718 60 1,778 Total Rx 3,864	96.6% 3.4% 100.0% Market Share 79.7%	\$52.58 \$59.75 <b>\$52.82</b> \$ <b>\$ Per Rx</b> \$58.15
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN	N N THALMIC	Brand Tobradex Pediotic	Manufacturer Alcon Monarch	\$90,326 \$3,585 <b>\$93,911</b> Total <b>\$\$</b> \$224,710 \$13,130	1,718 60 1,778 Total Rx 3,864 980	96.6% 3.4% 100.0% Market Share 79.7% 20.2%	\$52.58 \$59.75 <b>\$52.82</b> \$ <b>Per Rx</b> \$58.15 \$13.40
ELECTROLYTE, ORAL RINGERS SOLUTION, LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN	MAC'd?	Brand Tobradex	Manufacturer Alcon	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81	1,718 60 1,778 Total Rx 3,864 980 3	96.6% 3.4% 100.0% Market Share 79.7% 20.2% 0.1%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN	MAC'd?	Brand Tobradex Pediotic	Manufacturer Alcon Monarch	\$90,326 \$3,585 <b>\$93,911</b> Total <b>\$\$</b> \$224,710 \$13,130	1,718 60 1,778 Total Rx 3,864 980	96.6% 3.4% 100.0% Market Share 79.7% 20.2%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total	MAC'd?	Brand Tobradex Pediotic	Manufacturer Alcon Monarch	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81	1,718 60 1,778 Total Rx 3,864 980 3	96.6% 3.4% 100.0% Market Share 79.7% 20.2% 0.1%	\$52.58 \$59.75 <b>\$52.82</b> <b>\$\$ Per Rx</b> \$58.15 \$13.40
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC	MAC'd?	Brand Tobradex Pediotic	Manufacturer Alcon Monarch	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81	1,718 60 1,778 Total Rx 3,864 980 3	96.6% 3.4% 100.0% Market Share 79.7% 20.2% 0.1%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03%	MAC'd? Y Y	Brand Tobradex Pediotic Pred-G	Manufacturer Alcon Monarch Allergan	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920	1,718 60 1,778 Total Rx 3,864 980 3 3 4,847	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.80	MAC'd?	Brand Tobradex Pediotic Pred-G Brand	Manufacturer Alcon Monarch Allergan  Manufacturer	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920	1,718 60 1,778 Total Rx 3,864 980 3 4,847	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03%	MAC'd? Y Y	Brand Tobradex Pediotic Pred-G	Manufacturer Alcon Monarch Allergan	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920	1,718 60 1,778 Total Rx 3,864 980 3 3 4,847	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.80 CIPROFLOXACIN	MAC'd?	Brand Tobradex Pediotic Pred-G Brand	Manufacturer Alcon Monarch Allergan  Manufacturer	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920	1,718 60 1,778 Total Rx 3,864 980 3 4,847	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.80 CIPROFLOXACIN  STEROIDS DERMATOLOGIC	MAC'd?	Brand Tobradex Pediotic Pred-G Brand	Manufacturer Alcon Monarch Allergan  Manufacturer	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920	1,718 60 1,778 Total Rx 3,864 980 3 4,847	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.80 CIPROFLOXACIN	MAC'd?	Brand Tobradex Pediotic Pred-G  Brand Ciprodex	Manufacturer Alcon Monarch Allergan  Manufacturer	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920	1,718 60 1,778 Total Rx 3,864 980 3 4,847	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09 \$\$ Per Rx \$74.90
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.80 CIPROFLOXACIN  STEROIDS DERMATOLOGIC Share of FFS Rx's: 0.72% Per Member SFY05 YTD: \$4.26	MAC'd?	Brand Tobradex Pediotic Pred-G  Brand Ciprodex	Manufacturer Alcon Monarch Allergan  Manufacturer Bayer  Manufacturer	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920	1,718 60 1,778 Total Rx 3,864 980 3 4,847	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%  Market Share 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09 \$\$ Per Rx \$74.90
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.80 CIPROFLOXACIN  STEROIDS DERMATOLOGIC Share of FFS Rx's: 0.72% Per Member SFY05 YTD: \$4.26 TRIAMCINOLONE	MAC'd? N MAC'd? Y Y MAC'd? N MAC'd?	Brand Tobradex Pediotic Pred-G  Brand Ciprodex  Brand Aristocort	Manufacturer Alcon Monarch Allergan  Manufacturer Bayer  Manufacturer Fujisawa	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920 Total \$\$ \$241,247	1,718 60 1,778 Total Rx 3,864 980 3 4,847 Total Rx 3,221	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%  Market Share 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09 \$\$ Per Rx \$74.90
ELECTROLYTE,ORAL RINGERS SOLUTION,LACTATED Total  STEROID ANTIBIOTIC COMBO OPHT Share of FFS Rx's: 0.05% Per Member SFY05 YTD: \$0.79 TOBRAMYCIN NEOMYCIN GENTAMICIN Total  STEROID ANTIBIOTIC COMBO OTIC Share of FFS Rx's: 0.03% Per Member SFY05 YTD: \$0.80 CIPROFLOXACIN  STEROIDS DERMATOLOGIC Share of FFS Rx's: 0.72% Per Member SFY05 YTD: \$4.26	MAC'd?	Brand Tobradex Pediotic Pred-G  Brand Ciprodex	Manufacturer Alcon Monarch Allergan  Manufacturer Bayer  Manufacturer	\$90,326 \$3,585 \$93,911 Total \$\$ \$224,710 \$13,130 \$81 \$237,920 Total \$\$ \$241,247	1,718 60 1,778 Total Rx 3,864 980 3 4,847 Total Rx 3,221	96.6% 3.4% 100.0%  Market Share 79.7% 20.2% 0.1% 100.0%  Market Share 100.0%	\$52.58 \$59.75 \$52.82 \$\$ Per Rx \$58.15 \$13.40 \$26.88 \$49.09 \$\$ Per Rx \$74.90

<b>F</b>	T	1					*
MOMETASONE FUROATE FLUTICASONE	Y	Elocon Cutivate	Schering GlaxoSmithKline	\$97,063 \$83,944	2,302 2,452	3.1% 3.3%	\$42.16 \$34.23
FLUOCINONIDE	Y	Lidex	Medicis	\$67,580	3,624	4.8%	\$18.65
DESOXIMETASONE	Y	Topicort	Taro	\$62,255	1,854	2.5%	\$33.58
FLUOCINOLONE ACETONIDE	Y	Synalar	Medicis	\$62,114	1,978	2.6%	\$31.40
DESONIDE	N	DesOwen	Galderma	\$54,046	2,745	3.7%	\$19.69
HALOBETASOL	N	Ultravate	Westwood	\$51,861	713	1.0%	\$72.74
DIFLORASONE	Υ	Psorcon	Aventis	\$29,011	478	0.6%	\$60.69
ALCLOMETASONE	N	Aclovate	GlaxoSmithKline	\$16,146	403	0.5%	\$40.07
FLURANDRENOLIDE	N	Cordran	Watson	\$8,262	192	0.3%	\$43.03
PREDNICARBATE	N	Dermatop	Dermik	\$8,181	188	0.3%	\$43.52
NEOMYCIN				\$6,814	119	0.2%	\$57.26
AMCINONIDE	N	Cyclocort	Fujisawa	\$6,646	165	0.2%	\$40.28
HALCINONIDE	N	Halog	Westwood	\$5,624	89	0.1%	\$63.19
CLOCORTOLONE	N	Cloderm	HealthPoint	\$4,124	80	0.1%	\$51.55
Total	<u> </u>			\$1,284,678	75,009	100.0%	\$17.13
CTIMUL ANTO	<del> </del>						
STIMULANTS							
Share of FFS Rx's: 1.24%							
Per Member SFY05 YTD: \$35.85	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
AMPHETAMINE	Υ	Adderall	Shire	\$4,955,138	55,778	43.2%	\$88.84
METHYLPHENIDATE	Y	Ritalin	Novartis	\$4,168,111	59,211	45.8%	\$70.39
MODAFINIL	N	Provigil	Cephalon	\$1,160,657	5,000	3.9%	\$232.13
DEXTROAMPHETAMINE	Y	Dexedrine	GlaxoSmithKline	\$351,782	6,865	5.3%	\$51.24
DEXMETHYLPHENIDATE METHAMPHETAMINE	N	Focalin	Novartis	\$79,479	1,347	1.0%	\$59.00
METHAMPHETAMINE DEMOLINE	N	Desoxyn	Ovation	\$57,626	232	0.2%	\$248.39
PEMOLINE T-4-1	Υ	Cylert	Abbott	\$48,075	731	0.6%	\$65.77
Total				\$10,820,867	129,164	100.0%	\$83.78
CTIMUL ANTO ATOMOVETINE	+						
STIMULANTS ATOMOXETINE	<del></del>						
Share of FFS Rx's: 0.24%							
Per Member SFY05 YTD: \$8.96	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
ATOMOXETINE	N	Strattera	Lilly	\$2,704,908	24,485	100.0%	\$110.47
SULFONAMIDES							
Share of FFS Rx's: 0.42%							
Per Member SFY05 YTD: \$1.15	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
SULFAMETHOXAZOLE	Y	Septra	Monarch	\$286,704	40,650	93.9%	\$7.05
SULFASALAZINE	Υ	Azulfidine	Pharmacia	\$48,930	2,532	5.9%	\$19.32
SULFADIAZINE	Υ			\$11,002	49	0.1%	\$224.54
SULFISOXAZOLE	Υ	Gantrisin	Roche	\$598	38	0.1%	\$15.72
Total				\$347,233	43,269	100.0%	\$8.02
SYSTEMIC ENZYME INHIBITORS							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$1.71	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
GEFITINIB	N	Iressa	AstraZeneca	\$300,852	179	83.6%	\$1,680.74
ALPHA-1-PROTEINASE INHIBITOR	N	Aralast/Prolastin	Baxter/Bayer	\$215,298	35	16.4%	\$6,151.38
Total							
				\$516.150	214	100.0%	\$2,411.92
				\$516,150	214	100.0%	\$2,411.92
SYSTEMIC FNZYME REPLACEMENT				\$516,150	214	100.0%	\$2,411.92
SYSTEMIC ENZYME REPLACEMENT				\$516,150	214	100.0%	\$2,411.92
Share of FFS Rx's: 0.00%	MVCIAS	Drond	Manufacturor				, , -
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE	N	Cerezyme	Genzyme	Total \$\$ \$455,400	Total Rx	Market Share 73.6%	<b>\$\$ Per Rx</b> \$7,115.63
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA				Total \$\$ \$455,400 \$202,397	Total Rx 64 23	Market Share 73.6% 26.4%	<b>\$\$ Per Rx</b> \$7,115.63 \$8,799.87
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE	N	Cerezyme	Genzyme	Total \$\$ \$455,400	Total Rx	Market Share 73.6%	<b>\$\$ Per Rx</b> \$7,115.63 \$8,799.87
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE  AGALSIDASE BETA  Total	N	Cerezyme	Genzyme	Total \$\$ \$455,400 \$202,397	Total Rx 64 23	Market Share 73.6% 26.4%	<b>\$\$ Per Rx</b> \$7,115.63 \$8,799.87
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES	N	Cerezyme	Genzyme	Total \$\$ \$455,400 \$202,397	Total Rx 64 23	Market Share 73.6% 26.4%	<b>\$\$ Per Rx</b> \$7,115.63 \$8,799.87
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES Share of FFS Rx's: 0.27%	N N	Cerezyme Fabrazyme	Genzyme Genzyme	Total \$\$ \$455,400 \$202,397 \$657,797	Total Rx 64 23 87	Market Share 73.6% 26.4% 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES  Share of FFS Rx's: 0.27%  Per Member SFY05 YTD: \$2.73	N N MAC'd?	Cerezyme Fabrazyme  Brand	Genzyme Genzyme Manufacturer	Total \$\$ \$455,400 \$202,397 \$657,797	Total Rx 64 23 87 Total Rx	Market Share 73.6% 26.4% 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE	N N	Cerezyme Fabrazyme  Brand Declomycin	Genzyme Genzyme  Manufacturer ESP Pharma	Total \$\$ \$455,400 \$202,397 \$657,797  Total \$\$ \$434,792	Total Rx 64 23 87  Total Rx 645	Market Share 73.6% 26.4% 100.0%  Market Share 2.3%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$Per Rx \$674.10
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73	N N N MAC'd? N	Cerezyme Fabrazyme  Brand	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth	Total \$\$ \$455,400 \$202,397 \$657,797	Total Rx 64 23 87 Total Rx	Market Share 73.6% 26.4% 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES  Share of FFS Rx's: 0.27%  Per Member SFY05 YTD: \$2.73  DEMECLOCYCLINE  MINOCYCLINE	MAC'd?	Cerezyme Fabrazyme  Brand Declomycin Minocin	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth	Total \$\$ \$455,400 \$202,397 \$657,797  Total \$\$ \$434,792 \$233,539	Total Rx 64 23 87  Total Rx 645 6,257	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE	MAC'd? N Y	Cerezyme Fabrazyme  Brand Declomycin Minocin Vibra-mycin/Vibratab	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer	Total \$\$ \$455,400 \$202,397 \$657,797  Total \$\$ \$434,792 \$233,539 \$107,417	Total Rx 64 23 87  Total Rx 645 6,257 14,433	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES Share of FFS Rx's: 0.27%  Per Member SFY05 YTD: \$2.73  DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE DOXYCYCLINE TETRACYCLINE	MAC'd? N Y	Cerezyme Fabrazyme  Brand Declomycin Minocin Vibra-mycin/Vibratab	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE DOXYCYCLINE TETRACYCLINE	MAC'd? N Y	Cerezyme Fabrazyme  Brand Declomycin Minocin Vibra-mycin/Vibratab	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES Share of FFS Rx's: 0.27%  Per Member SFY05 YTD: \$2.73  DEMECLOCYCLINE MINOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE Total	MAC'd? N Y	Cerezyme Fabrazyme  Brand Declomycin Minocin Vibra-mycin/Vibratab	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES Share of FFS Rx's: 0.27%  Per Member SFY05 YTD: \$2.73  DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TOTAL  THROMBIN INHIBITORS	MAC'd? N Y	Cerezyme Fabrazyme  Brand Declomycin Minocin Vibra-mycin/Vibratab	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE AGALSIDASE BETA  Total  TETRACYCLINES Share of FFS Rx's: 0.27%  Per Member SFY05 YTD: \$2.73  DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE TOTAL  THROMBIN INHIBITORS Share of FFS Rx's: 0.00%	MAC'd? N Y Y	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle	Total \$\$ \$455,400 \$202,397 \$657,797  Total \$\$ \$434,792 \$233,539 \$107,417 \$49,042 \$824,791	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546 27,881	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44 \$7.49 \$29.58
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE TOtal  THROMBIN INHIBITORS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.96	MAC'd? N Y Y MAC'd?	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin Brand	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle  Manufacturer	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042     \$824,791  Total \$\$	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546 27,881	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44 \$7.49 \$29.58
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE TOtal  THROMBIN INHIBITORS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.96	MAC'd? N Y Y MAC'd?	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin Brand	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle  Manufacturer	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042     \$824,791  Total \$\$	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546 27,881	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44 \$7.49 \$29.58
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE Total  THROMBIN INHIBITORS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.96 LEPIRUDIN  THROMBOLYTIC ENZYMES	MAC'd? N Y Y MAC'd?	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin Brand	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle  Manufacturer	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042     \$824,791  Total \$\$	Total Rx 64 23 87  Total Rx 645 6,257 14,433 6,546 27,881	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44 \$7.49 \$29.58
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE Total  THROMBIN INHIBITORS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.96 LEPIRUDIN  THROMBOL YTIC ENZYMES Share of FFS Rx's: 0.00%	MAC'd? N Y Y Y Y	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin  Brand Refludan	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle  Manufacturer Berlex	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042     \$824,791  Total \$\$     \$288,879	Total Rx 64 23 87  Total Rx 645 6.257 14,433 6.546 27,881  Total Rx 29	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%  Market Share 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44 \$7.49 \$29.58 \$\$ Per Rx \$9,961.34
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE TETRACYCLINE TOtal  THROMBIN INHIBITORS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.96 LEPIRUDIN  THROMBOLYTIC ENZYMES Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.00% Per Member SFY05 YTD: \$0.00%	MAC'd? N Y Y Y MAC'd? N MAC'd?	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin  Brand Brand Brand Brand	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle  Manufacturer Berlex  Manufacturer	Total \$\$     \$455,400     \$202,397 \$657,797  Total \$\$     \$434,792 \$233,539 \$107,417 \$49,042 \$824,791  Total \$\$ \$288,879	Total Rx 644 623 87  Total Rx 645 6,257 14,433 6,546 27,881  Total Rx 29	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%  Market Share 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44 \$7.49 \$29.58 \$\$ Per Rx \$9,961.34
Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$2.18 IMIGLUCERASE AGALSIDASE BETA Total  TETRACYCLINES Share of FFS Rx's: 0.27% Per Member SFY05 YTD: \$2.73 DEMECLOCYCLINE MINOCYCLINE DOXYCYCLINE TETRACYCLINE Total  THROMBIN INHIBITORS Share of FFS Rx's: 0.00% Per Member SFY05 YTD: \$0.96 LEPIRUDIN  THROMBOLYTIC ENZYMES Share of FFS Rx's: 0.00%	MAC'd? N Y Y Y Y	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin  Brand Refludan	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle  Manufacturer Berlex	Total \$\$     \$455,400     \$202,397     \$657,797  Total \$\$     \$434,792     \$233,539     \$107,417     \$49,042     \$824,791  Total \$\$     \$288,879	Total Rx 64 23 87  Total Rx 645 6.257 14,433 6.546 27,881  Total Rx 29	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%  Market Share 100.0%	\$\$ Per Rx \$7,115.63 \$8,799.87 \$7,560.89 \$\$ Per Rx \$674.10 \$37.32 \$7.44 \$7.49 \$29.58 \$\$ Per Rx \$9,961.34
Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$2.18  IMIGLUCERASE  AGALSIDASE BETA  Total  TETRACYCLINES  Share of FFS Rx's: 0.27%  Per Member SFY05 YTD: \$2.73  DEMECLOCYCLINE  MINOCYCLINE  DOXYCYCLINE  TETRACYCLINE  TOTAL  THROMBIN INHIBITORS  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.96  LEPIRUDIN  THROMBOLYTIC ENZYMES  Share of FFS Rx's: 0.00%  Per Member SFY05 YTD: \$0.00%  Per Member SFY05 YTD: \$0.00%  Per Member SFY05 YTD: \$0.00%	MAC'd? N Y Y Y MAC'd? N MAC'd?	Brand Declomycin Minocin Vibra-mycin/Vibratab Achromycin  Brand Brand Brand Brand	Genzyme Genzyme  Manufacturer ESP Pharma Wyeth Pfizer ESI Lederle  Manufacturer Berlex  Manufacturer	Total \$\$     \$455,400     \$202,397 \$657,797  Total \$\$     \$434,792 \$233,539 \$107,417 \$49,042 \$824,791  Total \$\$ \$288,879	Total Rx 644 623 87  Total Rx 645 6,257 14,433 6,546 27,881  Total Rx 29	Market Share 73.6% 26.4% 100.0%  Market Share 2.3% 22.4% 51.8% 23.5% 100.0%  Market Share 100.0%	\$7,115.63 \$8,799.87 \$7,560.89 \$7,560.89 \$674.10 \$37.32 \$7.44 \$7.49 \$29.58 \$\$ Per Rx \$9,961.34

Share of FFS Rx's: 2.10%							
D M OFVOE VTD- 60.00	*****	D 1	Manufactura	T-1-1 00	T-1-I D.	Market Obarra	66 D D
Per Member SFY05 YTD: \$9.66 L-THYROXINE	MAC'd?	Brand Synthroid	Manufacturer Abbott	Total \$\$ \$2,865,661	Total Rx 218,300	Market Share 98.5%	\$\$ Per Rx \$13.13
LIOTHYRONINE	N	Cytomel	Monarch	\$2,865,661	1,050	0.5%	\$29.52
THYROID	N	Various	IVIOITATOTI	\$18,142	2,208	1.0%	\$8.22
LIOTRIX	N	Thyrolar	Forest	\$165	9	0.0%	\$18.32
Total		,		\$2,914,963	221,567	100.0%	\$13.16
				<b>4</b> =,0 : 1,0 00			*
TOPICAL MUPIROCIN							
Share of FFS Rx's: 0.04%							
Per Member SFY05 YTD: \$0.67	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
MUPIROCIN	N	Bactroban	GlaxoSmithKline	\$202,277	3,913	100.0%	\$51.69
inci incent		- Daoirobair	Olaxo Olimani amio	<b>4_4_</b>	0,0.0	1001070	4000
URINARY ANTI-INFECTIVES							
Share of FFS Rx's: 0.03%							
Per Member SFY05 YTD: \$0.46	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
METHENAMINE	N N	Hiprex	Aventis	\$136,087	2,749	98.6%	\$49.50
FOSFOMYCIN	N	Monurol	Forest	\$2,141	38	1.4%	\$56.34
Total				\$138,227	2,787	100.0%	\$49.60
URINARY TRACT ANALGESIC							
Share of FFS Rx's: 0.04%							
Per Member SFY05 YTD: \$0.16	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
PHENAZOPYRIDINE	N N	Pyridium	WC Prof	\$49,685	3,745	100.0%	\$13.27
,	11	. ,		Ψ-10,000	5,1 45	. 30.0 /0	Ψ10.21
VACCINES							
Share of FFS Rx's: 0.00%							
Per Member SFY05 YTD: \$0.00	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
TYPHOID VACCINE	N N	Vivotif Berna		\$831	10tai KX 28	100.0%	\$\$ Per KX \$29.68
TTPHOID VACCINE	IN	VIVOLII BEITIA	Berna	φου i	20	100.0%	\$29.00
VACINAL DDEDADATIONS							
VAGINAL PREPARATIONS							
Share of FFS Rx's: 0.12%							
Per Member SFY05 YTD: \$2.12	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	\$\$ Per Rx
METRONIDAZOLE ESTROGENS,CONJUGATED	N N	Metrogel Vaginal Premarin	Galderma Wyeth	\$173,327 \$147,324	2,872 2,253	23.0% 18.0%	\$60.35 \$65.39
ESTROGENS, CONJUGATED  ESTRADIOL	N	Estring	Pharmacia	\$122,130	2,233	16.1%	\$60.58
TERCONAZOLE	N	Terazol	Ortho	\$118,284	3,050	24.4%	\$38.78
CLINDAMYCIN	N	Cleocin Vaginal	Pharmacia	\$44,581	846	6.8%	\$52.70
BUTOCONAZOLE	N	FemStat	Roche Labs	\$17,257	355	2.8%	\$48.61
MICONAZOLE	Y	Mycelex	Bayer	\$10,503	691	5.5%	\$15.20
CLOTRIMAZOLE NYSTATIN	Y	Gyne-Lotrimin Various	Schering-Plough	\$3,717	320 64	2.6% 0.5%	\$11.62 \$38.98
SULFANILAMIDE	N N	Various		\$2,495 \$688	15	0.5%	\$45.85
ACETIC ACID	N	Aci-Jel	Ortho	\$386	17	0.1%	\$22.70
PROPIONIC ACID	N	110.00		\$233	14	0.1%	\$16.66
Total				\$640,926	12,513	100.0%	\$51.22
							•
VANCOMYCIN							• •
Share of FFS Rx's: 0.04%	MAC'd?	Brand	Manufacturer	Total \$\$	Total Rx	Market Share	
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31	MAC'd?	Brand Vancocin	Manufacturer	Total \$\$ \$393.897	Total Rx	Market Share	\$\$ Per Rx
Share of FFS Rx's: 0.04%	MAC'd?	Brand Vancocin	Manufacturer Lilly	Total \$\$ \$393,897	Total Rx 3,678	Market Share 100.0%	
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN							\$\$ Per Rx
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES							\$\$ Per Rx
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08%	Y	Vancocin	Lilly	\$393,897	3,678	100.0%	\$\$ Per Rx \$107.10
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06		Vancocin Brand	Lilly	\$393,897 Total \$\$	3,678 Total Rx	100.0% Market Share	\$\$ Per Rx \$107.10 \$\$ Per Rx
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08%	Y	Vancocin	Lilly	\$393,897	3,678	100.0%	\$\$ Per Rx \$107.10
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN	Y	Vancocin Brand	Lilly	\$393,897 Total \$\$	3,678 Total Rx	100.0% Market Share	\$\$ Per Rx \$107.10 \$\$ Per Rx
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS	Y	Vancocin Brand	Lilly	\$393,897 Total \$\$	3,678 Total Rx	100.0% Market Share	\$\$ Per Rx \$107.10 \$\$ Per Rx
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18%	MAC'd?	Vancocin  Brand  DDAVP	Manufacturer Aventis	\$393,897 Total \$\$ \$1,527,768	3,678  Total Rx 8,828	100.0% Market Share 100.0%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93	Y	Vancocin Brand	Lilly	\$393,897  Total \$\$ \$1,527,768	Total Rx 8,828	Market Share 100.0%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18%	MAC'd?	Vancocin  Brand  DDAVP	Manufacturer Aventis	\$393,897 Total \$\$ \$1,527,768	3,678  Total Rx 8,828	100.0% Market Share 100.0%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER	MAC'd?	Vancocin  Brand  DDAVP  Brand	Manufacturer Aventis  Manufacturer	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239	3,678  Total Rx  8,828  Total Rx  9,618	100.0%  Market Share 100.0%  Market Share 50.1%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL	MAC'd?	Brand DDAVP Brand Calciferol Hectorol	Manufacturer Aventis  Manufacturer Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$56,288 \$35,352 \$28,041	Total Rx 8,828 Total Rx 9,618 4,322 727 288	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE	MAC'd?	Brand DDAVP Brand Calciferol Hectorol Aqua-Mephyton	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008	Total Rx 8,828 Total Rx 9,618 4,322 727 288 1,991	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL	MAC'd?	Brand DDAVP Brand Calciferol Hectorol	Manufacturer Aventis  Manufacturer Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393	3,678  Total Rx 8,828  Total Rx 9,618 4,322 727 288 1,991 113	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER	MAC'd?	Brand DDAVP Brand Calciferol Hectorol Aqua-Mephyton	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$3,393 \$6,219	Total Rx 8,828 Total Rx 9,618 4,322 727 288 1,991 113 218	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.6% 1.1%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL	MAC'd?	Brand DDAVP Brand Calciferol Hectorol Aqua-Mephyton	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393 \$6,219 \$5,063	3,678  Total Rx 8,828  Total Rx 9,618 4,322 727 288 1,991 113	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER MULTIVITAMINS	MAC'd?	Brand DDAVP  Brand Calciferol Hectorol Aqua-Mephyton DHT	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$3,393 \$6,219	Total Rx 8,828 Total Rx 9,618 4,322 727 288 1,991 113 218 218	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6% 1.1%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53 \$23.23
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER MULTIVITAMINS PYRIDOXINE MULTIVITAMINS PYRIDOXINE MULTIVITAMIN, Adult #2 Without Vitamin K VITAMIN A	MAC'd?	Brand DDAVP  Brand Calciferol Hectorol Aqua-Mephyton DHT	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393 \$6,219 \$5,063 \$4,592	Total Rx 8,828 Total Rx 9,618 4,322 727 288 1,991 113 218 218 1,070 72 57	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6% 1.1% 5.6% 0.4% 0.3%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53 \$23.23 \$4.29 \$52.46 \$47.85
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER MULTIVITAMINS PYRIDOXINE MULTIVITAMINS PYRIDOXINE MULTIVITAMIN, Adult #2 Without Vitamin K VITAMIN A MULTIVITS W-IRON, HEMATINIC	MAC'd?	Brand DDAVP  Brand Calciferol Hectorol Aqua-Mephyton DHT	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393 \$6,219 \$5,063 \$4,592 \$3,777	Total Rx 8,828 Total Rx 9,618 4,322 727 288 1,991 113 218 218 1,070 72 57 149	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6% 1.1% 5.6% 0.4% 0.3% 0.8%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53 \$23.23 \$4.29 \$52.46 \$47.85 \$9.00
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER MULTIVITAMINS PYRIDOXINE MULTIVITAMINS PYRIDOXINE MULTIVITAMIN, Adult #2 Without Vitamin K VITAMIN A MULTIVITS W-IRON,HEMATINIC PARICALCITOL	MAC'd?	Brand DDAVP  Brand Calciferol Hectorol Aqua-Mephyton DHT	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393 \$6,219 \$5,063 \$4,592 \$3,777 \$2,727 \$1,340 \$1,109	Total Rx 8,828 Total Rx 9,618 4,322 727 288 1,991 113 218 218 1,070 72 57	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6% 1.11% 5.6% 0.4% 0.3% 0.8% 0.0%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53 \$23.23 \$4.29 \$52.46 \$47.85 \$9.00 \$221.84
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER MULTIVITAMINS PYRIDOXINE MULTIVITAMIN, Adult #2 Without Vitamin K VITAMIN AMULTIVITS W-IRON,HEMATINIC PARICALCITOL MULTIVITS W-IRON,HEMATINIC PARICALCITOL MULTIVITS W-FE,OTHER MIN	MAC'd?	Brand DDAVP  Brand Calciferol Hectorol Aqua-Mephyton DHT  Vitamin B6	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393 \$5,219 \$5,063 \$4,592 \$3,777 \$2,727 \$1,340 \$1,109 \$884	Total Rx 8,828  Total Rx 9,618 4,322 727 288 1,991 113 218 218 1,070 72 57 149 5 85	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6% 1.1% 5.6% 0.4% 0.3% 0.8% 0.0% 0.0%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$173.06 \$\$13.49 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53 \$23.23 \$4.29 \$52.46 \$47.85 \$9.00 \$221.84 \$10.40
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER MULTIVITAMINS PYRIDOXINE MULTIVITAMIN, Adult #2 Without Vitamin K VITAMIN A MULTIVITS W-IRON,HEMATINIC PARICALCITOL MULTIVITS W-FE,OTHER MIN THIAMINE	MAC'd?	Brand DDAVP  Brand Calciferol Hectorol Aqua-Mephyton DHT  Vitamin B6	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393 \$6,219 \$5,063 \$4,592 \$3,777 \$2,727 \$1,340 \$1,109 \$884 \$755	Total Rx 8,828  Total Rx 9,618 4,322 727 288 1,991 113 218 218 1,070 72 57 149 5 85	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6% 1.1% 5.6% 0.4% 0.3% 0.8% 0.0% 0.4% 0.1%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ 173.06 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53 \$23.23 \$4.29 \$52.46 \$47.85 \$9.00 \$221.84 \$10.40 \$31.44
Share of FFS Rx's: 0.04% Per Member SFY05 YTD: \$1.31 VANCOMYCIN  VASOPRESSOR HORMONES Share of FFS Rx's: 0.08% Per Member SFY05 YTD: \$5.06 DESMOPRESSIN  VITAMINS Share of FFS Rx's: 0.18% Per Member SFY05 YTD: \$0.93 VITAMIN B COMPLEX CLASSIFIER ERGOCALCIFEROL MVI, Adult #1 With Vitamin K DOXERCALCIFEROL PHYTONADIONE DIHYDROTACHYSTEROL VITAMINS CLASSIFIER MULTIVITAMINS PYRIDOXINE MULTIVITAMIN, Adult #2 Without Vitamin K VITAMIN AMULTIVITS W-IRON,HEMATINIC PARICALCITOL MULTIVITS W-IRON,HEMATINIC PARICALCITOL MULTIVITS W-FE,OTHER MIN	MAC'd?	Brand DDAVP  Brand Calciferol Hectorol Aqua-Mephyton DHT  Vitamin B6	Manufacturer Aventis  Manufacturer  Schwarz  Bone Care Internation	\$393,897  Total \$\$ \$1,527,768  Total \$\$ \$96,239 \$58,288 \$35,352 \$28,041 \$28,008 \$8,393 \$5,219 \$5,063 \$4,592 \$3,777 \$2,727 \$1,340 \$1,109 \$884	Total Rx 8,828  Total Rx 9,618 4,322 727 288 1,991 113 218 218 1,070 72 57 149 5 85	Market Share 100.0%  Market Share 50.1% 22.5% 3.8% 1.5% 10.4% 0.6% 1.1% 5.6% 0.4% 0.3% 0.8% 0.0% 0.0%	\$\$ Per Rx \$107.10 \$\$ Per Rx \$173.06 \$\$ Per Rx \$10.01 \$13.49 \$48.63 \$97.37 \$14.07 \$74.28 \$28.53 \$23.23 \$4.29 \$52.46 \$47.85 \$9.00 \$221.84 \$10.40

13 21 21 19,184 Total Rx 18,986 Total Rx 36,799	21 0.1% 2 0.0% 19,184 100.0%  al Rx Market Share 18,986 100.0%  al Rx Market Share 36,799 100.0%	\$2.4 \$2.6 \$14.6 \$14.6 \$\$ Per Rx \$5.3
19,184  Total Rx  18,986  Total Rx	al Rx	\$14.69 \$\$ Per Rx \$5.39 \$\$ Per Rx
Total Rx 18,986 Total Rx	al Rx	\$14.69 \$\$ Per Rx \$5.30 \$\$ Per Rx
18,986 Total Rx	al Rx Market Share 100.0%	\$5.36 \$\$ Per Rx
18,986 Total Rx	al Rx Market Share 100.0%	\$5.36 \$\$ Per Rx
18,986 Total Rx	al Rx Market Share 100.0%	\$5.36 \$\$ Per Rx
18,986 Total Rx	al Rx Market Share 100.0%	\$5.36 \$\$ Per Rx
Total Rx	al Rx Market Share 36,799 100.0%	\$\$ Per Rx
	36,799 100.0%	**
	36,799 100.0%	**
	36,799 100.0%	**
	36,799 100.0%	**
36,799		\$6.2
		-
Total Rx	al Rx Market Share	\$\$ Per Rx
3,814	3,814 100.0%	\$11.94
Total Rx		\$\$ Per Rx
15,061	-,	
849 297		
236 203		\$24.23
16.646		\$16.6
10,040	10,040	<b>\$10.00</b>
Total Rx	al Rx Market Share	\$\$ Per Rx
5,770	-, -	
	206 3.4%	\$4.22
	5,976 100.0%	\$9.1
5,976		
		I .
	al Rx Market Share	\$\$ Per Rx
5,976		
5,976 Total Rx	638 90.0%	\$1,319.12
5,976  Total Rx 638	638 90.0% 26 3.7%	\$1,319.12 \$2,897.59
8 7		